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 CHAPTER 1 
 
      INTRODUCTION 
 
 
 
1.1 Schizophrenia 
 
Schizophrenia is a severe mental disorder characterized by disturbances in 
thinking, sense of self, affect, motivation, behaviour and interpersonal 
functioning. The pathology of schizophrenia is also heterogeneous. Although 
social, environmental and genetic risk have been identified as factors that play a 
role in the development of schizophrenia, the exact etiology still remains unclear 
(Ferreira, 1961). Currently available treatments can reduce the severity of the 
symptoms but cannot cure the disorder.  
 
1.1.1 Evolution and Origins of the Concept of Schizophrenia 
 
Schizophrenia was first identified as a disease by Benedict Augustin Morel 
(1809–1873). Benedict Augustin Morel, a French physician, coined the term 
“Dementia Praecox” in 1860 to describe a mental disorder which initially struck 
in young adult age and subsequently lead to degeneration of mental functioning. 
The term “Dementia Praecox” was further systematically elucidated by German 
psychiatrist Emil Kraepelin (1856-1926). Dementia praecox, as it was thought to 
be a degeneration of the brain (Dementia), beginning at a relatively young age 
(praecox) and ultimately leading to the disintegration of the entire personality. 
Emil Kraepelin believed biological and genetic malfunction to be the primary 
causes for this mental disease and thought to that the delusions, hallucinations 
and bizarre behavioral abnormalities seen in people with schizophrenia could be 
ultimately traced to a physical abnormality or disease. 
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Eugen Bleuler (1857-1939), a Swiss psychiatrist, opposed Emil Kraepelin’s 
views that dementia praecox is a disease of the brain or irreversible brain 
damage. In 1911, he introduced a striking change in both the terminology and 
understanding of the disorder. He coined the term “Schizophrenia” and 
suggested that the name of the disease is changed because of its characteristic 
disorganization of several mental functions. He divided symptoms of 
schizophrenia into four fundamental symptoms, which he thought were 
characteristic of schizophrenia. The four As identified by Eugen Bleuler are given 
below (Table 1.1). 
          EUGEN BLEULER’S FOUR As 
 Associational disturbances (Thought 
Disorder) 
 Ambivalence (Refers to an underlying 
emotional attitude with co-existing 
contradictory impulses (Bleuler 1911) 
 Affect (Problems in outward expression of 
emotion) and 
 Autism (Impaired communication, 
excessive rigidity and emotional 
detachment) 
   
                           Table 1.1 Eugen Bleuler’s four As 
 
The influential new perspective on defining schizophrenia features was 
provided by a German psychiatrist, Kurt Schneider (1887-1967). In 1959, 
Schneider listed a group of symptoms and called them as “First-Rank 
symptoms” (Table 1.2). He tried to make the diagnosis of schizophrenia more 
precise by identifying a certain group of symptoms as being characteristic of 
schizophrenia. He attempted to identify features that were highly specific to 
schizophrenia. The characteristic symptoms of schizophrenia chosen by him 
varied considerably from the basic and fundamental symptoms of Eugen Bleuler. 
Kurt Schneider emphasised diagnostically differentiating symptoms that could 
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be precisely observed and occurred frequently to be instrumental in the 
differential diagnosis (Andreasen & Carpenter, 1993).  
         
     SCHNEIDERIAN FIRST-RANK SYMPTOMS 
 Audible thoughts 
 Voices heard arguing or discussing or both 
 Voices heard commenting one’s action 
 Somatic hallucination 
 Thought withdrawal and other experiences 
of influenced thought 
 Thought insertion (The delusion that 
thoughts are being inserted into one’s mind 
by someone else) 
 Thought broadcasting or thought diffusion 
and delusional perception 
 
                              Table 1.2 Schneiderian First-Rank Symptoms 
 
Schneiderian first-rank symptoms have played a prominent role in the recent 
diagnostic systems: in International Classification of Diseases (ICD-10) as well as 
in Diagnostic and Statistical Manual of Mental Disorders DSM-III and DSM-IV. 
Both ICD-10 and DSM-IV emphasize the presence of the First-Rank symptoms as 
being symptomatically sufficient for the diagnosis of schizophrenia. 
1.1.2 Symptoms of Schizophrenia 
The symptoms of schizophrenia vary widely in severity and type from 
individual to individual (Tandon et al., 2009). Nancy Andreasen (1985) suggested 
two symptom dimensions as a result of a factor analytic study. She developed 
measurement scales of symptoms found in factor analytic studies that some 
heaped together with certain other symptoms occurred. She described one factor 
called "positive symptoms" - including delusions and hallucinations - and the 
other factor as "negative symptoms" - language impoverishment and social 
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withdrawal. The symptoms of schizophrenia fall into two categories “positive” 
and “negative” symptoms. Overt psychotic behavior such as delusions, 
hallucinations, disorganized speech and disturbed behavior are called positive 
symptoms. The positive symptoms are exaggerations or distortions of normal 
thoughts, emotions and behavior. Positive symptoms serve as signs of presence 
of very uncommon thoughts and perceptions that involve a loss of contact with 
reality. Delusions or deeply entrenched false beliefs are the most common 
disturbance of thought content associated with schizophrenia patients. 
Hallucinations are false perception not corresponding to the objective stimuli 
present in the environment. Hallucinations are false perceptions involving one of 
the five senses although they are auditory ex: patients hear voices in most cases. 
Although hallucinations do not correspond to actual stimuli, they are real to 
patients with schizophrenia. Disorganized speech is also one of the common 
symptoms in schizophrenia. Their language can be grossly distorted to the point 
of incomprehensibility. Some people with schizophrenia speak with odd 
intonations and lack the normal expressiveness and gestures common in 
everyday talk. 
 
Many people with schizophrenia also have negative symptoms. Negative 
symptoms are those that involve functioning lower than the level of behavior 
regarded as normal (Halgin & Whitbourne, 2005). The most common negative 
symptoms are alogia, affective flattening and avolition. Alogia is a loss of words 
or notable lack of spontaneity or responsiveness in conversation. In affective 
flattening, an individual seems unresponsive, with relatively motionless body 
and facial reactions while maintaining minimal eye contact. The symptoms of 
avolition involve a lack of initiative and unwillingness to act. Many patients with 
schizophrenia also experience anhedonia, a loss of interest in or ability to 
experience pleasure from activities that most of people find appealing. 
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1.1.3 Diagnosis of Schizophrenia – Modern Classifications 
 
 
The Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) 
(American Psychiatric Association, 1994) and the International Classification of 
Diseases (ICD-10) (World Health Organization, 1993) provides the criteria for 
diagnosing schizophrenia and other mental disorders. The Diagnostic and 
Statistical Manual of Mental Disorders IV (DSM-IV) is most widely used system 
for diagnosing schizophrenia and other mental disorders. The American 
psychiatric association presents the criteria for diagnosis of schizophrenia in the 
“Diagnostic and Statistical Manual of Mental Disorders IV” (Table 1.3). The ICD-
10 classification for mental and behavioral disorders also plays a vital role in the 
diagnosis of schizophrenia and related disorders. The criteria and standard 
requirements for diagnosis of schizophrenia as per ICD-10 are given below 
(Table 1.4). 
1.1.4 DSM-IV versus ICD-10 Classification Systems 
 
 
On the surface the Diagnostic and Statistical Manual of Mental Disorders 
IV (DSM-IV) and the International Classification of Diseases (ICD-10) 
classifications appears very similar. There are differences exist. Even though 
efforts have been made to structure the gap between ICD-10 and DSM-IV and 
push them closer, remarkable differences still remain related to subtypes, 
definition and duration of schizophrenia and also classification of certain other 
psychotic disorders classified with schizophrenia. ICD-10 categorizes schizotypal 
disorder, persistent delusional disorder, acute and transient psychotic disorders, 
induced delusional disorder and schizoaffective disorder. The Diagnostic and 
Statistical Manual for Mental Disorders, Fourth Edition- (DSM-IV) does not 
include the category of schizotypal disorders with psychotic disorders but, 
categorized under cluster A personality disorders. 
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Table 1.3 American Psychiatric Association, Diagnostic and Statistical Manual 
of Mental Disorders IV 
Diagnostic and Statistical Manual For Mental Disorders, Fourth Edition- (DSM-
IV) Diagnostic Criteria For Schizophrenia 
A) Characteristic symptoms: Two or more for the following, each present for a 
significant portion of time during a one month period or less if sufficiently 
treated: 
• Delusions. 
• Hallucinations. 
• Disorganized speech (Ex: Frequent derailment or incoherence). 
• Grossly disorganized or catatonic behavior. 
• Negative symptoms, that is, affective flattening, alogia or avolition. 
 
Note: Only one criterion- A symptom is required if delusions are bizarre 
or hallucinations consist of a voice keeping up a running commentary on 
the person’s behavior or thoughts, or two or more voices conversing with 
each other. 
 
B) Social/Occupational dysfunction: For a significant portion of the time since the 
onset of the disturbance, one or more major areas of functioning such as work, 
interpersonal relations, or self-are are markedly below the level achieved prior to 
the onset (or when the onset is in childhood or adolescence, failure to achieve 
expected level of interpersonal, academic or occupational achievement). 
C) Duration: Continuous signs of the disturbances persist for at least 6 months. This 
6 month period must include at last 1 month of symptoms (or less if successfully 
treated) that meet Criterion A (that is, active-phase symptoms) and may include 
prodromal or residual symptoms. During these prodromal or residual periods, 
the signs of the disturbances may be manifested by only negative symptoms or 
two or more symptoms listed in Criterion A present in an attenuated from (for 
example, odd beliefs, unusual perceptual experiences). 
D) Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and 
Mood Disorder with Psychotic Features have been ruled out because either no 
major depressive, manic or mixed episodes have occurred during active-phase 
symptoms; their total duration has been brief relative to the duration of the active 
and residual periods. 
E) Substance/General medical condition exclusion: The disturbance is not due to 
the direct physiological effects of a substance (For example:  drug of abuse, a 
medication) or a general medical condition. 
F) Relationship to a Perverse Developmental Disorder: If there is a history of 
Autistic Disorder or another Pervasive Developmental Disorder, the additional 
diagnosis of the Schizophrenia is made only if prominent delusions or 
hallucinations are present for at least a month (Or less if successfully treated). 
American Psychiatric Association, Diagnostic and statistical Manual of Mental Disorders IV 
(APA 1994) 
Source: Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of 
Mental Disorders. IV Edition. Washington, DC: American Psychiatric Association. 
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Table 1.4 International Classification of Diseases ICD-10 Diagnostic Criteria 
for Schizophrenia (WHO 1993). 
International Classification of Diseases ICD-10 Diagnostic Criteria For 
Schizophrenia 
Either at least one of the syndromes, symptoms, and sign listed below under (1), 
or at least two of the symptoms and signs listed under (2), Should be present for 
most of the time during an episode of psychotic illness lasting for at least one 
month (Or at some time during most of the days): 
1) At least one of the following must be present: 
 a) Thought echo, thought insertion or withdrawal, or thought 
broadcasting. 
 b) Delusions of control, influence or passivity, clearly referred to 
body or limb Movements or specific thoughts, actions or 
sensations; delusional perception. 
 c) Hallucinatory voices giving a running commentary on the 
patient’s behavior, or discussing the patient among themselves, or 
other types of hallucinatory voices coming from some part of the 
body. 
 d) Persistent delusions of other kinds that are culturally 
inappropriate and completely impossible (ex: Being able to control 
the weather, or being in communication with aliens from another 
world). 
2) Or at least two of the following: 
 a) Persistent hallucinations in any modality, when occurring every 
day for at least one month, when accompanied by delusions 
without clear affective content, or by persistent over-valued ideas. 
 b) Neologisms, breaks or interpolations in the train of thought, 
resulting in incoherence or irrelevant speech. 
 c) Catatonic behavior, such as marked apathy, paucity of speech, 
and blunting or incongruity of emotional responses. 
3) Most Commonly Used Exclusion Criteria: 
 1) If the patient also meets criteria for manic episode or depressive 
episode, the criteria listed under I (1) and I (2) above must have 
been met before the disturbance of mood developed. 
 2) The disorder is not attributable to organic brain disease, or to 
alcohol or drug-related intoxication, dependence, or withdrawal. 
International Classification of Diseases (ICD-10) Diagnostic Criteria for 
Schizophrenia (WHO 1993) 
 
 
Source: Adapted from the ICD-10 Classification of Mental and Behavioural Disorders 
–Diagnostic Criteria for Research – World Health Organization, Geneva (1993). 
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1.1.5 Subtypes of Schizophrenia 
 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
distinguishes between several different types of schizophrenia. The four basic 
subtypes of schizophrenia described in DSM-IV are paranoid, hebephrenic 
(disorganized in DSM-IV), catatonic and undifferentiated. The subtypes are 
distinguished by the combination of symptoms a person experiences.  
1.1.5.1 Paranoid Schizophrenia 
 
Paranoid schizophrenia is characterized predominantly by the presence of 
persecution or grandeur. People with paranoid type are preoccupied with one or 
more bizarre delusions or have auditory hallucinations, but without 
disorganized speech or disturbed behavior. People with paranoid type of 
schizophrenia show limited deterioration of mental aptitude, emotional effect 
and behavior than other schizophrenic subtypes. 
1.1.5.2 Disorganized type 
 
The disorganized type is characterized by an amalgam of symptoms that 
incorporates disturbed behavior, disorganized speech and irrelevant effect. 
Disorganized symptoms refer to the presence of confusion in thinking, inability 
to think clearly, disordered or incoherent speech, and grossly disorganized 
behavior like rhythmic gestures. Absurd grinning and grimacing are also 
frequent in patients with disorganized type. 
1.1.5.3 Catatonic type 
 
When the prominent symptom in a person with schizophrenia is bizarre 
motor behaviors or postural or movement abnormalities, the person is diagnosed 
as having catatonic type. Stuporous catatonia and excited catatonia are two forms 
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of catatonic schizophrenic subtype. The common characteristic of stuporous and 
excited catatonia forms is the obvious abnormality of motor behavior. The person 
with stuporous catatonia may be in a state of absolute stupor or may show a vast 
decline in extemporaneous movements and activity. Patients with excited 
catatonia show an extreme psychomotor agitation. Periodic catatonia is an 
infrequent but fascinating form of catatonia. 
1.1.5.4 Undifferentiated type 
 
Undifferentiated type is used when a person shows complex symptoms of 
schizophrenia such as hallucinations, delusions, incoherence and disturbed 
behavior, but does not meet the criteria for paranoid or catatonic or disorganized 
types of schizophrenia.  
 
The other two diagnostic classifications in the schizophrenia spectrum 
disorders are residual type and schizophreniform disorder.  
 
1.1.5.5 Residual type 
 
Residual type is characterized by a past history of at least one episode of 
schizophrenia, but no longer does. This diagnosis made when there are 
prominent negative symptoms or two or more deteriorating characteristic 
symptoms, but the person currently lacks prominent positive symptoms (ex: 
hallucinations, delusions, disorganized speech or catatonic behavior).  
 
1.1.5.6 Schizophreniform Disorder 
 
Individuals with schizophreniform disorder have psychotic symptoms 
that are same as those found in schizophrenia, except for period (Halgin & 
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Whitbourne, 2005). Schizophreniform disorder symptoms last longer than those 
of brief psychotic disorder but not so long that the practitioner would diagnose 
the individual as having schizophrenia. Most importantly, active symptoms last 
from one to six months. If the symptoms last more than six months, the 
practitioner is more likely to make the diagnosis of schizophrenia (Halgin & 
Whitbourne, 2005). Some people with schizophreniform disorder will completely 
recover and will not suffer in further episodes of psychosis (Walker et al., 2004). 
 
1.1.5.7 Schizoaffective Disorder 
 
Among other psychotic disorders, the diagnosis of schizoaffective 
disorder made to the individual who experience either major depressive episode, 
a manic episode or mixed episode at the same time that they meet the diagnosis 
for schizophrenia (Halgin & Whitbourne, 2005). In this disorder, during the 
period of active symptoms, there is the duration of minimum two weeks during 
which the individual does not have prominent mood symptoms but continues to 
have psychotic symptoms (ex: delusions, hallucinations). 
 
1.1.6 Phases of Schizophrenia 
 
 The onset of clinical symptoms of schizophrenia may be sudden or 
gradual and not dramatic (Walker et al., 2004). There are three phases of 
schizophrenia. Important to the diagnosis of schizophrenia is a marked 
disturbance lasting at least six months. During this six-month period is an active 
phase of symptoms, such as hallucinations, delusions, disorganized speech, 
disturbed behaviour and negative symptoms (Halgin & Whitbourne, 2005). The 
active period does not appear without warning signs. Most but not everyone 
have a prodromal phase, a period earlier to the active phase which people show 
a gradual deterioration in social and interpersonal functioning. During this phase 
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individuals may begin to lose interest in their usual pursuit and socially isolate 
themselves. Prodromal phase is characterized by much maladaptive behaviour, 
such as eccentricity, poor grooming, inappropriate emotionality, unusual beliefs, 
odd perceptual experience, inability to work productively and decreased energy 
(Lieberman et al., 2001; Walker et al., 2004). For many individuals, the active 
phase is followed by a residual phase (Halgin & Whitbourne, 2005). In residual 
phase individuals may be listless, have a trouble in concentration and be abjure. 
Moreover the symptoms in this phase are similar to those of prodromal period.  
 
1.1.7 Epidemiology of Schizophrenia 
 
1.1.7.1 Prevalence 
 
The frequencies of occurrence of a disease are usually given in prevalence 
or incidence rates. Prevalence is the ratio of the number of occurrences of a 
disease or disorder to the number of units at risk in the population. The relative 
amount of people who manifest a disorder or disease at a given point of time is 
point prevalence. The relative amount of people who manifest a disorder or 
disease over a definite period of time is period prevalence. The relative amount 
of the people who have ever manifested a disease or disorder, who are alive on a 
given day is a life time prevalence. Lifetime morbid risk is the chance factor of an 
individual developing the disease or disorder during a specific period of their 
life. 
 
The annual occurrence rate of schizophrenia is 0.2 - 0.4 per 1000, unrelated 
to gender with a life time prevalence of about 1 percent in the general population 
(Jablensky, 1999; Carpenter & Buchanan, 1994). McGrath et al. (2008) in their 
systematic review used 1,721 prevalence estimates from 188 studies (132 general 
population based studies, 15 migrant studies and 41 studies reported the 
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prevalence in other special groups) related to the prevalence of schizophrenia. Of 
that 132 general population studies, they identified 21 for point prevalence, 34 for 
period prevalence and 24 for life time prevalence. Nine studies for life time 
morbid risk, 44 studies in patient census derived data. On the basis of combined 
prevalence data, they found no significant difference between urban or rural or 
mixed urban and rural sites and no significant difference across periods. They 
also found that the prevalence and incidence of schizophrenia in migrant was 
higher compared to the native-born individuals. Their study found a significant 
difference in distribution of prevalence estimates when sorted by economic 
status, while developed nations having higher estimates than less developed 
economies. 
 
1.1.7.2 Gender, Age and Cultural Features 
 
The age of onset in schizophrenia for men is between 18 and 25, whereas 
modal age of onset for women is between 25 and mid of thirties (Halgin & 
Whitbourne, 2005). Schizophrenia onset is quite uncommon for individual below 
10 years of age or over 40 years. Male is disproportionately large numbers in 
previous studies of childhood onset schizophrenia (Spencer & Campbell, 1994).  
 
Epidemiological studies reveal that no culture, race or society found to be 
free from schizophrenia. Schizophrenia represents a serious public health 
problem (World Health Organisation, 1997). Previous research studies revealed 
that the rates of schizophrenia are further developed in some ethnic minority 
groups such as second-generation of Afro-Caribbean people in the United 
Kingdom (Boydell et al., 2001). 
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1.1.7.3 Comorbidity 
 
Psychological comorbidities are common among schizophrenia patients. 
Substance abuse is the most common comorbidity in schizophrenia patients 
(Strakowski et al., 1993; Rosenthal, 1998; Buckley et al., 2009) includes stimulants, 
alcohol, hallucinogens, caffeine and tobacco. Patients with schizophrenia are also 
more likely to be diagnosed with comorbid disorders including anxiety (Sim et 
al., 2006; Hwang & Bermanzohn, 2001) and depressive disorders (Buckley et al., 
2009).  
 
Strakowski et al. (1993) study on comorbidity in psychosis included 102 
patients with a first episode psychosis successively hospitalized. They examined 
the patients for the presence of psychiatric disorders and medical conditions. 
Patients were diagnosed based on structured Clinical Interview for DSM-III-R 
and rated weekly on symptom rating scales. They measured final symptom 
rating scales, duration of hospitalization and prognosis and recovery on the basis 
on the stands of operationalized criteria. Their study found comorbid diagnoses 
in 52% of the patients and 37.7% with multiple comorbid diagnoses. Their study 
reported that the most common comorbid diagnosis was substance abuse. They 
also reported patients with affective psychoses were notably more likely than 
those with nonaffective psychoses to have a comorbid substance abuse diagnosis. 
 
 
 
1.1.8 Etiology of Schizophrenia 
 
1.1.8.1 Biological Explanations 
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Biological elucidations of schizophrenia have their origins in writings of 
Emil Kraepelin (1913). Emil Kraepelin thought of schizophrenia as disease 
caused by degeneration of brain tissue. Kraepelin idea gave way for later probing 
of such factors as brain structure and genetics, which are currently contributing 
to a person’s biological vulnerability to schizophrenia.  
 
1.1.8.2 Structural and Functional Brain Abnormalities 
 
Arrival of sophisticated neuroimaging technologies such as computerized 
tomography, magnet resonance imaging (MRI), single photon emission 
computed tomography (SPECT), positron emission tomography (PET) and 
functional magnetic resonance imaging (FMRI) enabled researchers to study the 
structural and functional abnormalities precisely. The most common structural 
abnormalities consistently reported findings using computerized tomography 
has been that brains of individual with schizophrenia have enlarged ventricles, 
specifically enlargement of lateral ventricles (Chua & McKenna, 1995). In 
neuroimaging studies hippocampus is repeatedly found to distinguish patients 
with schizophrenia from normal individuals (Schmajuk, 2001). The advent of 
magnet resonance imaging scan technique gives higher resolution imaging and 
distinguishes the brain white matter and gray matter. This allows researchers to 
study the complex areas of the brain. Several disorders of the brain may lead to 
psychotic symptoms (Miller & Manson, 2002). 
 
Gur et al. (2000) investigated reduced dorsal and orbital prefrontal gray 
matter volume in schizophrenia. They performed magnetic resonance imaging 
(MRI) in 70 schizophrenia patients and 81 normal controls. They quantified gray 
and white matter volumes of different areas of the prefrontal cortex. They found 
reduced volume of prefrontal gray matter in patients with schizophrenia. 
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1.1.8.3 Neurotransmitters 
 
Neurotransmitters are the chemical messengers that allow the brain cells 
to interact with each other. The thought of neurotransmitter abnormality in 
schizophrenia dates long back. Earlier neurotransmitter theories concentrated on 
epinephrine and followed by noradrenaline, glutamate, and serotonin 
abnormalities in patients with schizophrenia. Despite of all, dopamine gained 
support and dominates neurotransmitters basis of schizophrenia research. The 
dopamine hypothesis predicts that the symptoms found in schizophrenia such as 
hallucinations, delusions and deficits of attention can be attributed to an 
excessive activity of neurons that mutually exchange information with each other 
through dopamine transmission (Carlsson, 1988).  
 
The two supporting proofs for this hypothesis were: antipsychotic 
medications reduce the occurrence of delusions and hallucinations by blocking 
the dopamine receptor called as D2 receptor. The dopamine receptors D2 
involved in schizophrenia (Abi-Dargham et al., 2000). The antipsychotic 
medications with blocking effects of D2 improve the schizophrenia symptoms 
(Seeman, 1980). The second proof is that the antipsychotic drugs biochemically 
related to dopamine such as amphetamines or L-Dopa increases the chances of 
psychotic symptoms. 
 
Beyond dopamine, blood tests for serotonin levels (Csernansky & 
Newcomer, 1994) and effects of clozapine in schizophrenia patients (Masellis at 
al., 1998) show evidence that those abnormalities in serotonin neurotransmitter 
system likely to play a key role in schizophrenia than early thoughts.  
 
Masellis at al. (1998) study on clinical reactivity to clozapine medication in 
patients with schizophrenia used pharmacokinetic approach in 185 patients with 
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schizophrenia who have been likely evaluated for medication clozapine 
response. Their study demonstrated the vital role of serotonin neurotransmitter 
system. 
 
Emerging evidence suggests that abnormalities in GABAergic neurons in 
the prefrontal brain circuits may also play a role in progression of cognitive 
impairments concord with schizophrenia (Carlsson at al., 2001). 
 
Cholinergic projections to the cortex and the basal forebrain play an intact 
role in various cognitive processes seem to be impaired in schizophrenia 
(Robbins, 1997). The current result patterns for cholinergic involvement in 
schizophrenia are not as abundant as the serotonergic involvement, but still 
convincing.  
 
1.1.8.4 Genetic Explanations 
 
One of the well grounded finding in schizophrenia is that certain 
vulnerability to the illness transmitted genetically (Heston, 1966; Gottesman, 
1991; Tsuang et al., 2001). The four types of studies in an attempt to assess the 
contributions of genetics are family and twin studies, adoption studies, high-risk 
studies and biological marker studies. The family pattern of schizophrenia gives 
persuasive evidence in favor of biological explanations. Gottesman (1991) in a 
review of family, twin and adoption studies summarized the compelling 
evidence of the role of genetics in schizophrenia. The high concordance rate may 
be derivable preferentially to genetics or member of the family live in the same 
home.  
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1.1.8.5 Family and Twin Studies 
 
Twin studies also play a pivotal role in expanding phenotypes outside the 
limits of clinical presentation, to accommodate promising bio markers (Cardno & 
Gottesman, 2000). Franzek and Beckmann (1998) study on genetic framework of 
schizophrenia spectrum psychoses used different diagnostic systems includes, 
zygosity diagnoses based on molecular genetics methods and a zygosity 
inventory. They investigated family history, twin concordance, frequency and 
severity of the birth related complications of 23 dizygotic (DZ) and 22 
monozygotic (MZ) twin pairs. They formulated diagnoses as per the DSM-III-R 
criteria and Leonhard’s nosology. They found none of thirty seven monozygotic 
twins diagnosed as having systematic schizophrenia, although six twenty-five 
dizygotic index twins received this diagnosis. Their study found that the 
identical twins have high concordance rate, near to 90 percent. Their study 
suggests that schizophrenia spectrum psychoses may consist of etiologically and 
clinically heterogeneous subgroups with various genetic backgrounds.   
 
1.1.8.6 Adoption Studies 
 
Adoption studies provide evidence of disposition for schizophrenia in 
families mainly due to genetic factors. Adoption studies track the rate of 
schizophrenia in children brought up by parents with no schizophrenia, but 
whose biological parents have schizophrenia. Heston (1966) investigated the 
incidence of schizophrenia in adoptees with biological parents with 
schizophrenia and without biological parents with schizophrenia. Heston (1966) 
study found schizophrenia only in the offspring of mothers with schizophrenia. 
Five of 47 persons born to mothers with schizophrenia were schizophrenic. 
Further the study found no cases of schizophrenia in 50 control subjects.   
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Kety (1988) study on the prevalence of schizophrenia in the biological and 
adoptive relatives of schizophrenia patient adoptees found that biological 
relatives of adoptees who suffered from schizophrenia had a remarkably higher 
chance of schizophrenia than the adoptive relatives who reared them. 
 
 Kety et al. (1994) study on mental illness in the biological and adoptive 
relatives of schizophrenia patient’s adoptees found that the schizophrenia 
particularly in their biological relatives and its rates was significantly greater 
than the biological relatives of the healthy controls. 
 
1.1.8.7 High-Risk Design 
 
Another approach to examining the relative contributions of 
environmental and genetics factors to schizophrenia is high-risk design (Halgin 
& Whitbourne, 2005). Keith et al. (1991) in the epidemiologic catchment area 
study found that the child with one parent with schizophrenia have a higher risk 
over their life time of becoming schizophrenic in contrast to a very minor chance 
in the general population. 
 
1.1.8.8 Studies of Biological Markers 
 
Another proposal among the genetic model is the effort by investigators to 
enroot a mathematical model that would elucidate how the disorder transmits 
from one generation to another generation (Halgin & Whitbourne, 2005). Very 
important measures search for biological makers are smooth pursuit movements 
and sustained attention. 
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1.1.8.9 Biological Stressors and Vulnerability 
 
Tragic events happen during the prenatal period and delivery may 
influence the development of schizophrenia among individual who have a 
genetic vulnerability to schizophrenia. Patients with schizophrenia are more 
likely to have a history of prenatal complications (McNeil et al., 2000; van Os & 
Selten, 1998). Investigators examined the pregnancy and birth records of adults 
given diagnoses of schizophrenia and recognized higher rate of obstetrical 
complications, pregnancy, delivery and the time after birth (Ohman & Hultman, 
1998). 
 
1.1.8.10 Psychosocial Factors 
 
This perspective focus on family systems, system of roles, interactions and 
patterns of communication in which individual with schizophrenia grew up. The 
relationship problems in family are thought to give a way to the development of 
unhealthy emotional responsiveness and cognitive distortions basic to the 
psychological symptoms of schizophrenia. The stress created by family members 
mirrored in the index of expressed emotion (EE), which provide a qualitative 
measure of the amount of emotions to which care takers or family persons speak 
in ways that reflect critical comments, hostility and emotional over-involvement 
(Halgin & Whitbourne, 2005). Individuals living in family showing high a level 
of expressed emotion have more chances to suffer a relapse than individuals who 
live in low expressed emotion families (Brown et al., 1972; Kavanagh, 1992).  
 
Expressed emotions may enhance neuropsychological deficits in 
increasing risk of schizophrenia in individuals with genetic vulnerability 
(Rosenfarb et al., 2000). Keri and Kelemen (2009) study on vulnerability to 
interpersonal criticism during family transactions in schizophrenia found family 
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criticism related to disturbance in thinking in patients with schizophrenia with 
poor attention and immediate memory.  
 
1.2 Schizophrenia and Neurocognitive Dysfunction 
 
The adverse clinical symptoms of devastating disorder schizophrenia 
primarily thought to affect cognition, but it also usually contributes to chronic 
problems with emotion and behaviour. Patients with schizophrenia not only 
suffer by the severity of the symptoms but also by deficits in cognition (Gold & 
Harvey, 1993). In schizophrenia, cognitive symptoms are present from the very 
early stage the disorder is first diagnosed. Neurocognitive impairments are 
fundamental characteristic in patients with schizophrenia (Kraepelin, 1971). 
Patients with schizophrenia suffer from a wide range of cognitive deficits (Keefe 
et al., 2006; Carroll, 2000; Green, 1996). Cognitive deficits are a core feature of 
schizophrenia that includes problems in speed of processing, attention or 
vigilance, working memory, verbal learning, verbal memory, visual learning, 
visual memory, reasoning and problem solving, verbal comprehension and social 
cognition (Nuechterlein et al., 2004; Green, 2006; Wilk et al., 2005). Cognitive 
deficits vary in degree of severity among patients with schizophrenia. Cognitive 
deficits can be enormous, severe and are probably present in most if not all 
patients with schizophrenia (Dickinson et al., 2007). Consistently implicated 
findings are on memory, attention and executive functions. 
 
1.2.1 Attention Deficits 
 
Attention is selective concentration or focus of cognitive resource on 
information while ignoring external stimuli. The distinction between different 
kinds of attention has suggested by number of psychologists. The two main 
aspects of attention further divided into selective attention and sustained 
attention (Krabbendam & Jolles, 2003). Selective attention refers to ability or 
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capacity to pay attention to relevant and necessary information while ignoring 
the less important. Sustained attention often referred to as vigilance in 
schizophrenia. Both selective attention and sustained attention deficits are 
reported in patients with schizophrenia. 
 
Attention deficits have been one of the widely affected cognitive domains 
in schizophrenia (Goldberg et al., 1993; Brickman et al., 2004; Kenny at al., 1997; 
Barr, 2001; Mueller et al., 2004; Elvevag & Goldberg, 2000). The Trail Making Test 
(TMT) is a standardized and widely used test measure of attention, speed and 
mental flexibility. The Trail Making Test consists of two parts. TMT-A 
(psychomotor speed) requires a participant to draw lines sequentially connecting 
twenty five encircled numbers on a sheet of paper. In TMT-B (set-shifting and 
flexibility) in which, participants alternates between numbers and letters (ex: 1, 
A, 2, B, 3, C, 4, D, etc). Patients with schizophrenia performed worse in the TMT 
A&B (Mojtabai et al., 2000). 
 
Horacek et al. (2006) studied about the association between resting brain 
metabolism and performance on the TMT A&B. They administered the Trail 
Making Test A & B on forty-two schizophrenia patients and 42 healthy controls. 
They studied resting brain metabolism by means of (18) FDG positron emission 
tomography. They found that patients with schizophrenia performed worse on 
both TMT-A (psychomotor speed) and TMT-B (set-shifting and flexibility). They 
also found that PET did not predict the performance on the TMT-A, but 
predicted that for TMT-B. Their study found PET uptake in the superior, middle 
and inferior frontal lobes bilaterally related with better performance in the TMT-
B. Their study demonstrated neurobiological basis for deficient TMT-B 
performance in patients with schizophrenia.  
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1.2.1.1 Selective Attention Deficits 
 
The Stroop Colour-Word Test/Task (SCWT) widely used to study 
selective attention, in which a word can be printed in discrepant colours. Lean on 
instructions the task is either of three: word reading, colour naming and 
interference (name of colours printed in conflicting colours). The attention task 
requires the participant to concentrate selectively on one dimension of stimulus 
ignoring inappropriate ones (Goldberg & Green, 2002; Krabbendam & Jolles, 
2003) 
 
Everett et al. (1989) administered shortened version of the Stroop Colour-
Word Test on 22 patients with schizophrenia, 18 non-schizophrenia patients with 
other psychiatric disorders (Depressed patients) and 22 non-psychiatric control 
participants. They found all patients showed deficits in all the stroop scales. They 
also found that patients with schizophrenia showed as much difficulty as non-
schizophrenia subjects on limited time selective attention task, but degraded 
remarkably more when selective attention had to be maintained. They found two 
different selective attention deficits marked in patients with schizophrenia. They 
are difficulty in selectively attending to noticeable aspect of complex stimulus 
and difficulties in maintaining selective attention over time. 
 
Mathalon at al. (2004) studied about the selective attention in 
schizophrenia. Their study included fifteen patients with schizophrenia and 
sixteen age and sex matched control subjects. They gave random sequence of 
equally probable loud and soft speech sounds and bright and dim checkerboard 
patterns exposed every 800 to 1200 msec. The participants need to press a button 
in reaction to soft speech sound in auditory attention task. They recorded event-
related potential (ERP) to test the unity and time course of auditory attention. 
They found that patients with schizophrenia actualized an early attentional filter 
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but failed to sustain selective attention later in the processing stream. They 
concluded executive control of auditory attention cannot be sustained in patients 
with schizophrenia.  
 
1.2.1.2 Sustained Attention Deficits 
 
The Continuous Performance Task/Test (CPT) widely used by researchers 
to assess sustained attention (Krabbendam & Jolles, 2003). The Continuous 
Performance Test task involves monitoring a random series of letters or digits 
that represent continuously, frequently at a rate of roughly about one per second. 
The subject has to detect target stimuli by pressing a response button and should 
refrain answering to the foils or distracting stimuli (Goldberg & Green., 2002). 
There are different versions of Continuous Performance Task/Test (CPT) is 
available. Some versions of CPT are with high processing loads.  
 
 Liu et al. (2002) study examined the deficits in sustained attention in 
schizophrenia in comparison to other disorders. Their study included 41 
inpatients with schizophrenia, 22 major depression patients without psychotic 
features, 22 bipolar without psychotic features and 42 bipolar patients with 
psychotic features. They have administered the Continuous Performance Test 
sessions with an undergrad version of the test and a twenty five percent of 
stimuli degradation version in which the stimulus images visually distorted. 
They administered CPT to schizophrenia patients and bipolar both at admission 
and discharge. They standardized the test scores in comparison with scores for a 
community sample of 345 participants with adjustment for age, sex and 
education. They found that all patients groups except the group with 
nonpsychotic major depression were significantly impaired in their ability to 
differentiate target from non target stimuli. They reported that patients with 
schizophrenia had the severest impairment followed by the other groups. They 
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also found, from admission until discharge, CPT test deficits remain unchanged 
among schizophrenia group. They reported that patients with schizophrenia had 
a less stringent reply criterion during the degraded continuous performance test. 
Their study concluded CPT test deficits are lasting vulnerability indicators for 
schizophrenia.  
 
These studies demonstrate the selective and sustained attention deficits in 
patients with schizophrenia. 
 
1.2.2 Memory 
 
 Memory is a person’s ability to store, retaining and recalling the past 
experiences and information. Short-term memory and long-term memory are 
two major categories of memory. Short-term memory permits recall for the time 
period of a few seconds to a minute without practice. The capacity of short-term 
memory is very restrictive. The information is accessible only for a valid period 
of time, but not kept indefinitely. Short–term memory foster by brief patterns of 
neuronal communication, under the influence on frontal and parietal lobes. 
Long–term memory can store much large quantities of information for 
conceivably extensive time period. The capacity of long term memory is 
abundantly large. Long-term memories are preserved by more fixed and 
permanent changes in brain neural connections. Working memory is the 
capability frantically to hold information in the mind needed to do complex tasks 
such as comprehension, learning and reasoning.  
 
Memory impairment is one of the major cognitive domains affected in 
patients with schizophrenia (McKeena et al., 1995). Several studies reported 
memory impairment in patients with schizophrenia (Brickman et al., 2004).  
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Saykin et al. (1991) studied neuropsychological function in schizophrenia. 
Their study included 36 unmedicated patients with schizophrenia and 36 age-
matched control participants. They administered a battery of neuropsychological 
tests. In their study schizophrenia patients showed generalized impairment 
relative to healthy controls and a selective deficit in memory.  
 
Kenny et al. (1997) studied cognitive impairments in schizophrenia. Their 
study included 17 adolescents with schizophrenia and 17 healthy controls. They 
administered number of neuropsychological tests. They administered the 
Trigram Recall with Interference Test as a measure of working memory. They 
reported that the adolescents with schizophrenia have generalized deficits in 
cognition, which is more pronounced on tests of attention and working memory. 
 
A meta-analysis by Aleman et al. (1999) on memory impairment in 
schizophrenia included seventy studies that reported measures of long-term 
memory and short-term memory (Digit Span). They found a significant and 
stable relation between schizophrenia and memory impairment. They also found 
that magnitude of memory impairment was not affected by factors like age, 
medication status, illness duration, symptomatology and positive symptoms. 
They also found a small significant relation between negative symptoms and 
memory impairment. Their study demonstrated a reliable association between 
memory impairment and schizophrenia. 
 
Boeker et al. (2006) study included twenty-two patients with paranoid 
schizophrenia and twenty-two age and sex matched controls participants. They 
administered a battery of neuropsychological tests (MWT-B, Trail Making Test 
A&B, The Tower of London Test, TAP battery of Attention, Wechsler Memory 
Scale-Revised, German version of Verbal Fluency Test, Autobiographical 
Memory Inventory-AMI), personality (Temperament and Character Inventory) 
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and psychopathological scale (PANSS). They have found that patients with 
schizophrenia showed deficits in executive function, working memory and 
episodic memory.   
 
Morice and Delahunty (1996) study on frontal and executive impairments 
in patients with schizophrenia found significant differences in schizophrenia 
patients compared with the healthy controls in two tests of working memory: 
alphabet span and sentence span test. They found an impaired memory 
performance in patients with schizophrenia. 
 
Mueller et al. (2004) study included 100 inpatients with chronic 
schizophrenia and 62 control participants. They examined neuropsychological 
deficits and their relationship to clinical symptoms in schizophrenia. They 
administered various neuropsychological tests. In their study schizophrenia 
patients showed pronounced cognitive deficits with verbal memory impairments 
best differentiating schizophrenia patients and healthy controls.   
 
Kravariti et al. (2007) study used z-transformed scores extracted with 
reference to forty-three control participants to compare cognitive profile and 
selectivity of cognitive deficits in nineteen recent onset and twenty-three chronic 
patients with adolescent-onset schizophrenia. In their study, compared with 
healthy controls both schizophrenia patient groups were impaired in intelligent 
quotient, verbal memory and planning.  
 
Forbes et al. (2009) systematic review and meta-analysis compared the 
working memory function in patients with schizophrenia and healthy controls. 
Their study conducted a meta-analysis on thirty-six measures of phonological, 
visuospatial and central executive working memory functioning included 441 
separate results from 187 different research studies. Their study reported 
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statistically significant effect sizes for all working memory measures displaying 
deficit in schizophrenia groups. They found considerable deficits in working 
memory in schizophrenia groups across all three working domains.  
 
The above studies show memory impairments in patients with 
schizophrenia. 
 
1.2.3 Executive Functions 
 
 “Executive function refers to those capabilities that enable a person to 
engage in independent, purposive, self serving behaviour successfully” (Lezak, 
1995). In cognitive neuropsychology, executive functions are generally defined as 
set of cognitive functions. Executive functions refer to the brain activity that 
maintain, co-ordinate, systemize, and incorporate the other functions of the 
cognitive faculty. Executive function deficits associated with a number of mental 
disorders especially schizophrenia. Patients with schizophrenia show deficits in 
executive functions (Brickman et al., 2004; Kenny at al., 1997; Zec, 1995), 
including poor processing cognitive information, reduced problem-solving skills 
and abilities as measured by the Tower of London test.  
 
Kenny et al. (1997) study included seventeen adolescent patients with 
schizophrenia and seventeen healthy controls. They administered a battery of 
neuropsychological tests. They have assessed executive functions using 
Wisconsin Card Sorting Test and the maze subtest of the WISC-R. The Wisconsin 
Card Sorting Task is a measure of cognitive flexibility. Participants have to sort 
cards according to four conceptual rules. They found a generalized 
neuropsychological impairment in adolescent patients with schizophrenia 
including executive functions.  
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Joshua et al. (2009) investigated executive functions in schizophrenia. 
Their study included 39 patients with schizophrenia, 40 bipolar disorder patients 
and 44 control participants. They administered the Hayling Sentence Completion 
Test on the entire group. The Hayling Sentence Completion Test is a measure of 
executive functions. The test consists of two sections of fifteen sentences each 
having the last word missing. In the first section, tester reads sentence loudly and 
the subject has to complete the sentences, granting a simple measure of speed in 
response. In the second section, the participant requested to finish the sentences 
with that word does not fit, yielding measures of response suppression ability 
and thinking time. In their study patients with schizophrenia significantly 
impaired in all measures of test compared to the control participants. The 
performance of schizophrenia patients was related to the higher ratings of 
cognitive disorganization.   
 
The abstraction of reasoning and problem solving used to epitomize a 
general accumulation of processes incorporated in logical thinking, planning, 
mental flexibility, taking suitable actions and preventing irrelevant actions, and 
choosing appropriate sensory information. The main feature of problem solving 
activity is a creation of the plan of action to achieve a particular goal (Hayes, 
1989). Problem solving is a larger domain of executive function. In general, the 
very term problem solving refers to efforts and ability to do something or solve 
problem successfully with skills and strategies. Problem solving is regard as the 
complex faculty of all intellectual functions. There are no intact solutions for 
solving the problem. Problem solving depends on the nature and complexity of 
the problem. Problems with planning are reported in patients with schizophrenia 
(Kravariti et al., 2007). 
 
Facing problems requires solution. But the action to solve the problem 
requires proper planning to achieve a certain goal. Problem solving is a mental 
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process and goal directed behaviour. The abilities required to solve the problem 
varies depending on the skill sets and confronted problem. Existing knowledge, 
proper planning, motivation and needs are important characteristics of problem 
solving. 
 
The Tower of London test (Shallice, 1982) is widely used 
neuropsychological test measure of planning, sequencing and problem solving. 
The initial investigations by Shallice used the Tower of London were with 
patients with lobe damage (Shallice, 1982). In the computerized version of the 
Tower of London Test, participants presented with the problem in computer 
where they required rearranging a set of coloured balls in the bottom half of the 
computer screen, so that the positions matched the goal arrangement presented 
in the top half of the screen. They consist of varying number tasks with 
increasing difficulty. The starting position of the balls varied. One trial given to 
the participants before the test starts. The participants instructed to complete the 
test as fast as they can with few numbers of moves. The scores are a number of 
solved tasks and total time taken to complete the Tower of London test. But 
different studies use different measures and different number of tasks.  
 
Anderson et al. (1996) study on validation and standardization of the 
Tower of London Test for paediatric population found significant correlations 
between the Tower of London test and other measures of executive function. 
 
Morris et al. (1995) study on problem solving in schizophrenia included 30 
patients with schizophrenia and twenty-seven healthy controls. The participants 
tested on the Three-Dimensional Computerized Tower of London test (3-D CTL 
Test). Their study found that patients with schizophrenia as measured with (3-D 
CTL Test Control) took considerably more moves and solved significantly fewer 
problems in the ten problem moves than healthy controls. The time taken by 
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schizophrenia patients was longer than those of healthy controls. They also 
reported that the response time tends to be longer in schizophrenia patients with 
negative symptoms. Their study suggests a deficit in problem solving among 
schizophrenia patients.  
 
Pantelis et al. (1997) study included thirty-six hospitalized patients with 
chronic schizophrenia. They tested patients using the Computerized Cambridge 
Neuropsychological Test Automated Battery (CANTLAB) and compared with 
those data of healthy controls and patients with the neurological disorders, 
matched age, sex and National Adult Reading Test IQ (NART IQ). The 
CANTLAB is a computer based cognitive assessment system consisting of a 
battery of neuropsychological tests (General memory and learning, working 
memory and executive functions, visual memory, attention and reaction time, 
semantic or verbal memory, and decision making) administered to the 
participants using a touch screen computer. They have tested the higher level of 
planning ability using the CANTLAB Tower of London test. The Tower of 
London task consisted of total 12 problems: 2 trials for each of the 2 and 3 move 
solutions and 4 trials for each of the 4 and 5 move solutions. They also recorded 
measurement of selection (initial movement) and execution (subsequent 
movement) latencies to estimate motor speed. Their study found that patients 
with schizophrenia impaired on visuo-spatial memory span compared with 
other groups. Schizophrenia patients found to be impaired on the spatial 
working memory. On the Tower of London task, they found that patients with 
schizophrenia made fewer perfect solutions and took more number of moves for 
completion. They reported that schizophrenia patients not impaired in their 
initial thinking (planning latencies), but remarkably prolonged subsequent 
thinking (execution) latencies. Their study reported an overall deficit of executive 
functioning in patients with schizophrenia.  
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Morice & Delahunty (1996) study included 17 patients with schizophrenia 
and seventeen healthy controls. All participants were administered the National 
Adult Reading Test (NART) and the eleven subtests of the Wechsler Adult 
Intelligence Scale –Revised to assess the current and premorbid IQ. They also 
administered the Wisconsin Card Sorting test (WCST), the Tower of London test 
(3 each of one-through six move problems) and five tests of short-term memory 
(Digit Span Forward, Word Span Forward, Digit Span Backward, Alphabet Span 
and Sentence Span). Their study found working memory deficits in patients with 
schizophrenia compared with controls. They found no difference in the Tower of 
London performance in the first three levels of complexity. However, they found 
a significant difference in the last three levels between patients and controls. 
Their study suggested that patients with schizophrenia have a deficit in 
processing complex information. 
 
Zhu et al. (2010) study investigated the functional changes in the 
prefrontal cortex of forty first episode schizophrenia patients and 40 age and 
gender-matched healthy controls using multichannel Near-Infrared spectroscopy 
(NIRS), while performing the Tower of London test. They found that patients 
with schizophrenia show a significantly decreased activation in the left 
prefrontal cortex and a poorer performance in the Tower of London test 
compared with the controls participants. This study confirms deficits in planning 
ability among patients with schizophrenia. Their study also found the links 
between reduced left prefrontal activity and test performance. 
 
An extensive review on neurocognitive impairments in patients with 
schizophrenia are presented below (Table 1.5) 
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Table 1.5 Deficits found in Specific Neurocognitive Domains in Schizophrenia 
Patients compared with Healthy Controls, ADHD and Bipolar Disorder. 
Study Participants Findings 
Arango et al., 1999 
 
Schizophrenia 
patients N=85, 
Healthy 
Controls N=36 
Deficits in verbal fluency (Control Oral 
Word Association Test), memory 
(Wechsler Memory Scale-Revised), speed 
of processing and Executive function 
(Trail Making Test A&B), and selective 
attention (Stroop Color and Word Test) in 
patients with schizophrenia. 
 
Øie & Rund, 1999 Schizophrenia 
patients N=19, 
ADHD 
patients N=20, 
Healthy 
controls N=30 
Deficits in verbal memory (California 
Verbal Learning Test), visual memory 
(Kimura Recurring Figures Test), speed of 
processing (Trail Making Test A&B and 
WISC-R Digit Span Test), and executive 
functions (Wisconsin Card Sorting Test, 
Wechsler Intelligence Scale for Children-
Revised similarities) in patients with 
schizophrenia. 
 
Morrison et al., 
2006 
Schizophrenia 
patients N=43, 
Healthy 
controls N=12 
Deficits in verbal and non-verbal 
intelligence in patients with 
schizophrenia. 
 
 
Toulopoulou et al., 
2003 
Schizophrenia 
patients N=25, 
Schizoaffective 
disorder N=5, 
Relatives of 
Schizophrenia 
patients 
N=115, 
Healthy 
controls N=66 
Deficits in verbal immediate recall, visual 
memory/learning (Wechsler Memory 
Scale), working memory (Executive Golf) 
and Planning (3D-Computerized Tower 
of London task) in patients with 
schizophrenia. 
 
 
 
 
 
Silver et al., 2003 Schizophrenia 
patients N=27, 
Healthy 
controls N=37 
Deficits in working memory (WAIS Digit 
Span Tests), attention (Continuous 
Performance Test), and executive 
functions in patients with schizophrenia. 
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Kravariti et al.,  
2003 
Schizophrenia 
patients N=42, 
Healthy 
Controls N=43 
Deficits in attention (Wechsler Memory 
Scale-Revised), verbal memory (Wechsler 
Memory Scale-Revised), visual memory 
(Wechsler Memory Scale-Revised), 
working memory (Executive Golf Task) 
and executive functions (Computer based 
Trial Making Task) in patients with 
schizophrenia. 
McClellan et al., 
2004 
Schizophrenia 
patients 
N=27,Bipolar 
patients N=22, 
Psychosis 
NOS N=20 
Compared to standardized norms, 
deficits found in verbal memory 
(California Verbal Learning Test-Children 
Version), visual memory (Wide Range 
Assessment of Memory and Learning), 
speed of processing (Test of Visual Motor 
Integration), planning and problem 
solving (Controlled Oral Word 
Association) and Executive functions 
(Wisconsin Card Sorting Test) in patients 
with schizophrenia. 
 
Ueland et al., 2004 Schizophrenia 
patients N=22, 
Healthy 
controls N=30 
Deficits in working memory (Digit span 
Backward Task, Wechsler Intelligence 
Scale for Children-Revised), psychomotor 
Speed (Digit Symbol WISC-R), Executive 
functions (Wisconsin Card Sorting Test) 
and visual memory (Kimura Recurring 
Figures test) in patients with 
schizophrenia. 
Mueller et al., 2005 Schizophrenia 
patients N=43, 
Healthy 
controls N=27 
Deficits in verbal fluency found in 
patients with schizophrenia. 
 
 
 
Rhinewine et al., 
2005 
Schizophrenia 
patients N=54, 
Healthy 
controls N=52 
Deficits in verbal memory (California 
Verbal Memory Test), attention (Trial 
Making Test-A /Continuous Performance 
Test) and Executive functions (Wisconsin 
Card Sorting Test; Trail Making Test-B) in 
patients with schizophrenia. 
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Kester et al., 2006 Schizophrenia 
patients N=15, 
Healthy 
controls N=25 
Deficits in planning and problem solving 
(The Iowa Gambling Task) in patients 
with schizophrenia. 
 
 
Rodriguez –
Sanchez et al., 2007 
Schizophrenia 
patients N=26, 
healthy 
controls N=28 
Deficits in speed of information 
processing in patients with 
schizophrenia. 
 
 
González-Blanch et 
al., 2007 
Schizophrenia 
patients 
N=131, 
healthy 
controls N=28 
Deficits in speed of processing/executive 
functions, motor dexterity, motor speed, 
sustained attention and; verbal learning 
and memory in patients with 
schizophrenia. 
 
Landrø and Ueland, 
2008 
Schizophrenia 
patients N=21, 
Healthy 
controls N=28 
Deficits in verbal learning and verbal 
fluency in patients with schizophrenia. 
 
 
 
Ojeda et al., 2008 Schizophrenia 
patients N=90, 
healthy 
controls N=30 
Deficits in verbal fluency, immediate and 
delayed memory in patients with 
schizophrenia. 
 
 
Sánchez et al., 2009 Schizophrenia 
patients N=95, 
healthy 
controls N=53 
Deficits in verbal memory, working 
memory, executive functions and 
processing speed in patients with 
schizophrenia. 
 
Wobrock et al., 2009 Schizophrenia 
patients N=24, 
bipolar 
disorder N=18 
and healthy 
controls N=23 
Deficits in attention, psychomotor 
performance, verbal working memory, 
cognitive flexibility and executive 
functions in patients with schizophrenia. 
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Noh et al., 2010 Schizophrenia 
patients 
N=114, 
healthy 
controls 
N=120 
Deficits in speed of processing, working 
memory, verbal learning & memory, 
attention/vigilance and; reasoning & 
problem solving in patients with 
schizophrenia 
 
 
Zilles et al., 2010 Schizophrenia 
patients N=31, 
healthy 
controls N=47 
Deficits in working memory (different 
working memory tasks) in patients with 
schizophrenia.  
 
 
 
All these research studies indicate overall neurocognitive impairment in a variety 
of domains in patients with schizophrenia. 
 
1.2.4 Discrepancy in Findings on Neurocognitive Impairment in Schizophrenia 
 
There are some studies that show neuropsychological performances in 
patients with schizophrenia to be normal. Liu et al. (2006) study included 122 
schizophrenia patients and 94 healthy control participants. Participants were 
administered a comprehensive neuropsychological test battery (Visual spatial 
ability, verbal ability, verbal memory, execution, visual memory, motor ability, 
metal control and attention). Their study reported that cognitive deficits were 
prevalent among schizophrenia patients but is not a common feature. 
 
The neuropsychological performances of a significant minority of patients 
with schizophrenia are normal (Reichenberg et al., 2009). A study by Palmer et al. 
(1997) administered a comprehensive neuropsychological test battery to 171 
patients with schizophrenia and 63 normal controls. Their study found that 27 
percent of the patients were neuropsychologically normal. A study by 
Holthausen et al. (2002) found 23 out of 118 (19%) patients with first onset 
schizophrenia are cognitively unimpaired. 
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1.2.5 Cognitive Impairment and Functional Outcomes in Schizophrenia 
 
Cognitive impairments connected to poor functional outcomes in patients 
with schizophrenia (Keefe et al., 2006; Green, 1996; Green et al., 2004; Green & 
Nuechterlein, 1999; Heaton & Pendleton, 1981). The cognitive domains most 
reliably connected to functional outcome in schizophrenia includes vigilance, 
immediate or verbal working memory, secondary verbal memory and executive 
functions (Green et al., 2000). Social problem solving, community outcome and 
psychosocial skill acquisitions are related functional outcomes (Goldberg & 
Green, 2002). Patients with schizophrenia often lack the ability to solve the 
problem left by stressful life events leads to poor quality of life. 
 
Cervellione et al. (2007) study included twenty-six schizophrenia early 
onset patients and twenty-six healthy controls. They examined by means of a 
comprehensive neuropsychological test battery, a median of thirteen months 
after a baseline testing. They examined the stability scores and relationship 
between baseline performances. In their study, schizophrenia patients impaired 
across neurocognitive variables at baseline and follow-up compared to healthy 
control participants. They also found the deficits remained stable over time. 
Their study found that follow-up social, communication, personal living and 
community living skills related to the working memory, verbal memory, 
attention/vigilance at a baseline; and specific cognitive spheres more strongly 
associated to functional outcomes.  
 
Sánchez et al. (2009) study included 95 patients with schizophrenia and 
fifty-three healthy control participants. All participants were given a battery of 
neuropsychological tests includes test for working memory, verbal memory, 
processing speed and executive functioning. They assessed the functional 
disability after six months follow-up with the Disability Assessment Schedule  
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after the neuropsychological and clinical examination. They found that 
schizophrenia patients perform worse than the healthy controls on all 
neurocognitive domains. They also found that most neurocognitive domains 
related with the patients functional disability shown after six months after 
admission to the study including vocational outcomes, self-care, family contact 
and social functioning. In their study, performance on processing speed 
associated to clinical, social and functional outcomes in patients with 
schizophrenia.  
 
Ojeda et al. (2008) study included 90 hospitalized patients with 
schizophrenia and thirty healthy control participants. They administered 
neuropsychological test battery includes tests for verbal memory, verbal fluency, 
motor speed, processing speed. They examined outcome measures using 
Disability Assessment Schedule (DAS-WHO) and number of hospitalizations. 
Their results confirmed the chronicity of clinical symptoms and impairment on 
functional disability. They found that verbal fluency, immediate and delayed 
memory predicts the functional outcome. After adding processing speed into 
regression analyses, the significance in verbal fluency and verbal memory 
declined significantly. They suggested that processing speed may be a central 
factor in relation between cognitive symptoms and functional outcomes in 
patients with chronic schizophrenia. 
 
All these studies show the cognitive deficits in patients with 
schizophrenia. 
 
 
 
38 
 
 
1.3 Sleep 
    “Sleep is the golden chain that ties health and our bodies together” 
Thomas Dekker 
Sleep is a complex, natural, reversible state occurring at regular intervals 
generated and regulated by different complex neuronal systems (Norwood & 
Teofilo Lee-Chiong, 2006; Teofilo Lee-Chiong, 2008). Previously, sleep was 
considered to be a passive state of brain. This supposition was invalidated by 
innovative experiments of Bremer in 1930 and it was recognized that sleep is 
actively produced by activity in particular regions of the brain. In 1937, Loomis et 
al. was first to notice that sleep is dissimilar during the entire night. Loomis et al. 
elucidated the different sleep stages based on EEG (Loomis et al., 1937). In 1953, 
Nathaniel Klietman a professor emeritus in physiology at the University of 
Chicago along with his student Eugene Aserinsky have been studying sleep 
difficulties in infants noticed the occurrence of rapid eye movements in sleeping 
infants (Aserinsky & Kleitman, 1953). This remarkable finding gave way to 
identify two individual states within sleep: non-rapid eye movement (non-REM) 
sleep and rapid eye movement (REM) sleep (Latta & Van Cauter, 2002). In 1957, 
Dement and Klietman in the study on dreaming and stage of sleep tested five 
subjects, waking them various times during the night (both during REM and 
NREM sleep) to test their dream recall. Their study found a significant 
association between REM sleep and dreaming (Dement & Kleitman, 1957).   
 
 
1.3.1 Polysomnography 
 
Polysomnography is considered as the single most important laboratory 
technique in a sleep study, using precise electrophysiological techniques 
(Chakroverty, 2003). Polysomnography consists of electrophysiological recording 
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of the brain cerebral cortex activity by electroencephalography (EEG), 
movements of eye by electrooculography (EOG) and muscle tone by 
electromyography (EMG).   
 
The electroencephalography is considered to be the dynamic electro 
physiologic procedure that evaluates the functions of the brain. The first 
electroencephalogram tracing from human was recorded by the German 
Physiologist Hans Berger in 1928. The electroencephalogram records the 
electrical activity and waveforms produced by cortical neurons (Westmoreland, 
2009). Electrooculography is a procedure for measuring the difference in 
potentials between the cornea and retina. Electromyography is a procedure for 
examining and recording electrical activity produced by skeletal muscles. This 
measurement aids the deduction of REM sleep (Rechtschaffen and Kales, 1968). 
 
The electroencephalogram, electrooculogram and electromyogram have 
become primary the means of monitoring the stages of human sleep. The 
recordings obtained can be scored visually as either wakefulness or the various 
stages of sleep.  
 
1.3.2 Sleep Stages and Scoring 
 
A criterion for scoring the stages of sleep based on EEG was first described 
by Loomis et al in 1937. They classified different EEG sleep features into 5 levels 
(A to E) (Davis et al., 1938). K-complex was first described by them in 1938. The 
etiology of naming as K-complex remains unclear (Ernst Niedermeyer, 2005). The 
stages of sleep proposed by Loomis et al are shown below in the table 1.6 
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Table 1.6 Old Terminology of Sleep Stages used by Loomis et al (1937) 
A Interrupted Alpha Normal waking 10 per 
second rhythm pattern 
B Low Voltage Alpha rhythm lost 
C Spindles Spindles of 14 per sec 
waves and random delta 
waves 0.2 per second 
D Spindle plus random Both types of waves 
increase in voltage, delta 
waves become stronger 
E Random Delta waves continues to 
increase in voltage and 
wavelength 
 
The sleep scoring was changed by Dement and Kleitman in 1957 after a 
serendipitous discovery of REM sleep. Dement and Kleitman classifications of 
sleep stages were shown below in the table 1.7 
 
Table 1.7 Dement & Kleitman Classification of Sleep Stages.  
1 Drowsiness From alpha dropout to 
vertex waves 
2 Light Sleep Spindles, vertex waves 
Complexes 
3 Deep Sleep Much slowing, K -
complexes, some spindles 
4 Very Deep Sleep Much slowing, Some K-
complexes 
REM REM Sleep desynchronization with 
faster frequencies 
 
Dement & Klietman criteria for scoring sleep stages were standardized by 
Rechtschaffen and Kales in 1968. After Rechtschaffen and Kales manual on sleep 
stage scoring was published, dramatic changes occurred in human sleep research 
(Silber et al., 2007). This manual is widely used for the scoring of the sleep stages. 
Rechtschaffen and Kales manual on sleep stage scoring was show below on table 
1.8 
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Sleep consists of two main states: non-rapid eye movement (non-REM) 
sleep and rapid eye movement (REM) sleep. Non rapid eye movement (non-
REM) sleep is further classified into four stages from the sleep stage 1 to sleep 
stage 4. Sleep stages 3 and 4 in non-REM are referred to as slow wave sleep 
(SWS) or deep sleep stage or delta sleep. The non-REM sleep is also called 
orthodox sleep. The first half of the night is dominated by NREM sleep and REM 
sleep will be greatest during the rest of the night. REM sleep occurs during the 
night that changes with NREM sleep for every 90 to 120 Minutes in the night. 
The arousal thresholds commonly lowest in sleep stage 1 and highest in sleep 
stage 4. Generally, rapid eye movement sleep and non-REM sleep periods 
substitute cyclically all over the night (Figure 1.1). The percentage and frequency 
of sleep stages varies during the night - in the early hours of sleeping slow wave 
sleep dominates, whereas REM sleep occurs very often in the second part of 
sleep (Rechtschaffen & Kales., 1968; Susmakova, 2004). REM sleep is also called 
paradoxical sleep. The sleep architecture will change during the different stages 
of lifespan of human life. 
 
 
Figure 1.1 Sleep Cycle Associated With Whole Night Sleep 
        (Picture from Thinquest stages of sleep, web: www.thinkquest.org) 
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Table 1.8 Rechtschaffen & Kales (1968) Scoring Sleep Stages 
 
STAGE ELECTROENCEPHALO
GRAM 
ELECTROOCULO
GRAM 
ELECTROMYOG
RAM 
STAGE 
WAKE 
* Alpha activity, and/or low voltage, 
mixed frequency activity. 
Often REMs. Usually not necessarily 
accompanied by high tonic 
EMG. 
STAGE 1 * A relatively low voltage, mixed 
frequency EEG without rapid eye 
movements (REMs) 
* Decrease in the amount, amplitude and 
frequency of alpha activity. 
* Scoring stage 1 requires absolute 
absence of clearly defined K-complexes 
and sleep spindles. 
* Vertex sharp wave may appear in 
conjunction with high amplitude 2-7 cps 
activity. The amplitude of the vertex is 
occasionally as high as 200µV. 
 
Characterized by the presence of 
slow eye movements each of 
several seconds duration. 
 
Rapid eye movements are absent. 
Tonic EMG levels are usually 
below those of relaxed 
wakefulness. 
STAGE 2 * Low voltage, mixed frequency EEG. 
* Presence of sleep spindles and (or) k-
complexes. 
* Spindle between 12-14 cycles per 
second (cps) of at least 0.5 sec. 
* K-complex-Negative sharp wave 
immediately followed by a positive 
component with a total duration should 
exceed 0.5 second. 
* Long periods may intervene between 
sleep spindles and k-complexes.  
* Absence of sufficient high amplitude, 
slow activity that defines stages 3 and 4. 
* If less than 3 minutes of record meeting 
requirements for stage 1 occur between 
sleep spindles and or K-Complexes in the 
absence of movement arousals or 
pronounced increases in muscle tone, 
intervening epochs are considered stage 
2. The intervening epochs are scored as 
stage 1 if the interval without sleep 
spindles or K-complexes lasts minutes or 
longer. 
 Low EMG activity. 
STAGE 3 * At least 20% but < not more than 50% 
of the epoch consists waves of 2 cps or 
slower waves having amplitudes greater 
than 75 µV from peak to peak. 
 Low EMG activity. 
STAGE 4 * More than 50% of the epoch consists of 
2 cps or slower waves having amplitude 
greater than 75 µV from peak to peak. 
 Low EMG activity. 
STAGE 
REM 
* Relatively low voltage, mixed 
frequency EEG activity. 
* Resembles stage 1. 
Vertex sharp waves are not prominent. 
* Saw tooth waves may seen. 
* Absence of sleep spindles and K-
complexes. 
 
 Low Amplitude 
electromyogram (EMG). 
MOVEME
NT TIME 
Scoring epoch during which polygraph 
record is obscured by movements of the 
subject. 
EOG tracings obscured in more 
than half of the epoch by muscle 
tension and or amplifier 
blockings. 
The change in pattern may 
consist either an increase in 
amplitude of the EMG signal 
or an amplifier blocking. 
Source: Modified and adapted from Rechtsschaffen, A & Kales, A manual Of 
Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human 
Subjects. Public health service, U.S. Government Printing Office, Washington, D.C., 1968  
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1.3.2.1 Microstructures of Sleep EEG 
 
Microstructures of sleep relay on quantification of phasic events like K-
complexes and spindles. Quantifying the microstructures of sleep like K-complex 
and spindles would give additional insight about the role of more specific sleep 
variables (Muzet, 2005). The changes and variances in the occurrence and 
frequency of sleep related phasic events may be associated with specific 
psychiatric disorders and may give insight into diagnostic improvements in the 
prognosis of complex psychiatric disorders (Muzet, 2005). 
1.3.2.1.1 K-complexes 
K-complexes are frequently seen in sleep stage 2 and prominent feature in 
non-REM sleep (Rechtschaffen & Kales, 1968; Happe et al., 2002; Muzet, 2005).  
 
 
                        Figure 1.2 Picture of K-complex in sleep EEG 
 
The K-complex is defined as large amplitude greater than 75μV negative-
positive wave, exceeding 0.5 sec duration (Rechtschaffen & kales, 1968). 
 
1.3.2.1.2 Neurophysiology of the K-complexes 
 
In sleep stages, the more K-complexes were indicative of deeper sleep 
(sleep stage2). The K-complexes are more frequent as the proximity of the slow 
wave sleep increases (Halasz et al., 1977; Colrain, 2005). Different studies 
explained the functions of K-complexes in variable terms. K-complexes are sleep-
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related evoked EEG phenomenon (Colrain & Crowley, 2005). K-complexes might 
be a sleep protective function (Wauquier et al., 1995; Vetter & Boker, 1962). K-
complexes engaged in sleep specific information processing during sleep 
(Colrain, 2005). K-complex carries characteristics of evoked potentials, which 
caters subattentive information processing (Muzet, 2005).  
 
Hálasz work long suggested that “K-complexes are complex 
multifunctional phenomenon of sleeping brain involved in information 
processing and defence against the arousal effect of sensori stimuli” (Hálasz et 
al., 2005). Further studies also accepted the view that k-complexes are reflective 
of a brain state that is conducive to sleep (Wauquier at al., 1995). Given new 
orientation of research about K-complexes indicated by researchers, it is 
reasonable to relate sleep specific information processing and sleep protective 
mechanism. 
 
1.3.2.1.3 Spindles 
 
The presence of sleep spindles is most common in sleep stage 2 NREM 
sleep (Rechtschaffen and Kales, 1968; Fogel et al., 2007). Sleep spindles been 
widely employed in sleep research. Sleep spindles and K-complexes are transient 
phenomena that may intervene between two events without change in sleep 
stage (Rechtschaffen and Kales, 1968).  
 
 
           Figure 1.3 Picture of sleep spindle in sleep EEG 
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1.3.2.1.4 Neurophysiology of Spindles 
 
Sleep spindles are associated with activation of the thalamus (Liu et al., 
2008). The sleep spindles are often seen over the central and frontal head regions 
(Shih et al., 2000). Sleep spindles are consequences of communication between 
cells in the thalamus and cortex. Spindles are mostly produced in the thalamus 
that co-ordinates incoming stimuli and sends it along to the cerebral cortex 
(Ferrarelli et al., 2007; Ferrarelli & Tononi, 2011). Sleep spindle activity is 
associated with the integration new information into existing knowledge 
(Tamminen et al., 2010).  
          
Gibbs and Gibbs (1962) study on the correlation of EEG sleep pattern with 
mental retardation reveals that individuals with mental retardation have unusual 
spindles. Later studies linked the dysfunctions of thalomacortical loops and 
abnormal spindles. Fogel et al. (2007) study examined the relationship between 
spindles and intelligent quotient. Their study found a positive correlation 
between intelligent quotient and number of spindles. A study by Clemens et al. 
(2005) on sleep related consolidation found a connection between sleep spindle 
activity and verbal memory consolidation.  
 
Figure 1.4 Sleep EEG and Wave Patterns of Different Stages (Source: Horne, J. A. (1988) Why 
We Sleep, The Function of Sleep in Humans and Other Mammals (Oxford University Press, 
Oxford). 
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1.3.3 Functions of Sleep 
 
Sleep is one of the most basic and important human drives. During sleep, 
growth and repair of tissues of the body are thought to occur and energy is 
conserved and stored (The American Heritage Science Dictionary, 2011). Sleep 
theories elucidate the important role of sleep for conservation of energy, neural 
growth and processing, thermoregulation, somatic growth regulation, memory 
and learning. There are two prominent theories about the functional purpose of 
sleep - Restoration theory and Ecological theory. 
 
1.3.3.1 Restoration Theory 
 
Restoration theory is also known as recuperative or restitutive theories. 
Restorative theories are based on the ideas of animals sleep. Sleep offers a chance 
for the human body to perform biochemical and physiological repairs while 
dedicating energy to repair and recovery of the human immunological and 
nervous system for proper functioning. Accordingly, the major function of sleep 
is to restore tissue and save energy (Oswald, 1966). 
 
 
      Figure 1.5 Physiological Restorations during Sleep (Oswald, 1966; Oswald  
       & Adam, 1984) 
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Stern and Morgane (1974) theoretical view of REM sleep function suggests 
that the function of REM sleep is to restore the level of neurotransmitters after 
daily activities.  
 
Further empirical evidence in support of restoration theory given by 
Shapiro and Colleagues in 1981. They performed sleep recordings in marathon 
runners for 4 successive nights followed by a 92 kilometres run. The study found 
significant increase in total sleep time and slow wave sleep (SWS) after a 
metabolic stress. Their finding demonstrates confirmed exercise effect of sleep 
and support for sleep restoration theory.  
 
Berry and Webb (1983) studied the relationship between sleep and mood 
variables among 36 male and 39 females. Their study correlated the data of two 
night sleep recordings with five mood scales of the Lorr Mood Scale 
administered prior to second night. They compared the correlation of first night 
sleep and mood variables with those obtained from the same mood variables and 
second night sleep. It was found that the people who slept well during given 
night had less anxiety on the next day compared to the people who had poor 
sleep or disturbed night sleep (Berry & Webb, 1983).   
 
Horne (1988) extends the idea of sleep pioneer Oswald. He developed a 
theory that incorporates aspects from both adaptive and restorative theories. 
According to his theory, sleep is divided into essential and optional components. 
Essential is core sleep consists slow wave sleep (SWS); while optional sleep is 
sleep stage 1, sleep stage 2 and REM. Core sleep is extremely beneficial for 
normal functioning of the brain, while time spent on lighter stages (stage 1 and 2) 
and REM sleep are only optional.  
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1.3.3.2 Ecological Theory 
 
Ecological theory is also known as behavioural theories. Ecological theory 
complies with restoration theory in terms of sleep and its purpose. Ecological 
theory focuses sleep from an evolutionary perspective. The observation of 
difference in sleep pattern and sleep duration between birds, mammals, animals 
and man led to evolutionary theory of sleep. Evolutionary theory suggests sleep 
is not necessary but, serve as an important survival function. Meddis (1975) 
articulates that sleep pattern in any species depends on the necessity to adapt 
threats in the environment and dangers. For some animals, sleep serve as 
function of keeping them fairly immobile and safe from predators. But, species in 
threat and danger from predators sleep relatively little to remain vigilant. He 
also suggests that the duration of sleep in species depends on predator avoidance 
and food requirements. All these theories show the varied functions of sleep. 
 
1.4 Sleep and Schizophrenia 
 
Sleep disturbances are common in patients with schizophrenia (Monti & 
Monti, 2006; Manoach & Stickgold, 2009), it may either due to distressing 
symptoms or side effect of antipsychotic medication (Benson, 2008; Monti & 
Monti, 2006). Sleep disturbances in patients with schizophrenia include difficulty 
in initiating and maintaining sleep, poor sleep efficiency, reduced total sleep 
time, day time fatigue that affects day today tasks. Sleep disorders are part of the 
clinical picture in schizophrenia. Thirty to eighty percent of patients with 
schizophrenia are found to have sleep disturbances (Cohrs, 2008). There is a 
unique relationship between the pathology of schizophrenia and poor sleep 
(Norwood and Lee-Chiong, 2006). In general, sleep appear to worsen during 
acute episodes (Kupfer et al., 1970), and improves following antipsychotic 
medication treatment (Krystal et al., 2008), or during remission. However, even 
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medicated and clinically stable patients subjectively experience chronic sleep 
disturbances.  
 
Early Studies in Sleep and Schizophrenia 
 
Earlier sleep studies in schizophrenia examined the promising role of 
REM sleep intrusions in the pathogenesis of schizophrenia (Benson, 2008). REM 
sleep abnormalities are not consistently replicated in successive studies, so the 
focus turned to evaluate the other features of sleep architecture like sleep latency, 
total sleep time, sleep efficiency, sleep stage 3 and 4, slow wave sleep, REM 
latency and quantification of spindles. 
 
1.4.1 Polysomnographic Features in Schizophrenia 
 
Distinctive sleep patterns may be one of markers in schizophrenia 
patients. Sleep parameters are divided into three groups: sleep continuity (sleep 
latency, number of wakening and wake after sleep onset, sleep efficiency, total 
sleep time), sleep architecture (The percentages of sleep stage 1, 2, 3 and 4, and 
stage REM), and REM sleep measures (REM latency). An extensive review of 
sleep parameters impairments in patients with schizophrenia are given below. 
 
 
1.4.1.1 Sleep Continuity  
 
Number of Wakening and Wake after Sleep Onset 
 
Increased wake time after sleep onset and number of awakening are 
reported impairments in sleep in patients with schizophrenia. Ganguli et al. 
(1987) study included 8 young never-medicated schizophrenia patients, 8 with 
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delusional depression, sixteen non-delusional depression and sixteen healthy 
controls. They conducted two consecutive nights of polysomnography. They 
found that patients with schizophrenia show increased wakefulness after sleep 
onset compared to other groups.  
 
Lauer et al. (1997) polysomnographically examined twenty-two drug-
naive patients with schizophrenia, paranoid type and twenty healthy controls. In 
addition, they assessed the ventricular brain ratio by means of computerized 
tomography. They found an increased wake time after sleep onset in patients 
with schizophrenia, specifically during first non-REM period compared to 
healthy controls.  
 
Yetkin et al. (2011) study on sleep architecture in patients with 
schizophrenia included thirteen adult male inpatients with schizophrenia, 
undifferentiated type and an age- and sex-matched group of healthy controls. 
They conducted polysomnographic recordings. They found more awakenings 
and increased duration of awakenings after falling asleep among schizophrenia 
patients compared to the healthy controls. 
 
These studies confirm the poor continuity of sleep in patients with 
schizophrenia. 
 
1.4.1.1.1 Total Sleep Time 
 
The reduced of total sleep time was observed in patients with 
schizophrenia. Yetkin et al. (2011) study on sleep architecture in schizophrenia 
patients included thirteen adult male inpatients with schizophrenia, 
undifferentiated type and an age- and sex-matched group of healthy controls. 
They conducted polysomnographic recordings and scored sleep EEG according 
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to Rechtschaffen and Kales, 1968 standard criteria. They found less total sleep 
time in patients with schizophrenia compared to the healthy controls. 
 
1.4.1.1.2 Sleep Efficiency 
 
Sleep efficiency is the ratio of time spent asleep to the amount of time 
spent in bed. Poor sleep efficiency is another impaired sleep parameter reported 
in patients with schizophrenia. Keshavan et al. (1998) study included thirty 
unmedicated patients with schizophrenia and thirty age and sex-matched 
healthy controls. They visually scored sleep data as well as used automated 
period amplitude analyses and power spectral analyses. They found reduced 
sleep efficiency in patients with schizophrenia compared to healthy controls. 
 
Yetkin et al. (2011) study on sleep architecture in schizophrenia patients 
included thirteen adult male inpatients with schizophrenia, undifferentiated type 
and an age- and sex-matched group of healthy controls. They conducted 
polysomnographic recordings. They found lower sleep efficiency in patients with 
schizophrenia compared to healthy controls. 
 
These studies show poor sleep efficiency in patients with schizophrenia. 
 
 
1.4.1.1.3 Sleep Onset Latency 
 
Sleep onset latency is the length of time taken for the transition of sleep 
from full wakefulness to sleep stage 1. Increased sleep onset latency is one of 
impaired sleep parameters reported in patients with schizophrenia. Keshavan et 
al. (1998) study included thirty unmedicated patients with schizophrenia and 
thirty age and sex-matched healthy controls. They visually scored sleep data as 
well as used automated period amplitude analyses and power spectral analyses. 
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They found longer sleep latency in patients with schizophrenia compared to 
healthy controls. 
 
Hoffmann et al. (2000) study compared the quantitative EEG measures 
during non-REM sleep among age-matched symptomatic unmedicated 
schizophrenia patients, depressed and healthy control men. They included 
thirteen participants in each group. They scored sleep data according to 
Rechtschaffen and kales 1968 standard criteria. They found that sleep latency in 
schizophrenia group was three times longer than healthy controls and twice as 
long as in depressive group. 
 
Yang and Winkelman (2006) study investigated the relationship between 
clinical symptom severity and sleep EEG parameters in a relatively 
diagnostically similar group of patients with schizophrenia. They obtained sleep 
EEG data in fifteen drug-free inpatients with schizophrenia, undifferentiated 
type and sex-matched healthy controls. They visually scored sleep EEG data 
according to Rechtschaffen and kales 1968 standard criteria. Their study reported 
profound difficulties in sleep initiation in patients with schizophrenia. 
 
Yetkin et al. (2011) study on sleep architecture in patients with 
schizophrenia included the thirteen adult male inpatients with schizophrenia, 
undifferentiated type and an age- and sex-matched group of healthy controls. 
They conducted polysomnographic recordings and scored sleep EEG according 
to Rechtschaffen and kales 1968 standard criteria. Their study reported longer 
sleep latency in schizophrenia patients. 
 
These studies show impaired sleep onset latency in patients with 
schizophrenia. 
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1.4.1.2 Sleep Architecture 
 
1.4.1.2.1 Slow Wave Sleep 
 
 
Slow wave sleep is thought to be the most “restorative” sleep. Slow wave 
sleep was generally found to be decreased in patients with schizophrenia. The 
most reliable sleep EEG abnormality in schizophrenia is slow wave sleep (SWS) 
deficit. Keshavan et al. (1998) study compared sleep data of visually scored as 
well as automated period amplitude analyses and power spectral analyses of 
thirty unmedicated schizophrenia patients and thirty age and sex-matched 
healthy controls. They found a decreased visually scored delta sleep in patients 
with schizophrenia compared to healthy controls.  
 
Yang and Winkelman (2006) study investigated the relationship between 
clinical symptom severity and sleep EEG parameters in a relatively 
diagnostically similar group of patients with schizophrenia. They obtained sleep 
EEG data in fifteen drug-free inpatients with schizophrenia, undifferentiated 
type and sex-matched healthy controls. They visually scored the sleep EEG data 
according to Rechtschaffen and kales 1968 standard criteria. They found a 
profound slow wave sleep deficit in schizophrenia patients compared to the 
healthy controls.  
 
While these studies show slow wave sleep deficits in patients with 
schizophrenia. On contrary, Ganguli et al. (1987) and Yetkin et al. (2011) studies 
on sleep EEG in patients with schizophrenia did not find slow wave sleep deficits 
in patients with schizophrenia. 
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1.4.1.3 Stage REM 
 
Reduced percentage of REM sleep also frequently reported in patients 
with schizophrenia. Evidence for a disinhibition of REM sleep mechanisms is 
inconsistent. Yetkin et al. (2011) study on sleep architecture in patients with 
schizophrenia included the thirteen adult male inpatients with schizophrenia, 
undifferentiated type and an age- and sex-matched group of healthy controls. 
They conducted polysomnographic recordings. In their study, the percentage of 
REM sleep was reduced in patients with schizophrenia compared to healthy 
controls.  
 
1.4.1.4 REM Sleep Measures 
 
1.4.1.4.1 REM Sleep Latency 
 
Reduced REM sleep latency frequently reported in patients with 
schizophrenia. Poulin et al. (2003) study included eleven patients with acute 
schizophrenia drug-naive with eleven healthy controls. They scored sleep stages 
and visually identified the phasic events occur during REM sleep. They found 
reduced REM sleep latency in patients with schizophrenia compared to the 
healthy controls.  
 
On contrary, Yetkin et al. (2011) study on sleep architecture found no 
significant difference in REM sleep latency between schizophrenia patients and 
healthy controls. 
 
An extensive review on sleep EEG in patients with schizophrenia is presented 
below in the table 1.9 
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Table 1.9 Review on Sleep EEG Abnormalities in Patients with Schizophrenia. 
Research study Population Clinical 
information 
Findings of the 
study 
Kempenaers et al., 
1988 
Schizophrenia 
patients N=9 
Controls N=9 
Depression N=9 
 
Inpatients with 
schizophrenia. 
 
Poorly efficient 
sleep due to 
delayed sleep 
onset. 
Tandon et al., 
1992 
Schizophrenia 
patients N=40, 
Controls N=15 
20 drug-naive 
patients with 
schizophrenia, 
20 drug free but 
previously 
medicated patients 
with 
schizophrenia. 
Drug naive and 
previously 
medicated 
patients had 
significantly 
greater 
impairment of 
sleep continuity 
and shorter REM 
latency compared 
with controls 
 
Riemann et al., 
1995 
Schizophrenia 
patients N=10, 
Controls N=10, 
Major depressive 
disorder N=10 
 
Inpatients with 
schizophrenia. 
Impairments in 
sleep efficiency. 
Benson et al., 1996 Schizophrenia 
patients N=14, 
nonpsychiatric 
comparison 
subjects N= 15 
 
Inpatients with 
schizophrenia. 
In patients with 
schizophrenia, 
they found long 
sleep latencies, 
reduced sleep 
efficiency, stage 4 
deficit and short 
REM latency. 
 
Lauer et al., 1997 Schizophrenia 
patients N=22, 
Controls N=20 
Drug-naive 
patients with 
schizophrenia- 
Paranoid type. 
Compared with 
controls patient 
with 
schizophrenia 
showed reduced 
total sleep time, 
reduced sleep 
efficiency, 
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reduced sleep 
stage 2, increased 
sleep onset 
latency, more 
number of 
awakenings and 
increased amount 
of wakening. 
 
Röschke et al. 
1998 
Schizophrenia 
patients N=11, 
Controls N=11 
 
Inpatients with 
schizophrenia. 
REM Latency. 
Keshavan et al., 
1998 
Schizophrenia 
patients N=30, 
Controls N=30 
 
 
Unmedicated 
patients with 
schizophrenia. 
Schizophrenia 
patients showed 
Reduced delta 
sleep, reduced 
total sleep time, 
reduced sleep 
efficiency and 
sleep latency 
compared with 
healthy controls. 
 
Hoffmann et al., 
2000 
Schizophrenia 
patients N=13, 
Controls N=13 
Major depressive 
disorder N=13 
Symptomatic but 
unmedicated 
patients with 
schizophrenia. 
Sleep latency in 
patients with 
schizophrenia was 
three times longer 
than normal 
controls and twice 
than depressive 
disorder. 
 
Poulin et al., 2003 Schizophrenia 
patients N=11, 
Controls N=11 
Acute 
schizophrenia 
never treated with 
neuroleptics. 
 
Compared with  
healthy controls, 
patients with 
schizophrenia 
showed: 
Decreased stage 4, 
reduced REM 
sleep latency, 
difficulty in 
initiation of sleep. 
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Yang & 
Winkelman., 2006 
Schizophrenia 
patients N=15, 
controls N=15 
Inpatients with 
schizophrenia. 
Profound 
difficulties in 
sleep initiation 
and maintenance, 
poor sleep 
efficiency, slow 
wave sleep deficit 
and increased 
REM density 
among patients 
with 
schizophrenia. 
 
 
 
1.4.1.5 Microstructures of Sleep EEG in Schizophrenia 
 
While there is sufficient information and significant research on 
macrostructures of sleep EEG in schizophrenia, not many studies have been 
conducted on the microstructures of sleep EEG in schizophrenia. 
 
1.4.1.5.1 K-complexes and Schizophrenia 
 
There are no studies reported abnormalities in K-complexes in patients 
with schizophrenia. 
 
1.4.1.5.2 Spindles and Schizophrenia 
  
Ferrareli et al. (2010) investigated spindle deficits in a larger sample of 
schizophrenia patients. They performed whole night EEG recordings in 49 
patients with schizophrenia, 20 non-schizophrenia patients receiving 
antipsychotic medication and 44 healthy controls. They assessed slow wave 
sleep. They reported that the spindle deficits can be reliably established in 
patients with schizophrenia. 
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Ferrarelli et al. (2007) engaged with a 256-electrode high density EEG to 
examine sleep rhythms variations between patients with schizophrenia, healthy 
controls and people with history of depression. Their study included 17 healthy 
controls, 18 medicated schizophrenia patients and 15 participants with history of 
depression. They recorded the first sleep episode of the night with 256-electrode 
high density EEG and analyzed for variations in EEG power spectra, power 
topography and sleep specific cortical oscillations. They found a reduced sleep 
spindle activity, number of spindles, amplitude, duration and integrated spindle 
activity in schizophrenia patients. A review on sleep EEG microstructures in 
schizophrenia is presented as follows (Table 1.10). 
 
Table 1.10 Review on Sleep EEG Microstructure abnormalities in 
Schizophrenia. 
 
Research Study Population Clinical 
Information 
Findings 
Ferrarelli et al., 
2007 
Schizophrenia 
patients N=18, 
Controls N=17, 
Depression N=15 
Medicated 
patients with 
schizophrenia. 
Reduced number 
of spindles, 
amplitude, 
duration and 
integrated spindle 
activity in 
schizophrenia 
patients. 
 
Ferrarelli et al., 
2010 
Schizophrenia 
patients N=49, 
Controls N=44, 
Non schizophrenic 
taking 
antipsychotic 
medication N=20 
 
Patients with 
schizophrenia on 
antipsychotic 
medication 
Patients with 
schizophrenia 
showed spindle 
deficit. 
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1.4.1.6 Medications and their Effects on Sleep in Schizophrenia 
 
The key treatment to improve sleep in schizophrenia patients is 
administrating medications that have effects on neurotransmitter systems which 
play a pivotal role in sleep wake functions (Krystal et al., 2008). Antipsychotic 
medications often improve and reverse sleep architectural abnormalities in 
schizophrenia patients (Krystal et al., 2008). Presently used antipsychotic 
medications are divided into typical and atypical agents (Norwood & Lee-
Chiong, 2006). Previous studies have examined the effects of the first generation 
antipsychotics on sleep of schizophrenia patients by means of polysomnographic 
methods (Benson, 2008). Empirical studies of the medication effects on sleep in 
patients with schizophrenia treated with second generation antipsychotics 
examined the effects of atypical antipsychotics like clozapine, risperidone, 
olanzapine and paliperidone (Benson, 2008). 
 
Salin-Pascual et al. (1999) examined 20 drug free inpatients with 
schizophrenia (DSM-IV). They polysomnographicaly tested patients for 5 
consecutive nights: 1 adaption night; 2 base line nights (first for sleep disorder 
screening); and 2 nights with olanzapine medication - atypical antipsychotic 
(10mg olanzapine, one hour before sleep onset). They found that sleep continuity 
variables and total sleep time show overall improvement. They found reduced 
sleep stage 1, while sleep stage 2 and delta wave were significantly enhanced. 
They also found an increase in Rapid eye movement density by second 
medication night. They concluded that the total sleep improvement was due to 
increase in sleep stage 2 and delta sleep. 
 
Lee et al. (2001) study included five patients with schizophrenia and five 
age and sex-matched healthy controls. All participants underwent nocturnal 
polysomnography before atypical anti-psychotic agent clozapine therapy, during 
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early and late clozapine therapy. They monitored serum and cortisol level during 
each nocturnal polysomnography. In their study, clozapine improved sleep 
continuity and increased sleep stage 2 from the beginning of therapy.  
 
Neuroleptic withdrawal often associated with sleep disturbances in 
patients with schizophrenia (Nofzinger et al., 1993). Neylan et al. (1992) study 
included eighteen clinically stable male patients with schizophrenia taking 
haloperidol. They examined three nights of polysomography for baseline 
measures and later after again neuroleptic withdrawal. They obtained sleep 
measures at the point of relapse (n=9) or after a six weeks drug free period if the 
patient with schizophrenia continued to remain clinically stable (n=9). They 
found neuroleptic withdrawal lead to decline REM and non-REM sleep and a 
reduction of REM latency in both groups. They further reported that relapsers 
varied from non-relapsers in that they had a significant decrease in sleep 
efficiency, total sleep time, sleep stage 2 and non-REM sleep. They also reported 
that the level of psychosis inversely correlated with sleep efficiency, total sleep 
time; sleep stage 4 in the drug free patients.  
 
Chouinard et al. (2004) in their large meta-analysis investigated sleep 
characteristics in schizophrenia patients without neuroleptic treatment at the 
time of polysomnography recording. They investigated 20 sleep studies included 
652 participants (321 schizophrenia patients and 331 healthy controls) on several 
sleep parameters including sleep latency, total sleep time, sleep efficiency index, 
total awake time, sleep stage 2 percentage, sleep stage 4 percentage, slow wave 
sleep percentage, REM sleep percentage and REM latency. They found that 
schizophrenia patients have increased sleep latency, decreased total sleep time 
and decreased sleep efficiency index. In moderator analysis, they reported that 
sleep problems were worse for the neuroleptic withdrawal group relatively than 
never treated group. They also found that never treated schizophrenia patients 
61 
 
 
show significantly increased total awake time and diminished sleep stage 2 
percentage. They indicated that sleep disorders may be magnified by residual 
effects of neuroleptic withdrawal, while rest seemed to be attenuate by 
neuroleptic treatment.  
 
  These studies on consequence of antipsychotic medications in sleep in 
schizophrenia patients show improvement in sleep architecture and 
maintenance. 
 
1.4.1.7 Discrepancy and Inconsistency in Sleep EEG Findings in Schizophrenia 
 
The factors that could influence sleep EEG findings in schizophrenia 
include heterogeneity of duration of illness, diagnoses, patient selection criteria, 
clinical symptomatology and chronicity of illness. It is evident that sleep EEG 
findings in schizophrenia patients are inconsistent and discrepant. Some of the 
reasons for the inconsistency are: the difference in scoring methods, non-
standardized diagnostic criterion, several sleep studies have not included 
habituation night so sleep parameters reported were worse and incomplete 
adaptation to the change in sleep environment may also one of causative factor 
for variations. Some other influential variables cannot be denied include, sample 
selection (inpatient or outpatient), age, gender and co-morbidity. 
 
As discussed above, medications and their effects are also a primary 
concern. Several studies included patients taking neuroleptics and other 
antipsychotics which might conceal the true state of sleep. Unmedicated patients 
tend to have worse sleep compared with the other groups. In some studies, 
patients were clinically stable while in others they were not. 
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1.4.1.8 Sleep and Quality of Life in Schizophrenia 
 
Sleep is closely related to every aspect of daily life. Sleep disturbances 
affects health and reduces the quality of life (Monti & Monti, 2008). Quality of 
sleep is associated with quality of life in schizophrenia patients.  
 
Ritsner et al. (2004) investigated the relationship between perceived 
quality of life and subjective sleep quality among patients with schizophrenia. 
They evaluated 145 schizophrenia patients with measures of symptom severity, 
emotional distress, adverse effects, quality of life and quality of sleep (Pittsburgh 
Sleep Quality Index, PSQI). Pittsburgh Sleep Quality Index is one of most 
standardized measures to evaluate subjective sleep quality, provides a global 
score and scores seven components. They found that poor sleepers reported 
lower mean scores on all quality of life domains and were more depressed and 
distressed, and had more adverse effects to the medications than good sleepers. 
 
1.5 Sleep and Neurocognitive Function 
 
The role of sleep in memory, learning, performance and mood has been 
extensively studied. There is extensive support for bidirectional relationship 
between sleep physiology and enhanced cognitive performance. Sleep 
disturbances and sleep deprivation are known to affect cognition (Chee & 
Chuah, 2008). Sleep is certainly needed for a proper and well-balanced mental 
functioning (Stickgold et al., 2001). Lack of proper sleep clearly affects thinking, 
cognitive and motor performance (Pilcher & Huffcutt, 1996). 
 
1.5.1 Sleep Deprivation and Cognitive Performance 
 
Sleep deprivation affects neurocognitive performance (Harrison & Horne, 
2000a; Durmer & Dinges, 2005). Sleep deprivation adversely impairs the higher- 
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order functioning or executive function (Horne, 1993). Memory tasks are highly 
negatively influenced by the sleep deprivation.  
 
Pilcher and Huffcutt (1996) in their meta-analysis on effects on sleep 
deprivation on performance used data from 19 original research studies. Their 
analysis of 143 study coefficients and a total sample size of 1932 suggest that 
sleep deprivation robustly worsen human functioning. Their study found that 
the effects of sleep deprivation on fatigue and related mood states are greater 
than effects on cognitive or motor performance. They also indicated that partial 
sleep deprivation has a profound effect on function than effects of long-term or 
short-term sleep deprivation. 
 
Williamson and Marie Feyer (2000) investigated the performance effects in 
same participants over 28 hours of sleep deprivation and after measured doses of 
alcohol up to 0.1% blood alcohol concentration. Their study included 39 
participants. They used a randomised cross over control design. They 
administered several performance tests include the Mackworth Clock Test, 
simple reaction time, tracking, dual task, Symbol Digit Test, spatial memory 
search, memory and search test, and grammatical reasoning. Their study found, 
after 17-19 hours of without sleep test performance was equivalent or worse than 
that at a blood alcohol concentration of 0.05 %. They also found reaction time 
speeds up to 50 percent slower for some tests and accuracy were poorer than at 
this level of blood alcohol. They concluded moderate sleep deprivation impairs 
the cognitive performance. 
 
Harrison and Horne (2000b) investigated the effects of 36 hour of sleep 
deprivation on a neuropsychological test of temporal memory. Their study 
included 40 participants. They have screened and excluded the volunteers with 
smoking, heavy drinking, participants with sleep or medical problems, epilepsy 
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patients and participants with migraine. Only moderate consumers of caffeine 
took part in the study. They assigned participants in randomly within sex to one 
of four groups: control sleep deprived placebo, control non-sleep deprived with 
caffeine, sleep deprived with caffeine and sleep deprived with placebo. Caffeine 
and placebo were given double blind in their study. They have given caffeine or 
placebo before testing. They gave caffeine to reduce sleepiness. The participants 
were given tasks consist of colour photographs of unknown faces and had two 
components: recognition memory and recency discrimination (temporal 
memory) when previously shown face was presented. Their study found no 
significant development of recency with caffeine in the sleep deprivation 
controls. They also found that sleep deprivation groups had a poorer insight into 
their performance with recency. Their study concluded sleep deprivation impairs 
temporal memory. 
 
1.5.2 Sleep and Memory 
 
Recent research studies on the effects of sleep on consolidation of memory 
gained an acceptance. Slow wave sleep is thought to be the most restorative 
sleep. Both behavioural experiments and physiological studies suggest that slow 
wave sleep has beneficial effects on memory consolidation (Fowler & Sullivan, 
1973; Peigneux et al., 2001). Deep sleep or slow wave sleep has a beneficial effect 
on the consolidation of declarative memories (Gais & Born, 2004a; Walker, 2009; 
Plihal & Born, 1999). Whereas, there is no lasting benefit of declarative memory 
from periods abundant in REM sleep (Gais & Born, 2004a). Both non-REM and 
REM sleep play a key role in memory consolidation and learning. There is a 
transformation of information between and within neocortex and hippocampus 
during sleep that realizes the fixation of memory traces (Stickgold, 1998).  
 
65 
 
 
Gais and Born (2004b) studied about sleep and memory consolidation. 
Their study included 29 healthy men took part in one habituation night and two 
experimental nights. The subjects were placed on two groups (sleep experimental 
group N=18 and wake control group N=11). On each experimental night after 
electrodes were placed, participants learned two different memory tasks: 
declarative paired associate word list task and a non-declarative mirror trace 
task. They woke up test subjects in sleep experiment group three hours after 
sleep onset. The participants were asked to recall. The subjects in the wake 
control group were kept awake during the interval between learning and recall 
measures. The participants also requested to rate their subjective feelings on five 
point scale and the sleep quality after sleep. Their study demonstrates slow wave 
sleep related improvement of declarative memory. Their study also 
demonstrated offline enhancement on a paired-associate wordlist task following 
sleep, an improvement associated to early night sleep abundant in slow wave 
sleep.   
 
REM sleep facilitates consolidation of non-declarative memory (Plihal & 
Born, 1999). Plihal and Born (1999) studied about sleep and memory. Their study 
consisted of eleven healthy men in experimental sleep group and ten healthy 
men in wake control group. They administered the Word Stem Priming Task 
(non-declarative memory) and a mental spatial rotation task (declarative 
memory) to both groups. The Wordstem priming task were based on 2 lists of 
words, one serve as a study word list with an explicit learning instructions and 
other serve as novel word list. They tested repetition priming effects and recall of 
spatial memory after three hour retention gap, which followed learning and were 
placed in first half night or second half night. The participants in the sleep group 
slept concurrently the retention gap, while participants of the wake group were 
kept awake. Their study reported early retention sleep was overruled by slow 
wave sleep, whereas REM sleep period prevail during late retention sleep. They 
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found that behind early retention sleep, recall of spatial memory was greater to 
that of late retention sleep. Whereas, priming effect was more powerful behind 
late than early retention sleep. They have suggested that slow wave sleep 
promotes consolidation of declarative memory and REM sleep helps 
consolidation of non-declarative memory. 
 
1.5.3 Sleep and Problem Solving 
 
A study by Linde and Bergstrom (1992) investigated sleep loss on 
performance of complex problem solving tasks compared with exclusively short 
term memory tasks. Their study consisted of two tasks: first one examined 
immediate free recall, estimated to reflect the maintenance capability of working 
memory and the other one was lingual reasoning and problem solving measures, 
speculated to reflect the processing and monitoring capability of working 
memory. They kept participants in the experimental group awake and tested on 
various cognitive measures. Control group was allowed to sleep at home. They 
have found a remarkable decline in performance left by a sleep loss on Raven’s 
progressive matrices, a problem solving measure. But the control group who 
have slept well performed higher in the tests. Their study found that there is a 
significant decline in performance on sleep loss and improved performance 
following by sleep. 
 
Wagner et al. (2004) study on the effects of sleep on the occurrence of 
insight used modified version of a mathematical “number reduction task” 
(Thurstone & Thurstone, 1941) in healthy controls on awake group and sleep 
group. Participants apply a standard algorithm (consist of two simple rules) for 
reducing an eight-digit sequence to a final solution. Participants do not know 
that a simple shortcut exists. The percentage of participants who discover this 
shortcut or ‘hidden rule’ when they are retested was 22% in the awake group 
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versus 60% in the sleep group. They have concluded that sleeping allows the 
restructuring of new memory representations and facilitates extraction of explicit 
knowledge and insightful behavior. Striking experimental evidence of process 
sleep dependant creative insight was splendidly proved. 
 
A study by Cai et al. (2009) investigated the role of rapid eye movement 
(REM) sleep on creative problem solving using Remote Associate Test (RAT). 
The RAT is a simple word association test comprise of three words associated by 
a single concept. Each item requires the participant to combine or associate the 
three words extract from conjointly remote associate clusters. Their study 
included seventy-seven healthy participants without any neurological or 
psychological ailments. The participants were advised to be in the rest during the 
week prior to testing. They tested all the participants on the RAT twice in 1 day 
following by analogies. Participants were randomly assigned to a nap or quiet 
rest group. Participants in the nap group sleep were polysomnographically 
recorded for 90 minutes or up to two hours in bed, whereas the rest group heard 
music with polysomnographical monitoring for ninety minutes. Participants 
were given varied pre-exposure to the creative problem. Their study reported, 
compared with quiet rest and non-REM sleep, rapid eye movement (REM) sleep 
enhances creative problem-solving. 
 
1.6 Aim of the Study 
 
Patients with schizophrenia suffer from a wide range of cognitive deficits 
(Keffe et al., 2006). Sleep deprivation studies in healthy control participants 
shows sleep deprivation affects neurocognitive performance (Harrison & Horne, 
2000a; Durmer & Dinges, 2005) and adversely impairs the higher order 
functioning or executive functions (Horne, 1993). Moderate sleep deprivation 
impairs the cognitive performance (Williamson & Marie Feyer, 2000; Harrison & 
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Horne, 2000b). Memory consolidation studies show the positive effects of sleep 
on consolidation of memory in healthy controls (Gais & Born, 2004b). In 
particular slow wave sleep or deep sleep having beneficial effects on declarative 
memories (Gais & Born, 2004a; Walker, 2009) and REM sleep having beneficial 
effects on non-declarative memory (Plihal & Born, 1999). 
 
There is evidence of problem solving process being improved by sleep in 
the healthy controls (Wagner et al., 2004; Linde & Bergstrom, 1992). REM sleep 
enhances creative problem solving (Cai et al, 2009). Problem solving (Morris et 
al., 1995; Pantelis et al., 1997; McClellan et al., 2004; Kester et al., 2006; Noh et al., 
2010; Zhu et al., 2010) as well as sleep (Sleep continuity, sleep architecture, REM 
sleep measures and microstructures of sleep) (Monti & Monti, 2006; Manoach & 
Stickgold, 2009; Yang & Winkelman, 2006; Poulin et al., 2003; Keshavan et al., 
1998; Yetkin et al., 2011) has been shown to be impaired in patients with 
schizophrenia.  
 
To the best of my knowledge there are no reported studies on sleep and 
problem solving in patients with schizophrenia. The present study aimed at 
exploring and investigating relationships between sleep and problem solving in 
patients with schizophrenia.  
 
A consolidation paradigm used to investigate this question ex: 
participants are tested  a day- and night time condition following learning, 
separated by a week, with half of them being allocated to the night or the day 
condition first in a balanced design. Sleep parameters examined by means of 
polysomnography. 
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1.6.1 Hypotheses  
 
1) Schizophrenia patients show impairment on neuropsychological tests 
compared with healthy controls. 
2) Schizophrenia patients will have impaired sleep parameters compared 
with controls. 
3) Schizophrenia patients will have deficits in problem solving. 
4) Night time interval (Post sleep performance) will be more beneficial than 
day time interval for problem solving. 
5) Sleep parameters will be related to problem solving performance in 
schizophrenia patients. 
 
Title of the Study: Sleep and problem solving in schizophrenia. 
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 CHAPTER 2 
          Methodology 
 
2.1 Place and Period of Study 
 
The data were collected from April 2009 to October 2010 in the Sleep 
Laboratory, Department of Experimental Psychology, Heinrich Heine University 
of Düsseldorf, Germany and in the Department of Clinical Psychology and 
Psychotherapy, University of Wuppertal, Wuppertal, Germany. 
 
2.2 Participants  
    
2.2.1 Schizophrenia Patients 
 
 Schizophrenia patients had a mean age of 41.25 years (SD = 8.69) and an 
average of 12 years of education (SD = 1.41) (Table 2.1). The patients were 8 
males and 12 females. Inclusion criteria were an age of 18 to 55 years, fluency in 
German, an IQ > 70 and stable medication for the last 2 weeks. Patients met the 
Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria for a 
diagnosis of schizophrenia or schizo-affective disorder was considered for the 
present study. Diagnoses were ascertained by means of the Structured Clinical 
Interview for DSM-IV (SCID, German version Wittchen et al., 1997) and the 
Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987). 
 
All patients were screened to exclude substance use or dependence, 
diagnosed sleep or neurological disorders and benzodiazepine use at the time of 
the study. Of the twenty schizophrenia patients, 13 had a diagnosis of paranoid 
schizophrenia, 2 were diagnosed with residual type and 5 had schizoaffective 
disorder. The majority of patients (N = 13) were diagnosed as belonging to the 
paranoid type (Table 2.2).  
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Table 2.1 Demographic Data of Schizophrenia Patients 
Variable Schizophrenia patients (N = 20) 
Age 
Mean age (years) (SD) 
 
41.25 (8.69) 
Sex               
Male                                      
Female                                   
 
8   (40%) 
12 (60%) 
Education 
Mean (years) (SD) 
 
12 (1.41) 
SD = Standard Deviation, N = Number 
 
The PANSS positive scale scores were 9 (Min) to 26 (Max) (M = 16.55, SD = 
5), on negative scale scores were (Min) 6 to 30 (Max) (M = 14.45, SD = 5.69) and 
on the global psychopathology scale scores were 16 (Min) to 49 (Max) (M = 32.50, 
SD = 8.95) (Table 2.2). The duration of illness was measured on the basis of time 
elapsed since the first diagnosis. This information is based on patient self-report 
and clinical records. 
 
Table 2.2 Clinical Characteristics of Schizophrenia Patients (N = 20) 
  
Diagnosis 
Paranoid schizophrenia (N) 
Schizoaffective disorder (N) 
Residual type (N)                      
 
13 (65%) 
5   (25%) 
2   (10%) 
Duration of illness  
Mean (years) (SD)      
 
13.43 (8.36) 
Medication 
Atypical antipsychotics (N) 
Typical antipsychotics (N) 
Typical and atypical antipsychotic (N) 
 
15 (75%) 
1   (5%) 
4   (20%) 
PANSS scores 
Positive scale scores (Mean) (SD) 
Negative scale scores (Mean) (SD) 
Global psychopathology scale (Mean) 
(SD) 
 
16.55 (5.00) 
14.55 (5.69) 
32.50 (8.95) 
SD = Standard Deviation, N = Number 
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The information about patient’s medication status was documented 
accordingly. Patients were on different medication protocols - atypical 
antipsychotic medication (N = 15), typical antipsychotics (N = 1) and; typical and 
atypical antipsychotics (N = 4). 
 
The patients were recruited from a variety of urban health centres, mainly 
from the Evangelical Foundation- Tannenhof, Remscheid, Germany. 
 
2.2.2 Healthy Controls 
 
Twelve healthy control participants took part in the study - 4 male and 8 
female participants aged from 21 to 50 years (M = 37.33, SD = 9.01). All 
participants were screened to exclude substance use or dependence, diagnosed 
sleep or neurological disorders and benzodiazepine use at the time of the study. 
The volunteers of healthy control group were recruited from the local campus 
and nearby universities. The pamphlets explaining the research study were 
distributed and posted on the university notice boards. The healthy controls 
were matched by age group, gender, level of education and socioeconomic status 
of the patient group. 
 
Table 2.3 Demographic Data of Healthy Controls 
Variable Controls (N = 12) 
Age 
Mean age (SD) 
Range 
 
37.4 (9.01) 
(21-50) 
Sex                
Men 
Women                                   
N   %  
4 
8 
33.3 
66.7 
 
 
Education 
Mean (years) (SD) 
 
12.33 (.99) 
SD = Standard Deviation, N = Number 
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2.2.3 Dropouts and Missing Data 
 
Seven participants were not included in the study (one patient withdrew 
after the initial assessment, another 3 patients terminated the procedure after the 
first night in the sleep laboratory and 2 patients and one control participant had 
to be excluded because of the missing data.  
 
2.2.4 Ethics and Study Approval  
 
Informed consent was obtained from each participant. The study was 
approved by the ethics committees of the University of Wuppertal & Heinrich 
Heine University of Düsseldorf, Germany. Participants received a remuneration 
of 60 Euros.  
 
2.3 Research Design 
 
Twenty schizophrenia patients and 12 healthy controls took part in the 
study. Participants underwent a day- and a night-time condition, separated by a 
week, with half of them being allocated to the night or the day condition first, in 
a balanced design. During day condition training occurred in the morning and 
testing approximately 8 hours later (M = 7.9 hours, SD = .3) in the evening. 
During the night condition, training occurred in the evening and testing 8 hours 
later in the morning. There were two versions of experimental task which were 
randomly presented either first or second time. The description of the research 
design is explained below in Table 2.4 and Table 2.5 
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Table 2.4 Description of the Research Design  
  
Status 
 
Schizophrenia patients (N 20) Healthy controls (N 12) 
Group 
 
Day before night N =10 Night before day N=10 Day before night N=6 Night before day N=6 
Block 
 
1 2 1 2 1 2 1 2 
Pre-post 
 
Pre-post Pre-post Pre-post Pre-post Pre-post Pre-post Pre-post Pre-post 
 
 
Table 2.5 Description of the Groups  
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2.3.1 Combined the Day and Night Condition/Blocks 
 
Preliminary analyses were made as described in the research design (Table 
2.4 & Table 2.5). In preliminary analyses is also to check the order effects (Day 
before night vs. night before day). In later stage, “Day before night” and “night 
before day”conditions/Blocks were combined respectively to within groups. 
Combining the “day before night” and “night before day” across the two orders 
resulted as “Interval” (Day interval vs. Night interval). Day interval vs. Night 
interval is the main analyses. 
 
2.4 Measures 
 
2.4.1 Structured Clinical Interview for DSM-IV SCID (Wittchen et al., 1997)  
 
The Structured Clinical Interview for DSM-IV (SCID) was developed in 
1990. SCID is extensively used in clinical trials and psychiatric research. 
Structured Clinical Interview for DSM-IV (SCID) is clinician administered 
diagnostic interview designed for use of professionals in the field of mental 
health. Structured Clinical Interview - SCID semi structure interview begins with 
a section on demographic data (ex: age, marital status, educational background, 
work background) and clinical background (ex: persisting chief complaints, 
treatment history, past episodes of psychiatric disturbance and present 
functioning). There are 7 diagnostic modules focused on different diagnostic 
groups (psychotic, substance abuse, mood, anxiety, somatoform, eating, and 
adjustment disorders). 
 
All available information like hospital records, hospitalization history, 
informants and patient observation should be used to rate the Structured Clinical 
Interview for DSM-IV (SCID). The Structured Clinical Interview for DSM-IV 
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(SCID) interview approximately takes one hour, but sometimes it may take 
longer in individuals with severe symptomatology. The Structured Clinical 
Interview for DSM-IV (SCID) is highly reliable for diagnosis of most of 
psychiatric disorders. 
 
 SCID is divided into different sections, each containing questions about 
different disorders. For the present research study, module-B (Psychotic and 
associated symptoms), module-C (differential diagnosis) and module-E 
(substance use disorders) were administered. Module-B and module-C were 
used for diagnosis of psychotic disorders, and module-E was used for the 
assessment of DSM-IV criteria for abuse and alcohol addiction, drugs and 
medicines. 
 
2.4.2 Positive and Negative Syndrome Scale – PANSS (Kay et al., 1987) 
 
The Positive and Negative Syndrome Scale (PANSS) is common scale in 
clinical studies for measuring the severity of symptoms in patients with 
schizophrenia. The PANSS assessment can be completed in 30 to 40 minutes 
approximately.  
 
The PANSS scale consists of thirty items on three sub scales. Seven items 
covering positive symptoms (delusions, conceptual disorganization, 
hallucinations, hyperactivity, grandiosity, suspiciousness /persecution, 
hostility), seven item covering negative symptoms (blunted effect, poor rapport, 
emotional withdrawal, passive /apathetic social withdrawal, difficulty in 
abstract thinking, lack of spontaneity and flow of conversation and stereotyped 
thinking) and sixteen covering general psychopathology (somatic concern, guilt 
feelings, anxiety, tension, mannerisms and posturing, depression, motor 
retardation, uncooperativeness, unusual thought content, disorientation, poor 
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attention, lack of judgment and insight, disturbance of volition, poor impulse 
control, preoccupation and active social avoidance).  
 
Each item was scored on a 7 point item specific Likert scale ranging from 1 
to 7. Thus the positive and negative subscales each range from 7 to 49 and the 
general psychopathology scale from 16 to 112. The reliability for each scale is 
quite high. 
 
2.4.3 Socio - Demographic Profile 
 
The socio-demographic data were obtained from all participants. 
 
2.5 Neuropsychological Tests 
 
2.5.1 VLMT-Verbal Learning and Memory Test (Helmstaedter at al., 2001)  
 
In order to assess verbal learning, memory and learning potential, a 
German adaptation of the Rey Auditory Verbal Learning test (Verbaler Lern- 
und Merkfaehigkeitstest -VLMT; Helmstaedter et al., 2001) was administered. 
The Verbal Learning and Memory Test require constructive learning and recall of 
a list of 15 words (List A) over five trials; free recall of this list after each trial is 
requested. After the five learning trials are complete, a second word list (list B) is 
presented for free recall to assess the effects of interference, finally unannounced 
recall of List A is requested after a delay of half an hour, and a recognition trial is 
performed. Recognition trial requires identification of the words of (list A) out of 
an orally presented list of fifty words which comprises the words from lists A 
and B, as well as new distracters words. The verbal learning performance was 
calculated by summing up the total number of correctly reproduced words over 
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the five learning trials. A number of scores can be derived. Here we present total 
number of correctly recalled words immediately and after delay. 
 
2.5.2 Trail Making Test A & B (Reitan et al., 1979) 
 
The Trail Making Test consists of two parts (A and B), each of which 
contains 15 circles distributed on a sheet of paper. In Part A, each circle contains 
a number from 1 to 15. After completing the sample test, the participant is 
instructed to begin at the number 1 and to locate and draw a pencil line to 2, then 
to 3, and so on until reaching the number 15 as faster as possible. Part B has both 
numbers and letters within the 15 circles, and the participant is instructed to 
alternate between them as the numerical and alphabetical sequences progress. 
The participant begins at 1, locates and draws a line to A, then to 2, then to B, and 
so on until completing the test. The score for each part of the test is the number of 
seconds required for completion.  
 
The Trial Making Test Part B is more challenging than Part A. Scoring is 
expressed in terms of the time in seconds required for completion of each of the 
two parts of the test. Both parts require perceptual tracking of a sequence and 
speeded performance, but Part B also requires divided attention. The ratio and 
difference scores are attempts to elucidate the added task requirements of Part B, 
and are thought to be purer measures of the more complex divided attention and 
alternating sequencing tasks required in Part B. 
 
2.5.3. Multiple Choice Word Comprehension Test (MWT-B; Lehr et al 1989) 
 
Verbal intelligence was assessed using the Multiple Choice Word Fluency 
Test -MWT-B (Mehrfachwahl-Wortschatz-Intelligenz-Test). In a thirty seven item 
list, containing five words per item (one correct word and four nonsense words), 
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the participants had to identify the correct word. The number of correct answers 
was analyzed. Participants asked not to mark the response randomly, if they do 
not know the answer. The raw scores and IQ value for the MWT-B were given 
below (Table 2.6). 
 
Table 2.6 Scores for the Multiple Choice Word Fluency Test (MWT-B) 
 
Total Score Intelligence Intelligence 
Quotient (IQ) 
0-5 Very low intelligence ≤ 72 
6-20 Low intelligence 73-90 
21-30 Average intelligence 91-109 
31-33 High intelligence 110-127 
34-37 Very high intelligence ≥ 128 
 
2.5.4 Digit Symbol Test (Oswald and Fleischmann., 1986)  
 
The Digit Symbol Test, a simplified version of the Oswald and 
Fleischmann (1986) was used. Nine digits have to be replaced as quickly as 
possible, with a symbol shown at the top of the page. The score represents the 
number of correct symbols drawn within 90 seconds. This test measures 
psychomotor performance, motor persistence, sustained attention, response 
speed, and visuo-motor coordination. The higher the score, the better the visual 
acuity and cognitive speed. 
 
2.5.5 Controlled Oral Word Association Test (Benton et al., 1983) 
 
The Controlled Oral Word Association Test used to measure verbal 
fluency. During this test participants are asked to produce as many words as 
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possible starting with F, A, S within one minute each. The participants are 
advised not to use proper names and different forms of the same words. The 
performance score is the sum of correct words.  
 
2.6 Experimental Task 
 
2.6.1 Tower of London Test (Shallice et al., 1982)  
 
Problem solving was assessed with two versions of the computerized 
version of the Tower of London test. Participants were presented with a problem 
in the computer. In this computerized test participants are shown coloured 
spheres arranged on poles. Displayed are a start position and a goal position and 
the task is to rearrange the spheres within a set number of moves as fast as 
possible to attain the goal position. If a task is not completed within the given 
number of moves it is registered as unsolved. Participants were given an initial 
practice task which they could carry out as often as they wished to familiarise 
themselves with the apparatus. There are 15 tasks with increasing difficulty.  
 
 
                               Figure 2.1 Model of the Tower of London Test 
 
Source: Adapted from Psychology Press, Taylor & Francis Group, London 
                             http://www.psypress.com/grome/figures/fig%209.7.jpg 
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   The scores are the number of solved tasks and total time taken to complete 
the Tower of London test. The Tower of London test (Shallice et al., 1982) is a 
widely used test measure of planning, sequencing and problem solving. Two 
versions of the test were used. 
 
2.7 Polysomonography 
 
Prior to retiring at the sleep laboratory, participants were wired for the 
standard polysomonographic sleep recordings. EEG leads were placed according 
to the International 10/20 system (Jasper, 1958). Recordings were conducted 
using the 16 channel polygraph (Biopac MP150 Data acquisition systems and 
Acqknowledge 3.9.1 software). Biopac MP150 data acquisition system and 
Acqknowledge 3.9.1 software is an interactive, intuitive program that let 
instantly view, measure, analyze and transform the data.  
 
Sleep EEG data were sampled at 1000 Hz and band-pass filtered between 
1 and 35 Hz for analysis. EOG data were sampled at 1000 Hz and band-pass 
filtered between 0.05 and 35 Hz and EMG data at 1000 Hz with band-pass filters 
of 10 and 500 Hz. Additionally, a notch filter was applied. 
 
Sleep EEG files were stored in .acq format. The following recordings were 
included: electroencephalogram (C3-A2, C4-A1), an electrooculogram (EOG), 
and a submental chin electromyogram (EMG). EEG electrode placements are 
briefly explained below. 
 
2.7.1 Electrode Placement 
 
2.7.1.1 EEG Electrode Placement 
 
EEG electrodes (C3 electrode derivation on left central scalp referenced to 
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the right earlobe & C4 electrode derivation on right central scalp referenced to 
the left earlobe) were fixed on participants head (Figure 2.2). In order to locate 
these two points (C3 & C4), a tape measure were applied from the nasion (at top 
edge of the nose, where the forehead is indented) to the inion (just underneath 
the occipital condyle, the bump at the back of the head). Half of the total distance 
is marked with a non permanent black marker. The tape is then placed from the 
preauricular notch of the left ear through this marked spot to the preauricular 
notch on the right ear. The mid-point is located again. The intersection of the two 
measurements locates the vertex. When the vertex is obtained, then 20% of that 
total distance from ear to ear is recalculated. The distance is then marked from 
the vertex toward the left ear and the right ear along with the line between the 
two ears. These are the locations of C3 and C4. Once the appropriate locations are 
marked, the marking points were cleaned and removed with gel. The conductive 
paste was used to fix the C3 and C4 electrodes. 
 
2.7.1.2 EOG Electrode Placement 
 
Electrode (E1) is placed approximately 1 cm above and slightly lateral to 
the outer canthus of one eye and reference electrode on ear lobe (A1). On the 
second eye movement channel are recorded the potential from an electrode 1cm 
below and slightly lateral to the outer canthus of the other eye (E2) referred to 
the earlobe (A1) (Figure 2.2). Both eyes are referenced to the same ear 
(Rechtschaffen and Kales 1968). 
 
2.7.1.3 EMG Electrode Placement 
 
Two electrodes were placed on the muscle area beneath the chin 
(submental) (Figure 2.2). 
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Figure 2.2 Picture Representing Placement of Electrodes 
Source: Rechtsschaffen, A & Kales, A manual Of Standardized Terminology, 
Techniques and Scoring System for Sleep Stages of Human Subjects. Public 
health service, U.S. Government Printing Office, Washington, D.C., 1968  
 
2.7.2 Sleep EEG Scoring  
 
The second night (experimental night) sleep EEG recordings were used for 
analysis. The sleep data was scored based on the tracings of C3. Thirty-second 
epochs were staged according to Rechtschaffen - Kales criteria (A Manual of 
standardized terminology, techniques and scoring system for sleep stages of 
human subjects). The Rechtschaffen - Kales (1968) criteria for scoring sleep stages 
were presented in the table 1.8. 
 
  84 
 
 
 
Figure 2.3 Sample Screenshot of Sleep EEG Recorded using Biopac 
Acqknowledge 3.9.1 Software 
 
The following parameters were analyzed: a) total sleep, defined as the 
actual time spent asleep; b) sleep latency, defined as the time from lights out 
until the onsets of three consecutive epochs of sleep stage 1; c) sleep efficiency, 
was defined as the percentage of time spent asleep divided by the total recording 
time; d) wake, defined as total time scored as wakefulness between sleep onset 
and final awakening; e) REM sleep period, defined by not less than 40 epochs of 
NREM sleep (sleep stage 1 through 4) subtending any two REM periods; f) REM 
latency, defined as the time from sleep onset until the first epoch of REM sleep; 
g) sleep stages 1, stage 2, stage 3, stage 4, defined as the number of epochs spent 
on each stages; h) K-complex, defined as negative sharp wave immediately 
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followed by a positive component with a total duration more than 0.5 seconds; i) 
spindles, defined distinct wave patterns 12-14 cycles per second (cps) of at least 
0.5 sec.  
 
 
Figure 2.4 Wave Patterns of Different Sleep Stages 
 
After scoring sleep EEG parameters in epochs, sleep parameters were 
converted from epoch (30 sec) to minutes (min). The time in minutes were 
calculated for the following sleep parameters: REM (TSR), Non-Rapid eye 
movement (TSN), total sleep stage 1 (TS1), total sleep stage 2 (TS2), total sleep 
stage 3 and stage 4 (TS3AND4), total sleep, REM latency, sleep latency, 
movement time and wake. The sleep architecture also defined in terms of the 
percentage of sleep time. The percentage was calculated for the following sleep 
parameters: sleep efficiency, stage 1, stage 2, stage 3 & 4, wake, movement time 
and total sleep. K-complexes and spindles were defined in terms of number. 
 
2.7.3 Sleep Parameters Examined 
 
The sleep parameters studied in the present study are given below in the table 
2.7. 
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Table 2.7 Sleep Parameters Investigated in the Present Study 
 
TSR (min) TSN (min) TS1(min) 
TS2 (min) TS3AND4 (min) TOTAL SLEEP (min) 
REM LATENCY (min) SLEEP LATENCY (min) SLEEP EFFECIENCY % 
NUMBER OF SPINDLES NUMBER OF K-COMPLEXES MOVEMENT TIME (min) 
TSW (min) REM % NREM % 
STAGE 1% STAGE 2% STAGE 3 & 4% 
WAKE% MOVEMENT TIME% TOTAL SLEEP% 
 
REM = Rapid eye Movement, NREM = Non-Rapid eye movement, TSR = Total sleep REM, 
TSN = Total sleep NREM, TS1 = Total sleep stage 1, TS2 = Total Sleep stage 2, TS3AND4 = 
Total sleep stage 3 and stage 4, TSW = Total stage wake. 
 
2.8 Procedure 
 
 
During the first contact patients were administered the standardised 
interviews to ascertain the diagnosis after which they were given information 
about the procedure and gave their informed consent. Within the following week 
they entered either the day interval or the night interval condition. Day-time 
testing took place in the morning and late afternoon at the Department of 
Clinical Psychology at the University of Wuppertal or the home of the 
participants. For the night interval condition participants spent two consecutive 
nights at the sleep laboratory of the Department of Clinical Psychology, 
University of Düsseldorf. The first night served to accustom participants to the 
sleeping conditions while being wired up for polysomnographic recordings. 
 
Testing conditions and groups were briefly explained in research design 
(Table 2.4) & (Table 2.5). The day testing and night testing procedure is further 
explained below. 
  87 
 
 
 
2.8.1 Day Testing  
 
 
Day-time testing took place in the morning and late afternoon at the 
Department of Clinical Psychology at the University of Wuppertal or the home of 
the participants. 
 
2.8.2 Night Testing 
 
On the habituation night, upon arrival of the participant at the sleep 
laboratory at 21:00 hr, a battery of neuropsychological tests including the Verbal 
Learning and Memory Test -VLMT, Trial Making test A & B, Multiple Choice 
Word Comprehension Test (MWT-B), Digit Symbol Test and Controlled Oral 
Word Association Test were administered. The neuropsychological testing lasts 
from 40 minutes to one hour.  
 
After the neuropsychological testing, the participant were given time to 
get ready for sleep. EEG electrodes were fixed on patient head as described 
above earlier (Figure 2.2). After checking electrode signals the acquisition starts. 
The participant according to their usual habits at home, freely chose lights out 
time. The room used for the recording had a comfortable bed, acoustic isolation, 
controlled temperature and light. The participants were woken up at 6 am in the 
morning. 
 
The recorded sleep data during the habituation night was not included for 
the analysis. 
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Figure 2.5 Shows Sleep Laboratory 
 
On the experimental night, upon arrival of the participant at the sleep 
laboratory at 21:00 hrs, the Tower of London test was administered. After the 
testing, just as described above the night testing procedure was the same as 
during the habituation night. But, the Tower of London test was administered 
once again to the participant in the morning after awake. The recorded sleep EEG 
data during the experimental night were used for analysis. The sleep EEG 
recordings were saved in .acq file format and stored on compact disc with the 
internal identification number. The recorded sleep data were analysed twice 
offline by two trained researchers. The scored sleep EEG data were documented 
in excel file and as well as in a hard copy. 
 
 
2.9 Statistical Data Analyses 
 
All statistical analyses were carried out using the program Statistical 
Package for the Social Sciences (SPSS) (PASW statistics 18 release 18.0.0). 
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2.9.1 Descriptive Measures 
 
T-tests were conducted to assess, group differences with regard to age and 
education. Sex differences were examined with Chi-square test. 
 
2.9.2 Neuropsychological Test Scores 
 
T-tests for independent samples were conducted to compare the 
neuropsychological test scores of schizophrenia patients and healthy controls. 
 
2.9.3 Experimental Tasks - Tower of London Test Measures – Preliminary 
Analyses 
 
In first step preliminary analyses, analyses of variance were carried out to 
ascertain that none of the independent variables interacted significantly with 
‘order’ (Day before night vs. night before day). 
 
2.9.3.1 Multivariate Analysis of Variance - Schizophrenia Patients versus 
Healthy Controls 
 
A 2 (Status: schizophrenia patients vs. healthy controls) x 2 (Group: day 
before night vs. night before day) x 2 (Block: block 1 vs. block 2) x 2 (pre-post: pre 
vs. post) four-way mixed MANOVA with repeated measures on the last two 
factors was performed using the number of solved tasks and total time taken as 
dependant variables. Bonferroni adjustments of p values were used to correct for 
multiple comparisons. Effect sizes are indicated in terms of η². All effects are 
reported as significant at p < .05.  
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2.9.3.2 Multivariate Analysis of Variance - Schizophrenia Patients 
 
A 2 (Group: day before night vs. night before day) x 2 (Block: block 1 vs. 
block 2) x 2 (Pre-post: pre vs. post) three-way mixed MANOVA with repeated 
measures on the last two factors was performed using the number of solved tasks 
and total time taken as dependant variables. Bonferroni adjustments of p values 
were used to correct for multiple comparisons. Effect sizes are indicated in terms 
of η².  All effects are reported as significant at p < .05. 
 
2.9.3.3 Multivariate Analysis of Variance - Healthy Controls 
 
A 2 (Group: day before night vs. night before day) x 2 (Block: block 1 vs. 
block 2) x 2 (Pre-post: pre vs. post) three-way mixed MANOVA with repeated 
measures on the last two factors was performed using the number of solved tasks 
and total time taken as dependant variables. Bonferroni adjustments of p values 
were used to correct for multiple comparisons. Effect sizes are indicated in terms 
of η². All effects are reported as significant at p < .05. 
 
2.9.4 Experimental Task- Tower of London test measures – Main Analysis  
 (Combined the Day and Night Condition/blocks) 
 
The combined blocks are named as “Interval” (Day interval vs. night 
interval).  
2.9.4.1 Multivariate Analysis of Variance - Day versus Night Interval 
(Schizophrenia patients vs. healthy controls) Main Analysis 
 
A 2 (Status: schizophrenia patients vs. healthy controls) x 2 (Interval: day 
interval vs. night interval) x 2 (Pre-post: pre vs. post) three-way mixed 
MANOVA with repeated measures on the last two factors was performed using 
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the number of solved tasks and total time taken as dependant variables. 
Bonferroni adjustments of p values were used to correct for multiple 
comparisons. Effect sizes are indicated in terms of η². All effects are reported as 
significant at p < .05. 
 
2.9.4.2 Multivariate Analysis of Variance - Day versus Night Interval 
(Schizophrenia Patients) 
 
A 2 (Interval: day interval vs. night interval) x 2 (Pre-post: pre vs. post) 
two-way mixed MANOVA with repeated measures was performed using the 
number of solved tasks and total time taken as dependant variables. Bonferroni 
adjustments of p values were used to correct for multiple comparisons. Effect 
sizes are indicated in terms of η². All effects are reported as significant at p < .05. 
 
2.9.4.3 Multivariate Analysis of Variance - Day versus Night Interval (Healthy 
Controls) 
 
A 2 (Interval: day interval vs. night interval) x 2 (pre-post: pre vs. post) 
two-way mixed MANOVA with repeated measures was performed using the 
number of solved tasks and total time taken as dependant variables. Bonferroni 
adjustments of p values were used to correct for multiple comparisons. Effect 
sizes are indicated in terms of η². All effects are reported as significant at p < .05. 
 
2.9.5 Sleep EEG Data 
 
2.9.5.1 Comparison of Sleep EEG Parameters between Patient Group and 
Control Group 
  
  92 
 
 
Independent sample t-tests were performed to compare the sleep EEG 
data of the second night between schizophrenia patients and healthy controls. 
 
2.9.5.2 Correlation of Sleep EEG Parameters and the Tower of London 
Measures 
 
Pearson product-moment correlation coefficients were computed to assess 
the relationship between sleep parameters and Tower of London test measures 
(number of solved tasks and total time taken). The following sleep parameters 
were examined REM, NREM, total sleep stage 1, total sleep stage 2, total sleep 
stage 3 and stage 4, total sleep duration, REM latency, sleep latency, sleep 
efficiency, number of spindles, number of k-complexes, movement time, total 
stage awake, REM percent, NREM percent, stage 1 percent, stage 2 percent, stage 
3 & 4 percent, awake percent, movement time percent and total sleep percent. 
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CHAPTER 3 
  
  RESULTS 
 
 
 
3.1 Descriptive Measures 
 
The total sample was comprised of 32 participants. Twenty schizophrenia 
patients and twelve healthy controls took part in the study. 
 
 
3.1.1 Schizophrenia Patients 
 
Schizophrenia patients had a mean age of 41.25 years (SD = 8.69) and an 
average of 12 years of education (SD = 1.41) (Table 3.1). The patients were 8 men 
(40%) and 12 women (60%). Of the 20 patients, 13 had a diagnosis of paranoid 
schizophrenia (65%), 5 were diagnosed with schizoaffective disorder type (25%) 
and 2 had schizoaffective disorder (10%) (Table 3.1) The majority of patients (N = 
13) were diagnosed as belonging to the paranoid type (Figure 3.1). The average 
duration of illness was 13.43 years (SD = 8.36). 
 
The mean scores of the PANSS for schizophrenia patients: on positive 
scale, scores were 9 (Min) to 26 (Max) (M = 16.55, SD = 5), on negative scale 
scores were 6 (Min) to 30 (Max) (M = 14.45, SD = 5.69) and on the global 
psychopathology scale scores were 16 (Min) to 49 (Max) (M = 32.50, SD = 8.95) 
(Table 3.1) (Figure 3.2).  
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          Figure 3.1 Distribution of Diagnostic Subtypes of Schizophrenia patients 
 
 
 
              Figure 3.2 PANSS Mean Scores of Schizophrenia Patients 
 
 
95 
 
 
 
Table 3.1 Demographic and Clinical Characteristics of Schizophrenia Patients 
and Healthy Controls 
 
Variable 
 
Patients (N = 20) Controls (N = 12) 
Age  
Mean age (years) (SD)        
(Range) 
 
 
41.25 (8.69) 
(26-54) 
 
37.4 (9.01) 
(21-50) 
Sex        
Men                                      
Women              
                      
N %  N %  
8 
12 
40 
60 
 
 
4 
8 
33.3 
66.7 
 
 
Education 
Mean (years) (SD) 
 
 
12    (1.41) 
 
12.33 (.99) 
Diagnostic subtypes 
 
Paranoid schizophrenia  
Schizoaffective disorder 
Residual type              
         
N %   
13 
5 
2 
65 
25 
10 
 
 
 
 
 
 
Duration of illness 
Mean (years) (SD) 
 
 
13.43 (8.36) 
 
 
Medication 
Atypical antipsychotics     
Typical antipsychotics     
Typical and atypical antipsychotics 
 
N %   
15 
1 
4 
75 
5 
20 
 
 
 
 
 
 
PANSS scores 
 
Positive scale scores (Mean) (SD) 
Negative scale scores (Mean) (SD) 
Global psychopathology scale (Mean) 
(SD) 
 
 
 
16.55 (5.00) 
14.55 (5.69) 
32.50 (8.95) 
 
 
 
 
SD = Standard Deviation, N = Number; PANSS = Positive and Negative 
Syndrome Scale 
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3.1.2 Healthy Controls 
 
Twelve healthy control participants took part in the study, 4 men (33.3%) 
and 8 women (66.7%). Participants had a mean age of 37.4 years (SD = 9.01) and 
an average of 12.33 years of education (SD = .98) (Table 3.1). 
 
In order to assess possible differences between schizophrenia patients and 
healthy controls on the demographic measures, t-tests were performed. There 
were no significant differences found between schizophrenia patients and 
healthy controls with regard to the age and number of school years (age t(30) = 
1.21, p = . 23; education t(30) = - .71, p = .47). For sex differences a Chi-square test 
was performed (Chi-square = 0.14, p = .70). 
 
3.2 Neuropsychological Test Scores 
 
Group means and standard deviations of neuropsychological test scores of 
the schizophrenia patients and healthy controls are reported in Table 3.2. 
 
3.2.1 Neuropsychological Performance (Schizophrenia Patients versus Healthy 
Controls) 
 
The neuropsychological test scores of schizophrenia patients (N = 20) were 
compared with those of healthy controls (N = 12). Independent samples t-tests 
were conducted to compare the neuropsychological test scores of schizophrenia 
patients and healthy controls (Table 3.2). The results showed patients with 
schizophrenia performed significantly worse than healthy controls on most 
neuropsychological tests.   
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Table 3.2 Neuropsychological Test Scores (Schizophrenia Patients vs. Healthy 
Controls) 
Measure Scores  
Patients 
(N = 20) 
Controls  
(N = 12) 
T-tests 
Mean ( SD) Mean (SD) t df p  
 
 
 
 
 
 
Multiple Choice Word 
Comprehension test 
(MWT-B) 
Raw  score 
 
 
29.10 
 
 
5.30 
 
 
30.00 
 
 
3.69 
 
 
- .51 
 
 
30 
 
 
.60 
MWT B – IQ  110.35 14.47 111.58 13.49 - .23 30 .81 
Trail Making Test 
 
TMT A (sec) 
 
 
46.87 
 
 
25.75 
 
 
36.83 
 
 
16.63 
 
 
1.20 
 
 
30 
 
 
.23 
TMT B (sec) 106.42 58.72 63.53 20.93 2.42 30 .02* 
TMT B - TMT A 59.54 51.26 26.61 24.88 2.07 30 .04* 
Digit Symbol Test 43.95 13.82 62.17 9.98 -3.97 30 .000*** 
Controlled Oral Word 
Association Test 
32.60 10.60 44.58 9.53 -3.20 30 .00** 
Verbal Learning and 
Memory Test –VLMT 
Supra margin (D1) 
 
 
6.65 
 
 
2.75 
 
 
9.67 
 
 
1.49 
 
 
-3.47 
 
 
30 
 
 
.00** 
Learning performance 
(D5) 
12.10 2.91 14.50 .79 -2.77 30 .01** 
Total Learning 
performance (∑D1-D5) 
49.85 14.13 65.08 4.03 -3.62 30 .001*** 
Recall performance of the 
interference list  (I) 
5.75 
 
2.61 
 
9.08 2.50 -3.54 30 .001*** 
Recall performance after 
interference (D6) 
9.75 
 
4.02 
 
13.75 1.13 -3.34 30 .00** 
Recall performance after a 
time lag (D7) 
9.30 
 
3.48 
 
14.08 1.31 -4.54 30 .000*** 
Forgetting to interference 
(D5-D6) 
2.40 1.90 .75 .96 2.78 30 .00** 
Forgotten after a time lag 
(D5-D7) 
2.75 1.91 .42 1.37 3.67 30 .001*** 
Recognition performance 
(W) 
10.80 
 
 
4.60 
 
 
14.58 .66 -2.80 30 .001*** 
p < .05 * = p < .05   ** = p < .01, *** = p < .001 
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3.2.2 Multiple Choice Word Comprehension Test (MWT-B) 
 
There was no significant difference between schizophrenia patients and 
healthy controls with regard to IQ scores as measured with the Multiple Choice 
Word Comprehension test (MWT-B) (patients M = 110.35, SD = 14.47; controls M 
= 111.58, SD = 13.49), t(30) = - .23, p = .81 (Figure 3.3). According to the manual of 
Multiple Choice Word Comprehension test (MWT-B) intelligent quotients of 110-
127 represent high intelligence. 
 
 
 
Figure 3.3 Multiple Choice Word Comprehension Test (MWT-B) IQ mean 
scores of schizophrenia patients and healthy controls (bars represent standard 
errors) 
 
3.2.3 Trail Making Test 
 
There was no significant difference between schizophrenia patients and 
healthy controls on the Trail Making Test A (TMT A) (psychomotor speed) 
(patients M = 46.87, SD = 25.75; controls M = 36.83, SD = 16.63), t(30) = 1.20, p = 
.23. There was a significant difference between schizophrenia patients and 
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healthy controls on the Trail Making Test B (TMT B) (set-shifting and flexibility) 
(patients M = 106.42, SD = 58.72; controls M = 63.53, SD = 20.93), t(30) = 2.42, p = 
.02. Schizophrenia patients had a worse performance with regard to TMT B 
compared with healthy controls. There was also a significant difference between 
schizophrenia patients and healthy controls with regard to Trail Making B - A 
(TMT B - TMT A) difference scores (patients M = 59.54, SD = 51.26; controls M = 
26.61, SD = 24.88), t(30) = 2.07, p = .04 (Figure 3.4). 
 
 
 
Figure 3.4 Trail Making Test mean scores of schizophrenia patients and 
healthy controls (bars represent standard errors). 
 
3.2.4 Digit Symbol Test 
 
There was a highly significant difference between schizophrenia patients 
and healthy controls with regard to the Digit Symbol Test (sustained attention) 
(patients M = 43.95, SD = 13.82; controls M = 62.17, SD = 9.98), t(30) = -3.97, p = 
.000 (Figure 3.5). The result shows that schizophrenia patients replace fewer 
symbols than healthy controls in the given time.  
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Figure 3.5 Digit Symbol Test mean scores of schizophrenia patients and 
healthy controls (bars represent standard errors) 
 
3.2.5 Controlled Oral Word Association Test 
 
There was a significant difference between schizophrenia patients and 
healthy controls with regard to the Controlled Oral Word Association Test 
(verbal fluency) (patients M = 32.60, SD = 10.60; controls M = 44.58, SD = 9.53), 
t(30) = -3.20, p = .00 (Figure 3.6). Patients with schizophrenia produce fewer 
words. 
 
  
Figure 3.6 Controlled Oral Word Association Test mean scores of 
schizophrenia patients and healthy controls (bars represent standard errors) 
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3.2.6 Verbal Learning and Memory Test –VLMT 
 
There were significant differences between schizophrenia patients and 
healthy controls with regard to all the domains of the Verbal Learning and 
Memory test (Verbal memory) – VLMT: On supra margin (D1), (patients M = 
6.65, SD = 2.75; controls M = 9.67, SD = 1.49), t(30) = -3.47, p = .00 ; learning 
performance (D5) (patients M = 12.10, SD = 2.91; controls M = 14.50, SD = .79), 
t(30) = -2.77, p = .01; total learning performance (∑ D1-D5) (patients M = 49.85, 
SD = 14.13; controls M = 65.08, SD = 4.03), t(30) = -3.62, p = .001; recall 
performance of the interference list (I) (patients M = 5.75, SD = 2.61; controls M = 
9.08, SD = 2.50), t(30) = -3.54, p = .001; recall performance after interference (D6), 
(patients M = 9.75, SD = 4.02; controls M = 13.75, SD = 1.13), t(30) = -3.34, p = .00; 
recall performance after time lag (D7), (patients M = 9.30, SD = 3.48; controls M = 
14.08, SD = 1.31), t(30) = -4.54, p = .000; forgetting to interference (D5-D6), 
(patients M = 2.40, SD = 1.90; controls M = .75, SD = .96), t(30) = 2.74, p = .00; 
forgotten after time lag, (D5-D7) (patients M = 2.75, SD = 1.91; controls M = .42, 
SD = 1.37), t(30) = 3.67, p = .001 and recognition performance (W), (patients M = 
10.80, SD = 4.60; controls M = 14.58, SD = .66), t(30) = -2.80, p = 
Figure 3.7 Verbal Learning and Memory Test – VLMT mean scores of 
schizophrenia patients and healthy controls 
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Summary  
 
Schizophrenia patients showed poorer performance on many variables of 
neuropsychological tests. Highly significant difference was found in the Digit 
Symbol Test (sustained attention, speed of processing and visuo-motor co-
ordination) and Verbal Learning and Memory Test (memory and learning 
potential).  There was a significant group difference with regard to Control Oral 
Word Association test (verbal fluency). There was no significant group difference 
with regard to the Multiple Choice Word Comprehension test (Verbal 
intelligence) and Trail Making Test – A (attention and psychomotor speed).  
 
 
3.3 Tower of London Test Measures 
 
 
In first step of a preliminary analyses, analyses of variance were carried 
out to ascertain that none of the independent variables interacted significantly 
with ‘order’ (Day before night vs. night before day) (see Appendix A and 
Appendix B). As there were no significant interaction effects the “day before 
night” and “night before day” conditions/blocks were combined respectively to, 
within groups. The combined blocks were named as “Interval” (Day vs. night 
interval). 
 
Day versus night interval mean scores and standard deviations for 
schizophrenia patients and healthy controls for measures of the Tower of London 
are presented in Table 3.3 and Table 3.4 respectively. The mean score figures 
were presented in Appendix A. 
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Table 3.3 Mean Scores for the Measures of the Tower of London - Day versus 
Night Interval (Number of solved tasks) 
 
Day vs. night interval 
 
Number of Solved Tasks 
Patients N = 20 Controls N = 12 
 
M                 SD           (Range) 
 
M             SD          (Range) 
 
Day interval 
 
 
Pre 
 
Post 
 
10.05               3.36           (1-14) 
 
10.90               2.25           (3-14) 
    10.50         2.15      (7-14) 
 
    11.16         2.28       (8-15) 
 
Night 
interval 
Pre 
 
Post 
 
9.95                2.41           (5-15) 
 
10.65               2.34           (5-15) 
   11.00         1.59       (8-13) 
 
11.66         1.43       (10-14) 
M = Mean, SD = Standard Deviation, N = Number 
 
 
Table 3.4 Mean Scores for the Measures of the Tower of London- Day versus 
Night Interval (Total time taken) 
 
Day vs. Night 
performance 
 
Total Time Taken 
Patients N = 20 Controls N = 12 
 
     M                 SD           (Range) 
 
M             SD          (Range) 
 
Day 
interval 
 
Pre 
 
Post 
 
579.28            372.80     (276-1803) 
 
504.61            291.24     (276-1499) 
307.54         106.04      (162-526) 
 
254.78         72.12        (149-371) 
 
Night 
interval 
Pre 
 
Post 
 
565.01            222.36     (264-1120) 
 
478.26            182.35      (255-920) 
303.87        113.15       (138-538) 
 
254.64         87.43        (123-407) 
M = Mean, SD = Standard Deviation, N = Number 
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3.3.1 Results of the Multivariate Analysis of Variance for the Measures of the Tower 
of London - Day versus Night Interval (Patients vs. Healthy Controls)  
 
A 2 (Status: schizophrenia patients vs. healthy controls) x 2 (Interval: day 
interval vs. night interval) x 2 (Pre-post: pre  vs. post) three-way mixed 
MANOVA with repeated measures on the last two factors was performed using 
the number of solved tasks and total time taken as dependent variables. The 
results are presented in Table 3.5. 
 
Table 3.5 Results of the Multivariate and Univariate Results for the Measures 
of the Tower of London – (Day vs. Night Interval) (Patients vs. Controls) 
Source F 
(2, 29) 
p η² 
Status (Patients vs. controls) 
Interval (Day vs. night) 
Interval x Status 
Pre-post  
Pre-post x Status 
Interval x Pre-post  
Interval x Pre-post x Status 
6.2 
.11 
.49 
20.19 
.95 
.04 
.11 
.00** 
.89 
.61 
.000*** 
.39 
.95 
.89 
.30 
.00 
.03 
.58 
.06 
.00 
.00 
Measure: Number of solved tasks 
 
Status  
Interval 
Interval x Status  
Pre-post  
Pre-post x Status  
Interval x Pre-post   
Interval x Pre-post x Status  
F (1, 30) 
 
.98 
.18 
3.41 
6.69 
.03 
.01 
.01 
 
 
.32 
.67 
.38 
.01** 
.84 
.89 
.89 
 
 
.03 
.00 
.02 
.18 
.00 
.00 
.00 
Measure: Total time taken 
 
Status  
Interval 
Interval  x Status  
Pre-post  
Pre-post x Status  
Interval x Pre-post  
Interval x Pre-post x Status  
F (1, 30) 
 
11.81 
.09 
.06 
38.87 
1.97 
.03 
.10 
 
 
.00** 
.76 
.80 
.000*** 
.17 
.85 
.74 
 
 
.28 
.00 
.00 
.56 
.06 
.00 
.00 
* = p < .05; ** = p < .01; *** = p < .001 
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Effects of the MANOVA 
 
Main Effects 
 
There was a significant main effect of status F(2, 29) = 6.2, p = .00, partial 
eta squared = .30. There was also a highly significant main effect of Pre-post F(2, 
29) = 20.19, p = .000, partial eta squared = .58. The main effect of day vs. night 
interval was not significant F(2, 29) = .11, p = .89, partial eta squared = .00. There 
was no significant difference between day and night intervals.  
 
Interaction Effects 
 
 There were no significant interaction effects. Univariate results were 
examined on the dependent variables number of solved tasks and total time 
taken separately. 
 
Effects of the ANOVA 
 
Number of Solved Tasks 
 
Main Effects 
 
There was a significant main effect of pre-post with regard to number of 
solved tasks M = 10.37 vs. 11.09, F(1, 30) = 6.69, p = .01, partial eta squared = .18. 
The number of solved tasks significantly increased in the post test measurement 
(Figure 3.8). The other main effects were not significant. 
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Figure 3.8 Main effect of pre-post with regard to number of solved tasks in the 
Tower of London test (bars represent standard errors) 
 
Interaction effects 
 
 There were no significant interaction effects. 
 
Total time taken 
 
Main effects 
 
There was a significant main effect of status with regard to total time taken 
M = 531.79 vs. 280.21, F(1, 30) = 11.81, p = .00. Schizophrenia patients took 
significantly longer to complete the tower of London test than healthy controls 
(Figure 3.9). There was a highly significant main effect of pre-post with regard to 
total time taken M = 438.92 vs. 373.07, F(1, 30) = 38.87, p = .000, partial eta 
squared = .56. The time taken to complete the Tower of London test significantly 
reduced in the post test measurement (Figure 3.10). The other main effects were 
not significant. 
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Figure 3.9 Significant main effect of status with regard to total time taken in 
the Tower of London test (bars represent standard errors) 
 
 
 
Figure 3.10 Highly significant main effect of Pre-post with regard to total time 
taken in the Tower of London test (bars represent standard errors) 
Interaction effects 
 
There were no significant interaction effects. 
 
Summary 
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Patients took significantly longer time compared with healthy controls in 
the Tower of London test. There was an increase in performance with regard to 
the number of solved tasks and total time taken in the post test measurement. 
There was no significant difference between night interval performances 
compared with day interval performance in both groups 
 
3.3.2 Results of the Multivariate and Univariate Analyses of Variance for the 
Measures of the Tower of London- Day versus Night Interval (Schizophrenia 
Patients) 
 
A 2 (Interval: day interval vs. night interval) x 2 (Pre-post: pre vs. post) 
two-way mixed MANOVA with repeated measures was performed using the 
number of solved tasks and total time taken as dependent variables. The results 
are presented in Table 3.6. 
 
Table 3.6 Results of the Multivariate and Univariate Analyses of Variance for 
the Measures of the Tower of London- Day versus Night Interval 
(Schizophrenia Patients) 
Source F 
(2, 18) 
p η² 
Interval (Day vs. night) 
Pre-post  
Interval x Pre-post 
.17 
13.26 
.17 
.84 
.000*** 
.83 
.01 
.59 
.01 
Measure: Number of solved tasks 
 
Interval 
Pre-post  
Interval x Pre-post  
(1, 19) 
 
.11 
4.3 
.04 
 
 
.73 
.05* 
.83 
 
 
 
.00 
.18 
.00 
Measure: Total time taken 
 
Interval 
Pre-post  
Interval x Pre-post  
(1, 19) 
 
.14 
26.46 
.13 
 
 
 
.70 
.000*** 
.71 
 
 
.00 
.58 
.00 
* = p < .05; ** = p < .01; *** = p < .001 
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Main Effects of the MANOVA 
 
Main Effects 
 
There was a highly significant main effect of pre-post F(2, 18) = 13.26, p = 
.000, partial eta squared = .59. There was a significant increase in performance 
from pre to the post test measures. Schizophrenia patients solved more tasks and 
took significantly less time to complete the Tower of London Test in the post test 
measurement. 
 
Interaction Effects 
 
 Interval by pre-post interaction was not significant. 
 
Univariate results were examined on the dependent variables number of 
solved tasks and total time taken separately. 
 
Effects of the ANOVA 
 
Number of Solved Tasks 
 
Main Effects 
 
There was a significant main effect of pre-post with regard to number of 
solved tasks M = 10.00 vs. 10.77, F(1, 19) = 4.3, p = .05, partial eta squared = .18. 
Schizophrenia patients improved in the post test measurement with regard to 
number of solved tasks (Figure 3.11). The main effect of interval was not 
significant F(1, 19) = .11, p = .73, partial eta squared = .00 
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Figure 3.11 Main effect of pre-post with regard to number of solved 
tasks in the Tower of London test (bars represent standard errors) 
 
Interaction Effects 
 
Interval by pre-post interaction was not significant F(1, 19) = 0.4, p = .83, 
partial eta squared = .00 
 
Total Time Taken 
 
Main Effects 
 
There was a highly significant main effect of pre-post M = 572.14 vs. 
491.43, F(1, 19) = 26.46, p = .000, partial eta squared = .58. Schizophrenia patients 
took less time in the post test measures of the Tower of London test (Figure 3.12). 
The main effect of interval was not significant F(1, 19) = .14, p = .70, partial eta 
squared = .00. 
 
 
 
111 
 
 
 
 
 
Figure 3.12 Main effect of pre-post with regard to total time taken in the Tower 
of London test (bars represent standard errors) 
 
Interaction Effects 
 
Performance by pre-post interaction was not significant F(1, 19) = .13, p = 
.71, partial eta squared = .00. 
 
Summary 
 
There was no significant difference between day and night intervals in 
schizophrenia patients. Compared with pre test measures, in the post test 
measures schizophrenia patients solved more tasks and took significantly less 
time to complete the Tower of London Test. 
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3.3.3 Results of the Multivariate and Univariate Analyses of Variance for the 
Measures of the Tower of London – Day versus Night Interval (Healthy 
Controls) 
 
A 2 (Interval: day interval vs. night interval) x 2 (pre-post: pre vs. post) 
two-way mixed MANOVA with repeated measures was performed using the 
number of solved tasks and total time taken as dependent variables. The results 
are presented in Table 3.07. 
 
Table 3.7 Results of Multivariate and Univariate analyses of Variance for the 
Measures of the Tower of London – Day versus Night Interval (Healthy 
Controls). 
Factor F 
(2, 10) 
p η² 
Interval (Day versus night) 
Pre-post  
Interval  x Pre-post 
.47 
23.96 
.00 
.63 
.000*** 
.99 
.08 
.82 
.00 
Measure: Number of solved tasks 
 
Interval 
Pre-post  
Interval x Pre-post  
F (1, 11) 
 
1.03 
3.32 
.00 
 
 
.33 
.09 
1.0 
 
 
 
.08 
.23 
.00 
Measure: Total time taken 
 
Interval 
Pre-post  
Interval x Pre-post  
F (1, 11) 
 
.00 
49.92 
.01 
 
 
.94 
.000*** 
.90 
 
 
 
 
.00 
.81 
.00 
 * = p < .05; ** = p < .01; *** = p < .001 
 
 
Effects in the MANOVA 
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Main Effects 
 
There was no significant main effect of interval F(2, 10) = .47, p = .63, 
partial eta squared = .08. But there was a highly significant main effect of pre-
post F(2, 10) = 23.96, p = .000, partial eta squared = .89. Control participants took 
significantly less time to complete the Tower of London test in the post test 
measures.  
 
Interaction Effects 
 
The interaction effect of interval by pre-post was not significant F(2, 10) = 
.00, p = .99, partial eta squared = .00.  
 
Effects of the ANOVA 
 
Univariate results were examined on the dependent variables number of 
solved tasks and total time taken separately. 
 
Number of Solved Tasks 
 
Main Effects 
 
There was no significant main effect of interval F(1, 11) = 1.03, p = .33, 
partial eta squared = .08. The main effect of pre-post on number of solved tasks 
was also not significant F(1, 11) = 3.32, p = .09, partial eta squared = .23 
 
Interaction Effects 
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The interaction effect of interval by pre-post with regard to number of 
solved tasks was not significant F(1, 11) = .00, p = 1.0, partial eta squared = .00. 
 
Total Time Taken 
 
Main Effects 
 
There was no significant main effect of interval F(1, 11) = .00, p = .94, 
partial eta squared = .00. But, there was a highly significant main effect of pre-
post on total time taken M = 305.70 vs. 254.71, F(1, 11) = 49.92, p = .000, partial eta 
squared = .81. Control participants took significantly took less time to complete 
the Tower of London test in the post test measurement (Figure 3.13).  
 
 
 
Figure 3.13 Highly significant main effect of Pre-post with regard to total time 
taken in the Tower of London test (bars represent standard errors) 
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Interaction Effects 
 
The interaction effect of interval by pre-post with regard to total time 
taken was not significant F(1, 11) = .01, p = .90, partial eta squared = .00. 
 
 
Summary 
 
There was no significant difference between day and night interval 
performances in the healthy controls. Healthy control participants took 
significantly took less time to complete the Tower of London test in the post test 
measurement.  
 
 
3.4 Sleep EEG Results 
 
Group means of sleep EEG parameters of schizophrenia patients and 
healthy controls were reported in Table 3.8. 
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Table 3.8 Comparison of Sleep EEG Parameters – Schizophrenia Patients vs. Healthy Controls 
Measure 
Score 
 Patients (N = 20) Controls (N = 12) T- tests 
Range Mean SD Range Mean SD t df p 
TSR (min) 22-147 77.25 32.33 45-143 82.62 26.97 - .84 30 .40 
TSN (min) 250-377 312.65 39.92 170-360 306.33 49.53 .39 30 .69 
TS1 (min) 28-241 96.45 56.74 3-177 62.70 44.94 1.75 30 .09 
TS2 (min) 54-223 125.45 48.41 94-226 141.91 42.74 - .97 30 .33 
TS3 AND4 (min) 17-210 90.87 59.77 28-179 102.25 48.99 - .55 30 .58 
TOTAL SLEEP (min) 299-437 386.77 37.95 215-446 405.50 62.57 - .05 30 .29 
REM LATENCY (min) 65-263 141.05 45.19 62-269 127.50 51.74 .77 30 .44 
SLEEP LATENCY (min) 8-59 26.60 14.40 9-95 43.54 28.96 -2.21 30 .03* 
SLEEP EFFECIENCY % 72-96 85.46 7.08 48-95 85.13 12.66 .09 30 .92  
  NO OF SPINDLES 0-97 15.95 24.53 0-49 17.16 15.35 - .15 30 .87 
NUMBER OF K-
COMPLEXES 
10-131 65.85 30.03 14-109 63.41 27.58 .22 30 .82 
MOVEMENT TIME  0-11 2.52 2.83 0-9 2.20 2.34 .32 30 .74 
TSW (min) 
REM % 
NREM % 
STAGE 1 % 
STAGE 2 % 
STAGE 3 & 4 % 
WAKE  % 
MOVEMENT TIME % 
  TOTAL SLEEP  % 
9-118 
8-36 
65-95 
7-63 
17-56 
5-49 
3-38 
0-4 
63-91 
58.05 
19.76 
81.01 
25.30 
32.50 
23.23 
15.83 
.67 
80.57 
33.20 
7.67 
8.27 
15.35 
12.47 
14.52 
10.51 
.80 
7.90 
4-234 
12-36 
67-88 
1-41 
21-53 
12-44 
1-109 
0-3 
45-93 
74.95 
21.35 
75.79 
15.53 
35.70 
24.68 
22.31 
.57 
84.47 
57.07 
5.55 
6.45 
10.33 
10.85 
10.85 
28.11 
.61 
13.03 
-1.06 
- .62 
1.86 
1.94 
- .73 
- .29 
- .93 
.36 
-1.05 
30 
30 
30 
30 
30 
30 
30 
30 
30 
.29 
.53 
.07 
.06 
.46 
.76 
.35 
.71 
.29 
REM = Rapid eye Movement, NREM = Non-Rapid eye movement, TSR = Total sleep 
REM, TSN = Total sleep NREM, TS1 = Total sleep stage 1, TS2 = Total Sleep stage 2, 
TS3AND4 = Total sleep stage 3 and stage 4, TSW = Total stage wake. 
* Sig .05 (2 –Tailed) p < .05 
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3.4.1 Sleep EEG Parameters (Schizophrenia Patients vs. Healthy Controls) 
 
Independent samples t-tests were performed to compare the sleep EEG 
parameters between schizophrenia patients and healthy controls. The results 
were presented in Table 3.8. There was a significant difference between the 
schizophrenia patients and healthy controls with regard to sleep latency 
(patients M = 26.60, SD = 14.40; controls M = 43.54, SD = 28.96), t(30) = -2.21, p = 
.03 (Figure 3.14). Schizophrenia patients had short sleep latency. There were 
marginally significant difference with regard to sleep stage 1 (TS1), NREM 
percentage and stage 1 percentage.  
 
There were no significant differences between schizophrenia patients and 
healthy controls with regard to other sleep parameters like sleep REM (TSR), 
Non-Rapid eye movement (TSN), total sleep stage 2 (TS2), total sleep stage 3 and 
stage 4 (TS3AND4), total sleep, REM latency, sleep efficiency, number of 
spindles, number of K-complexes , movement time, total stage wake (TSW), 
REM %, stage 2 %, stage 3 & 4 %, wake %, movement time % and total sleep %. 
 
 
 
Figure 3.14 Mean of sleep latency in schizophrenia patients and healthy 
controls (bars represent standard errors) 
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Summary 
 
The comparison of sleep EEG parameters between schizophrenia patients 
and healthy controls showed a significant difference in sleep latency and 
marginal significant in sleep stage 1 and sleep stage 1 percentage; and non-rapid 
eye movement percentage (NREM %). Schizophrenia patients had shorter sleep 
latency. Patients and healthy controls does not differed significantly with regard 
to other sleep parameters like sleep REM (TSR), Non-Rapid eye movement 
(TSN), total sleep stage 2 (TS2), total sleep stage 3 and stage 4 (TS3AND4), total 
sleep, REM latency, sleep efficiency, number of spindles, number of K-
complexes , movement time, total stage wake (TSW), REM %, stage 2 %, stage 3 
& 4 %, wake %, movement time % and total sleep %. 
 
 
3.4.2 Correlation between Sleep Parameters and the Tower of London Test 
Measures 
 
 Pearson product-moment correlation coefficients were computed to assess 
the relationship between sleep parameters and the Tower of London test 
measures (number of solved tasks and total time taken). The correlation analysis 
results of schizophrenia patients and healthy controls were presented below in 
Table 3.9 and Table 3.10 
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Table 3.9 Correlation between Sleep Parameters and the Tower of London Measures 
(Schizophrenia Patients) N = 20 
Measure Number of solved 
tasks (night -pre) 
Number of solved 
Tasks (night -post) 
Total time taken 
(night -pre) 
Total time taken 
(night-post) 
TSR (min) 
r 
p 
 
.13 
.57 
 
.14 
.53 
 
-.01 
.94 
 
-.06 
.77 
TSN (min) 
r 
p 
 
.01 
.95 
 
.04 
.86 
 
-.28 
.21 
 
-.31 
.18 
TS1 (min) 
r 
p 
 
-.18 
.43 
 
-.50* 
.02 
 
.16 
.49 
 
.21 
.37 
TS2 (min) 
r 
p 
 
.27 
.24 
 
.33 
.15 
 
.26 
.26 
 
.18 
.43 
TS3AND4 (min) 
r 
p 
 
-.03 
.88 
 
.24 
.29 
 
-.56* 
.01 
 
-.55* 
.01 
Total Sleep (min) 
r 
p 
 
.10 
.67 
 
.14 
.54 
 
-.35 
.12 
 
-.39 
.08 
REM Latency (min) 
r 
p 
 
-.03 
.88 
 
-.23 
.32 
 
-.11 
.62 
 
-.03 
.88 
Sleep Latency (min) 
r 
p 
 
-.13 
.57 
 
-.07 
.75 
 
.09 
.69 
 
.04 
.85 
Sleep Efficiency % 
r 
p 
 
.27 
.24 
 
.31 
.17 
 
-.21 
.36 
 
-.24 
.30 
Number of Spindles 
r 
p 
 
.09 
.69 
 
-.06 
.77 
 
.15 
.51 
 
.08 
.72 
Number of K-complexes 
r 
p 
 
.56 
.01 
 
.63** 
.00 
 
-.08 
.73 
 
-.03 
.88 
Movement Time (min) 
r 
p 
 
.04 
.84 
 
.06 
.78 
 
-.34 
.14 
 
-.28 
.21 
Total stage Wake (min) 
r 
p 
 
-.27 
.24 
 
-.27 
.24 
 
.24 
.29 
 
.27 
.24 
REM% 
r 
p 
 
-.11 
.64 
 
.10 
.64 
 
.04 
.84 
 
-.01 
.96 
NREM % 
r 
p 
 
-.07 
.76 
 
-.07 
.75 
 
-.00 
.98 
 
.02 
.91 
Stage 1 % 
r 
p 
 
-.18 
.43 
 
-.51* 
.02 
 
.20 
.39 
 
.26 
.25 
Stage 2 % 
r 
p 
 
.27 
.24 
 
.32 
.16 
 
.36 
.11 
 
.31 
.18 
Stage 3 & 4 % 
r 
p 
 
-.07 
.74 
 
.22 
.33 
 
-.53 
.01 
 
-.54* 
.01 
Wake % 
r 
p 
 
-.22 
.33 
 
-.21 
.36 
 
.26 
.26 
 
.30 
.18 
Movement Time % 
r 
p 
 
.24 
.91 
 
.04 
.84 
 
-.30 
.19 
 
-.25 
.27 
Total Sleep % 
r 
p 
 
.10 
.67 
 
.14 
.54 
 
-.35 
.12 
 
-.39 
.08 
* Correlation is significant at the 0.05 level (2-tailed), ** Correlation is significant at the 0.01 level (2-tailed) 
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Table 3.10 Correlation between Sleep Parameters and the Tower of London Measures 
(Healthy Controls) N = 12 
Measure Number of solved 
tasks (night-pre) 
Number of solved 
Tasks (night-post) 
Total time taken 
(night-pre) 
Total time taken 
(Night-post) 
TSR (min) 
r 
p 
 
.11 
.73 
 
-.04 
.89 
 
-.05 
.87 
 
-.03 
.92 
TSN (min) 
r 
p 
 
-.26 
.40 
 
-.11 
.72 
 
.27 
.39 
 
.21 
.49 
TS1 (min) 
r 
p 
 
-.40 
.18 
 
-.17 
.58 
 
.35 
.25 
 
.30 
.33 
TS2 (min) 
r 
p 
 
.07 
.82 
 
-.20 
.52 
 
-.40 
.19 
 
-.27 
.38 
TS3AND4 (min) 
r 
p 
 
.03 
.90 
 
.23 
.46 
 
.28 
.36 
 
.18 
.57 
Total Sleep (min) 
r 
p 
 
-.29 
.34 
 
-.12 
.70 
 
.44 
.14 
 
.44 
.14 
REM Latency (min) 
r 
p 
 
.02 
.94 
 
.07 
.82 
 
.09 
.77 
 
.17 
.58 
Sleep Latency (min) 
r 
p 
 
.19 
.53 
 
.20 
.52 
 
-.08 
.80 
 
.00 
.98 
Sleep Efficiency % 
r 
p 
 
-.29 
.34 
 
-.12 
.69 
 
.46 
.12 
 
.44 
.15 
Number of Spindles 
r 
p 
 
.27 
.39 
 
.15 
.62 
 
-.68* 
.03 
 
-.70* 
.01 
Number of K-complexes 
r 
p 
 
-.37 
.23 
 
-.12 
.69 
 
-.34 
.27 
 
-.14 
.66 
Movement Time (min) 
r 
p 
 
-.04 
.88 
 
-.09 
.76 
 
-.20 
.52 
 
-.01 
.95 
Total stage Wake (min) 
r 
p 
 
.22 
.49 
 
.12 
.70 
 
-.15 
.62 
 
-.10 
.74 
REM% 
r 
p 
 
.29 
.35 
 
.02 
.94 
 
-.30 
.33 
 
-.28 
.37 
NREM% 
r 
p 
 
.04 
.89 
 
.00 
.97 
 
-29 
.35 
 
-.38 
.21 
Stage 1 % 
r 
p 
 
-.33 
.28 
 
-.14 
.66 
 
.24 
.44 
 
.18 
.55 
Stage 2 % 
r 
p 
 
.23 
.45 
 
-.12 
.69 
 
-.62* 
.03 
 
-.50 
.09 
Stage 3 & 4 % 
r 
p 
 
.10 
.74 
 
.27 
.38 
 
.21 
.51 
 
.09 
.78 
Wake % 
r 
p 
 
.22 
.47 
 
.10 
.74 
 
-.28 
.36 
 
-.27 
.39 
Movement Time % 
r 
p 
 
.02 
.93 
 
-.06 
.84 
 
-.26 
.40 
 
-.09 
.77 
Total Sleep % 
r 
p 
 
-.29 
.34 
 
-.12 
.70 
 
.44 
.14 
 
.44 
.14 
* Correlation is significant at the 0.05 level (2-tailed), ** Correlation is significant at the 0.01 level (2-tailed) 
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3.4.3 Correlation - Schizophrenia Patients 
 
 
3.4.3.1 Number of Solved Tasks 
 
There was a significant negative correlation between the number of solved 
tasks (night-post) and total sleep stage 1 (TS1), r = - .50, n = 20, p = .02 (Figure 
3.15). There was a highly significant positive correlation between the number of 
solved tasks (night-post) and the number of K-complexes r = .63, n = 20, p = .00 
(Figure 3.16). Number of solved tasks (night-post) also negatively correlated with 
stage 1 %, r = - .51, n = 20, p = .02 (Figure 3.17). 
 
 
 
Figure 3.15 Scatterplot of total sleep stage 1 (min) related to number of solved 
tasks (night-post) in 20 schizophrenia patients (r = - .50, p = .02). Less minutes 
of total sleep stage 1 was related to a higher number of solved tasks in the 
Tower of London test. 
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Figure 3.16 Scatterplot of number of k-complexes related to number of solved 
tasks (night-post) in 20 schizophrenia patients (r = .63, p = .00).  A greater 
number of K-complexes were related to a higher number of solved tasks in the 
Tower of London test. 
 
Figure 3.17 Scatterplot of stage 1 as a percentage of total time related to number 
of solved tasks (night-post) in 20 schizophrenia patients (r = - .51, p = .02). A 
lower percentage of stage 1 was related to a higher number of solved tasks in 
the Tower of London test. 
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3.4.3.2 Total Time Taken 
 
There was a negative correlation between total time taken (night-pre) and 
total sleep stage 3 and stage 4 (TS3AND4), r = - .56, n = 20, p = .01 (Figure 3.18). 
There was also a negative correlation between total time taken (night-post) and 
total sleep stage 3 and stage 4 (TS3AND4), r = - .55, n = 20, p = .01 (Figure 3.19). 
There was also a negative correlation between total time taken (night-post) and 
stage 3 & 4 %, r = - .54, n = 20, p = .01 (Figure 3.20). 
 
 
 
 
Figure 3.18 Scatterplot of total sleep stage 3 and stage 4 (min) related to total 
time taken (night-pre) in 20 schizophrenia patients (r = - .56, p = .01). Less time 
total sleep stage 3 and stage 4 was related to more time taken in the Tower of 
London test. 
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Figure 3.19 Scatterplot of total sleep stage 3 and stage 4 (min) related to total 
time taken (night-post) in 20 schizophrenia patients (r = - .55, p = .01). Less 
duration of total sleep stage 3 and stage 4 was related to more time taken in the 
Tower of London test. 
 
Figure 3.20 Scatterplot of stage 3 & 4 as a percentage of total sleep time related 
to total time taken (night-post) in 20 schizophrenia patients (r = - .54, p = .01). 
Small percentage of stage 3 & 4 was related to more time taken in the Tower of 
London test. 
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Summary  
The relationship between sleep parameters and the Tower of London test 
performance was evaluated. Some performance measures were differentially 
correlated to sleep specific variables. Schizophrenia patients showed a negative 
correlation between sleep stage 1 and sleep stage 1 percentage with number of 
solved tasks. This finding suggests that the less time patient spent on sleep stage 
1, the more tasks they solve. There was a significant positive correlation between 
the total number of K-complexes and the number of solved tasks in the Tower of 
London test. This finding shows the more K-complexes, the more tasks were 
solved. In schizophrenia patients sleep stage 3 and 4 and its percentage 
negatively correlated with total time taken to complete the Tower of London test. 
This finding shows the less time spent on stage 3 and 4, the longer it took to 
complete the Tower of London test.  
 
3.4.4 Correlation - Healthy Controls 
 
3.4.4.1 Number of Solved Tasks 
 
The number of solved tasks did not significantly correlate with regard to 
sleep parameters like total sleep REM (TSR), total sleep NREM (TSN), sleep 
stage 1 (TS1), sleep stage 2 (TS2), sleep stage 3 and 4 (TS3AND4), total sleep, 
REM latency, sleep efficiency, number of sleep spindles, number of K-
complexes, movement time, total stage wake (TSW), REM %, stage 1 %, stage 2 
%, stage 3 and 4 %, wake %, movement time % and total sleep%. 
 
3.4.4.2 Total Time Taken 
 
There was a negative correlation between total time taken (night-pre) and 
number of spindles, r = - .68, n = 12, p = .03 (Figure 3.21). There was also a 
negative correlation between total time taken (night-post) and number of 
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spindles, r = - .70, n = 12, p = .01 (Figure 3.22). Total time taken (night-pre) 
negatively correlated with Stage 2 %, r = - .62, n = 12, p = .03 (Figure 3.23). 
 
Figure 3.21 Scatterplot of number of spindles related to total time taken (night-
pre) in 12 healthy controls (r = - .68, p = .03). Less number of spindles was 
related to more time taken. 
 
Figure 3.22 Scatterplot of number of spindles related to the total time taken 
(night-post) in healthy controls (r = - .70, p = .01). Fewer spindles were related 
with more time taken. 
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Figure 3.23 Scatterplot of stage 2 as a percentage of total sleep time related to 
total time taken (night-pre) in 12 healthy controls (r = - .62, p = .03). A smaller 
percentage of stage 2 percent was related to more time taken. 
 
Summary 
 
The relationship between sleep parameters and the Tower of London test 
performance was evaluated. Some performance measures were differentially 
correlated to sleep specific variables. In healthy controls, a smaller number of 
spindles were negatively correlated with more total time taken to complete the 
Tower of London test. The less number of spindles, the healthy controls took 
longer to complete the Tower of London test. A smaller percentage of sleep stage 
2 % was related to more time taken to complete the Tower of London test. 
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CHAPTER 4 
 
        DISCUSSION 
 
There is evidence of problem solving process being improved by sleep.  
Problem solving as well as sleep have been shown to be impaired in patients 
with schizophrenia. The present study aimed at investigating relationship 
between the two domains. The principal findings of the current investigation 
were listed below. There was no advantage to night time interval compared to 
day time interval for improved problem solving performance in both groups. 
Compared with the healthy controls, schizophrenia patients performed generally 
worse on the experimental tasks. Schizophrenia patients as well as healthy 
controls improved their performance in the second measurement occasion. 
Compared to control participants, schizophrenia patients were impaired in their 
performance of neuropsychological tests and took significantly longer to 
complete the Tower of London test. Shorter sleep onset latency was observed in 
schizophrenia patients. There was a marginal significant in sleep stage1 and 
sleep stage 1 percentage; and non-rapid eye movement percentage (NREM %). 
There were no significant differences between schizophrenia patients and 
healthy controls with regard to other sleep parameters.  
 
To explore our hypothesis that sleep specific parameters contribute to the 
beneficial effects in problem solving measures, we examined the relationship 
between sleep parameters and the Tower of London test, the major findings in 
the patient group were: 1) less sleep stage 1 (min) and its percentage was related 
to a higher number of solved tasks; 2) a greater number of K-complexes were 
related to a higher number of solved tasks; 3) less minutes of sleep stage 3 & 4 
(min) and its percentage were related to more time taken to complete the Tower 
of London test. No comparable results were observed for the healthy controls. In 
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the healthy control group, the major findings were: 1) fewer sleep spindles were 
related to more time taken to complete the Tower of London test 2) a smaller 
percentage of sleep stage 2 was related to more time taken to complete the Tower 
of London test. 
 
4.1 Neuropsychology 
 
Neurocognitive impairments are fundamental characteristics in patients 
with schizophrenia. Patients with schizophrenia suffer from a wide range of 
cognitive deficits (keefe et al., 2006). In the present study overall, schizophrenia 
patients exhibited poorer performance on many variables of neuropsychological 
assessments. Among the neuropsychological functions assessed in the present 
study, highly significant differences between schizophrenia patients and healthy 
controls were found in areas of sustained attention, verbal memory, working 
memory, verbal fluency, problem solving and executive functions.  
 
There was no significant difference between schizophrenia patients and 
healthy controls with regard to Trail Making Test-A (attention and psychomotor 
speed). Our study did not replicate the finding of deficits in TMT-A in 
schizophrenia patients (Horacek et al., 2006). Their study sample included young 
schizophrenia patients with a mean age of 24.3 years. But in the present study, 
the mean age of patients was 41.25 years. This might be one the reason for the 
differences. There was a significant difference with regard to the Trial Making 
Test-B. Schizophrenia patients took longer to complete the Trial Making Test-B 
(Mental flexibility and executive functions) compared to the healthy controls. 
The Trial Making Test-B is thought to require executive control and mental 
flexibility. Our study replicates the finding of executive function deficits in 
patients with schizophrenia (Brickman et al., 2004; Rhinewine et al., 2005; Arngo 
et al., 1999). The inadequacy to plan effectively, added to longer fixation and 
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lacking planning sequence and accomplishing was established piece of evidence 
as the centre neuropsychological substrate for the Trail Making Test (TMT) 
deficits in patients with schizophrenia (Wölwer & Gaebel, 2002). 
 
Schizophrenia patients and healthy controls did not differ significantly in 
verbal intelligence (Multiple Choice Word Comprehension Test- MWT-B). 
Morrison et al. (2006) study have reported verbal intelligence deficit in patients 
with schizophrenia. The present study did not confirm the finding of verbal 
intelligence deficit in patients with schizophrenia. Their study was a long time 
study with baseline and follow-up over an average of thirty three years. Their 
study used the Mill Hill Vocabulary Scale (MHVS) diagnostic instrument to 
assess verbal intelligence. This might be the reasons for the differences. 
Schizophrenia patients performed significantly worse than the healthy controls 
on the test of sustained attention, speed of processing and visuo-motor co-
ordination (Digit Symbol Test). There was a highly significant difference between 
schizophrenia patients and healthy controls on this test. The present study result 
replicates the finding of sustained attention deficits in patients with 
schizophrenia (Liu et al., 2002). There was a significant difference between 
schizophrenia patients and healthy controls on a test of verbal fluency 
(Controlled Oral Word Association Test). Schizophrenia patients showed a 
deficit in verbal fluency. Our study confirms the finding of verbal fluency deficits 
in patients with schizophrenia (Landrø & Ueland, 2008). 
 
There was a highly significant difference between schizophrenia patients 
and healthy controls on measures of memory and learning potential (Verbal 
Learning and Memory Test). Schizophrenia patients show a deficit in memory 
and learning potential. The present study confirms previous finding of 
pronounced memory impairments in patients with schizophrenia (Sartory et al., 
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2001, Mueller et al., 2004; Kravariti et al., 2007; Boker et al., 2006; Aleman et al., 
1999). 
 
Summary 
 
Summarizing our findings, patients with schizophrenia showed deficits as 
compared to healthy controls in a number of tasks that seem to tap higher levels 
of cognitive functioning. Patients with schizophrenia exhibit more neurological 
signs than healthy control participants. Neurocognitive deficits are well 
documented in patients with schizophrenia. In the present study sustained 
attention deficits are more pronounced in patients with schizophrenia. Memory 
impairments also appear to be highly evident in patients with schizophrenia. 
Information processing speed may also be regarded as a one of most affected 
cognitive domain in patients with schizophrenia. Taken together, the present 
findings on neuropsychological tests confirm the fact that patients with 
schizophrenia have neuropsychological impairments (Mojtabai et al., 2000; Wilk 
& Gold, 2005).  
 
4.2 Results of the Tower of London Test Measures  
 
4.2.1 Schizophrenia Patients vs. Healthy Controls (Day vs. Night Performance) 
 
Schizophrenia patients performed generally worse on the experimental 
task compared to the healthy controls and both groups showed learning on the 
tasks (ex: they performed better in the second measurement compared to the first 
measurement). There was no advantage to night-time interval compared to the 
day-time interval in schizophrenia patients as well as in healthy controls. In 
general sleep had no effect on the task performance in contrast to a comparable 
time of wakefulness in both groups. Compared with the control participants, 
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schizophrenia patients took significantly longer time to complete the Tower of 
London test. Schizophrenia patients took average of 532 seconds, whereas 
control participants took 281 seconds to complete the Tower of London test. 
There was no significant difference on the number of solved tasks between 
schizophrenia patients and healthy controls. Compared to pre-test measurement, 
in post-test measurement schizophrenia patients as well as healthy controls 
solved more tasks and took significantly less time to complete the Tower of 
London test.  
 
The findings of the present study in the direction of sleep and improved 
performance failed to confirm the findings of the research study by Wagner et al. 
(2004). Wagner et al. (2004) study on the effects of sleep on the occurrence of 
insight in healthy controls used a modified version of a mathematical “number 
reduction task” (Turnstone & Thurstone, 1941) in healthy controls on awake 
group and sleep group. Participants apply a standard algorithm (consisting of 
two simple rules) for reducing an eight-digit sequence to a final solution. 
Participants do not know that a simple shortcut exists. The percentage of 
participants who discover the shortcut or ‘hidden rule’ when they are retested 
was 22% in the awake group versus 60% in the sleep group. They have 
concluded that sleeping allows the restructuring of new memory representations 
and facilitates extraction of explicit knowledge and insightful behavior. There 
may be three reasons why the present results differ: (1) the type of tasks used is 
different from the present study (2) type of assessment also differs and; (3) 
control condition kept awake: keeping awake at night leads to deterioration in 
performance. 
 
The present study finding is not in line with the evidence of beneficial 
effect of sleep on improved problem solving performance. A study by Linde and 
Bergstrom (1992) investigated sleep loss on performance of complex tasks 
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problem solving compared with exclusively short term memory tasks. Their 
study included two tasks: first one examined immediate free recall, estimated to 
reflect the maintenance capability of working memory and the other one was 
lingual reasoning and problem solving measures, speculated to reflect the 
processing and monitoring capability of working memory. They have kept the 
participants in the experimental group awake and tested on various cognitive 
measures. Control group was allowed to sleep at home. They found a remarkable 
decline in performance left by a sleep loss on Raven’s progressive matrices, a 
problem solving measure. They also found that the control group who have slept 
well performed higher in the tests. Their study reported that there is a significant 
decline in performance on sleep loss and improved performance when followed 
by sleep. There are some of the possible reasons for the failure of a sleep induced 
improved performance in the present study. Firstly, type of task they used is 
different from the present study. Secondly, they kept the experimental group 
awake. The type of assessment is very different from the present study. Sleep 
and improved performance are not a very robust phenomenon. It depends on the 
type of learning and the time interval between learning and sleep. Thus, it may 
be possible that same of the other factors influencing the sleep and improved 
problem solving effect did prevent or override this effect.  
 
Incomplete adaption to the sleep laboratory environment may also be one 
of the reasons why our participants did not explicitly show overall beneficial 
post sleep performance in the Tower of London test. Secondly the present 
research study sample is too low to draw any such authentic conclusion. 
 
4.2.2 Schizophrenia Patients (Day Interval vs. Night Interval Performance) 
 
There was no significant difference in the Tower of London test 
performance between night time and day time interval. There was no advantage 
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to the night time interval compared with the day time interval. Schizophrenia 
patients significantly improved in post-test measures of the Tower of London 
test. In post-test measures, schizophrenia patients solved more tasks and took 
less time to complete the Tower of London test.  
 
4.2.3 Healthy Controls (Day Interval vs. Night Interval Performance) 
 
There was no significant difference in the Tower of London test 
performance between night time interval and day time interval. There was no 
advantage to the night time interval compared with the day time interval for the 
healthy controls as well. There was no significant difference on the number of 
solved tasks in the Tower of London test between pre-test and post-test 
measures. But there was a significant difference in total time taken between pre-
test and post-test measures. In the post-test measurement the total time taken to 
complete the test is drastically reduced.  
 
Summary 
 
Schizophrenia patients performed generally worse on the experimental 
task (The Tower of London Test) compared to the healthy controls and both 
groups showed learning on the tasks. There was an increase in performance in 
both the groups in the second measurement occasion. Generally sleep had no 
effect on task performance in contrast to a comparable time of wakefulness in 
both groups. There was no advantage to night time interval compared with the 
day time interval in both groups. Compared to the healthy controls, 
schizophrenia patients took significantly longer time to complete the Tower of 
London test.  
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4.3 Comparison of Sleep EEG Parameters – Schizophrenia vs. Healthy Controls 
 
The comparison of sleep EEG parameters between the two groups shows a 
significant difference in sleep onset latency. Schizophrenia patients had shorter 
sleep onset latency. There was a marginal significant difference in sleep stage 1, 
sleep stage 1 percentage and Non-rapid eye movement percentage (NREM %). 
The present study did not show the characteristic features of sleep disturbance 
reported in the previous research studies in patients with schizophrenia. We 
failed to find significant differences with regard to the other sleep parameters. 
 
Previous sleep studies in schizophrenia patients have compared sleep 
latency between schizophrenia patients and healthy controls (Keshavan et al., 
1998; Lauer et al., 1997; Yetkin et al., 2011) have shown increased sleep latency in 
patients with schizophrenia. The present study did not confirm the finding. In 
the present study sleep latency significantly differ between schizophrenia 
patients and healthy controls. Shorter sleep onset latency was observed in 
schizophrenia patients. However, this may be attributed to the sleep-promoting 
effect of the neuroleptic medication patients have taken.  
 
A study by Yetkin et al. (2011) on sleep architecture in patients with 
schizophrenia reported poor sleep efficiency in patients with schizophrenia. The 
present study results did not replicates the finding of poor sleep efficiency in 
patients with schizophrenia. The present study did not find a significant 
difference in sleep efficiency between schizophrenia patients and healthy 
controls. Their study included only male inpatients with schizophrenia. The 
difference in sleep efficiency may be because of this reason. There was a marginal 
significant difference in sleep stage 1 and its percentage (Stage 1 and stage 1%) 
between schizophrenia patients and healthy controls.  
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The present study did not find a significant difference in sleep stage 2 
percent (Stage 2%) between schizophrenia patients and healthy controls. The 
present finding is consistent with some previous research studies (Benson et al., 
1996; Ganguli et al., 1987; Jus et al., 1973; Riemann et al., 1995; Yetkin et al., 2011) 
found no significant differences in sleep stage 2 percent in schizophrenia 
patients. A study by Ferrarelli et al. (2007) examined sleep rhythms variations 
between schizophrenia patients and healthy controls also found no difference in 
sleep stage 2 in schizophrenia patients. 
 
Slow wave sleep deficit claimed to be typical for schizophrenia patients. 
Previous studies have shown a reduction of slow wave sleep in patients with 
schizophrenia (Caldwell & Domino., 1967; Keshavan et al., 1998; Poulin at al., 
2003; Hiatt et al., 1985). However in the present study we did not find slow wave 
sleep deficit in patients with schizophrenia. There was no significant difference 
between schizophrenia patients and healthy controls in either on sleep stage 3 
and 4 (TS3AND4) or sleep stage 3 and 4 percentage. The present study confirms 
the finding of Ganguli et al. (1987) study. Their study found slow-wave sleep 
percent of schizophrenia patients was similar to that seen in the healthy controls. 
The present study also confirms the finding of Tandon et al. (1992). Their study 
has found no difference in slow-wave sleep between schizophrenia patients and 
normal controls. A study by Lauer et al. (1997) also found no difference in slow 
wave sleep percentage between schizophrenia patients and healthy controls. 
Ferrarelli et al. (2010) and Yetkin et al., (2011) studies also found no slow wave 
sleep deficits in schizophrenia patients compared to the control participants. 
 
Poulin at al. (2003) study have compared REM latency between 
schizophrenia patients and healthy controls reported reduced REM latency in 
schizophrenia patients. In the present study REM latency did not differ 
significantly between patients with schizophrenia patients and healthy controls. 
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Their study included acute schizophrenia patients never treated with 
neuroleptics. But in the present study, patients were mildly symptomatically 
affected and were on medications. So the differences in finding may be due to 
this reason. But the present study confirms the finding of Ganguli et al. (1987) 
study. Their study found no difference in sleep REM latency in schizophrenia 
patients compared with control participants. The present study also confirms 
Caldwell and Domino (1967) and Yetkin et al. (2011) study. Their studies also 
observed no reduction in REM latency in patients with schizophrenia.  
 
Previous studies have compared the REM percent between schizophrenia 
patients and healthy controls (Benson et al., 1996; Ganguli et al., 1987; Jus et al., 
1973; Keshavan et al., 1998., Riemann et al., 1995; Yang & Winkelman., 2005) 
found no significant difference in REM percent. The present study confirms the 
finding. In the present study, REM percentage did not differ between 
schizophrenia patients and healthy controls. 
 
In the present study, total sleep time did not differ between schizophrenia 
patients and healthy controls. The present finding is consistent with the finding 
of Hoffmann et al. (2000). Their study found no difference in total sleep time 
between schizophrenia patients and healthy controls. But the present finding is 
inconsistent with the report of Keshavan et al. (1998) study. Their study found 
decreased total sleep time in schizophrenia patients compared to healthy 
controls. Keshavan et al. (1998) study included unmedicated schizophrenia 
patients. This may be one of the reasons for the differences in total sleep time.  
 
Macrostructures of sleep EEG rely on successful sleep epochs. The sleep 
EEG scores characterization by stages and epochs are macrostructures of the 
sleep (Muzet, 2005). Macrostructures of sleep are highly investigated domain. In 
clinical electrophysiology, both the macro and microstructures of sleep are 
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clinically relevant. But hardly few studied about the microstructures of sleep of 
EEG in patients with schizophrenia (K-complex and spindles). 
 
Ferrarelli et al. (2007) engaged 256-electrode high density EEG to examine 
whether sleep rhythms vary between patients with schizophrenia, healthy 
controls and people with history of depression. They found spindle deficits in 
patients with patients with schizophrenia. Another study by Ferrarelli et al. 
(2010) also reported sleep spindle deficits in schizophrenia patients and 
suggested impairments in specific neuronal circuits. In the present study, 
number of spindles did not differ significantly between schizophrenia patients 
and healthy controls. We did not find reduced sleep spindle activity in 
schizophrenia patients. There are a number of possible reasons for the differences 
in the present study. The present study used Rechtscaffen and kales, 1968 
manual for scoring sleep stages and used 16 channels polygraph. Ferrarelli et al. 
(2007) study had used 256-electrode high density EEG and used different scoring 
methods. Ferrarelli et al. (2010) also used 256-electrode high density EEG. These 
may be some of the possible reasons for the differences. 
 
K-complexes are well known to be a hallmark of sleep stage 2 (Happe et 
al., 2002). There are no reported abnormalities in K-complexes in patients with 
schizophrenia. The present study did not find significant differences in the 
number of K-complexes between schizophrenia patients and healthy controls. 
 
Summary 
 
Sleep parameters did not substantially differ between schizophrenia 
patients and healthy controls, except to shorter sleep onset latency in 
schizophrenia patients. If we see the overall sleep parameters in the present 
study, schizophrenia patients did not show worse or classical symptoms 
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consistently reported in previous sleep studies on schizophrenia. One of the 
primary reasons is, the present study included medicated and clinically stable 
patients with schizophrenia. The clinical rating scales confirmed the diagnosis of 
the schizophrenia patients and showed that they were only mildly 
symptomatically affected. The present study patient sample population did not 
included in-patients with schizophrenia. Some of the reasons why sleep studies 
on patients with schizophrenia failed to generate consistent findings were, some 
previous studies did not include habituation night so the results on sleep 
parameters were worse. Sleep EEG findings are influenced by treatment and 
phases of illness, problems with diagnostic procedure, difference in scoring 
methods, confound of age, confound of gender, degree of chronicity, 
schizophrenia subtypes and effects of the medication. 
 
4.4 Correlation between Sleep Parameters and the Tower of London Test 
 
The relationship between sleep parameters and problem solving (the 
Tower of London test) was evaluated in schizophrenia patients and healthy 
controls. Some performance measures were differentially correlated with specific 
sleep parameters. Schizophrenia patients showed a negative correlation between 
stage 1 sleep and its percent with the number of solved tasks in the Tower of 
London test. This finding suggest that if less time schizophrenia patient spent on 
stage 1 sleep, the more they solve tasks in the Tower of London test. No 
comparable results were observed for the healthy controls. 
 
In schizophrenia patients we observed a significant strong positive 
relationship between the total number of K-complexes and number of solved 
tasks in the Tower of London test. No comparable results were observed for the 
healthy controls. This finding suggests when the number of K-complexes are 
more, the more tasks they solve problems in the Tower of London test. The 
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correlation between the number of K-complexes and performance after sleep in 
schizophrenia patients shows that processes during stage 2 sleep, in which the K-
complexes predominantly occurs may be beneficial for the neuropsychological 
performance. K-complexes occur spontaneously but often are elicited by external 
or internal stimulation. They are assumed to suppress or indicate the suppression 
of cortical arousal evoked by stimulation or waking state activation like learning 
(Tononi & Cirelli, 2006). In sleep stages more K-complexes were indicative of 
deeper sleep and are more frequent as the proximity of the slow wave sleep 
(SWS) increases (Colrain, 2005; Halász et al., 1977). K-complexes possibly 
generated through an extra-thalamic or non-specific thalamic pathway (Colrain 
& Crowley, 2005). With regard to the latter function, K-complexes are proposed 
to be correlated to memory consolidation during sleep. Particularly, K-complexes 
are assumed to represent cortical down-state during sleep which is essential for a 
repeated practise of encoded memory engrams (Cash et al., 2009). K-complexes 
in humans have been shown to be identical to down-states in the slow wave 
sleep which are assumed to play a pivotal role in memory consolidation due to 
the replay of transient hippocampus-based activity into long term memory 
engrams (Cash et al., 2009). The higher the number of K-complexes, the more 
synaptic downscaling occurred and the better the encoded memory engrams can 
be consolidated. Thus it can be reasonable to assume that the correlation of a 
higher number of K-complexes with a better performance following these K-
complexes in patients indicates that the schizophrenia patients did incurred 
benefit from a more extensive downscaling of synaptic activity (Tononi & Cirelli, 
2006), although this effect was not strong enough for a general improvement 
compared to wakefulness.  
 
K-complexes in some of previous studies are explained in terms of arousal 
phenomenon (Roth et al., 1956). Some of previous studies suggest K-complexes 
maybe involved in sleep protective mechanism (Wauquier et al., 2009; 1995; 
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Muzet, 2005; Vetter & Boker, 1962). Some other reviews suggest K-complexes 
may engage in sleep specific information processing during sleep (Halász, 2005; 
Muzet, 2005).  
 
In schizophrenia patients sleep stage 3 and 4 (slow wave sleep or deep 
sleep or delta sleep) and its percentage negatively correlated with a total time 
taken to complete the Tower of London test. The result pattern suggests that if 
patients spend less time on sleep stage 3 and 4 (SWS), the longer they took to 
complete the Tower of London test. Slow wave sleep (SWS) often referred to as 
deep sleep and thought to be the most restorative sleep. 
 
Among the healthy controls the number of spindles negatively correlated 
with a total time taken to complete the Tower of London test. This finding 
suggests that if the number of spindles is less; the longer the participants took to 
complete the Tower of London test. Sleep spindles are widely studied in the 
sleep research. However, no study found a correlation between the number of 
spindles and problem solving performance.  
 
Among human sleep spindle activity are inferred to be related with 
memory consolidation (Gais et al., 2002; Clemens et al., 2005; Walker et al., 2002). 
Increased sleep stage 2 spindle activity is related to an increase in recall 
performance and thus, may reflect memory consolidation (Schabus et al., 2004). 
Sleep spindle activity may be associated with improved cognitive performance 
(Schabus et al., 2006). The function of the sleep spindle is associated to memory 
consolidation and intellectual ability (Fogel & Smith, 2011). These different 
findings on IQ and memory domains suggest the link between the sleep spindles 
and cognitive performances.  
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4.5 Hypotheses and Results at a Glance 
 
 
 
 
 
        
 
 
 
 
 
  
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
4.6 Conclusions 
 
The present study shows that patients with schizophrenia suffer from a 
wide range of cognitive deficits including sustained attention, verbal memory, 
Schizophrenia patients show 
impairment on neuropsychological 
tests compared with the healthy 
controls  
Support for this hypothesis found 
as schizophrenia patients 
performed worse in most 
neuropsychological tests 
Schizophrenia patients will have 
impaired sleep parameters 
compared with healthy controls 
 
Support for this hypothesis was 
not found, as patients and 
controls do not differ significantly 
in sleep parameters except sleep 
Latency 
Schizophrenia patients will have 
deficits in problem solving 
 
 
 
 
Support for this hypothesis 
partially found as patients took 
longer to complete the Tower of 
London test 
Night time interval (post sleep 
performance) will be more 
beneficial than day time interval 
for problem solving 
 
 
 
 
 
 
 
 
Support for this hypothesis not 
found as interval is not significant 
Specific sleep parameters will be 
related to improved problem 
solving performance in 
schizophrenia patients 
 
Support for this hypothesis found 
as the number of K-complexes 
related to measures of the Tower 
of London test 
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working memory, long term memory, verbal fluency, problem solving and 
executive functions. Sustained attention, speed of processing and working 
memory deficits are more pronounced in patients with schizophrenia. 
Schizophrenia patients took significantly longer to complete the Tower of 
London test.  
 
Compared to the healthy controls, schizophrenia patients performed 
generally worse on the Tower of London test. Both groups showed learning on 
the tasks ex: they performed better in second compared to the first measurement. 
In general sleep had no effect on task performance in contrast to the comparable 
time of wakefulness in both groups. There was no advantage of night time 
interval compared to the day time interval for improved problem solving in both 
groups.  
 
Sleep parameters did not substantially differ between schizophrenia 
patients and healthy controls, except shorter sleep onset latency in schizophrenia 
patients. The latter showed a marginally longer percentage of sleep stage 1 than 
the healthy controls. There were no other significant group differences with 
regard to sleep continuity (number of wakening and wake after sleep onset, sleep 
efficiency, total sleep time), sleep architecture (The percentages of sleep stage 2, 3 
and 4, and stage REM), and REM sleep measures (REM latency).  
 
However, some performance measures were differently correlated to 
specific sleep parameters. Sleep specific parameter, the number of K-complexes, 
somewhat had a beneficial effect for problem solving in patients with 
schizophrenia. Although this effect did not enhance total performance of the 
schizophrenia patients, the result shows that within the cognitive impairment of 
schizophrenia patients, beneficial effects of sleep can be assessed. These 
promoting effects of sleep were however too weak to generally enhance the 
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performance measures compared to a time of wakefulness or compared to 
healthy control participants. The overall results indicate different modes of 
problem solving associated to sleep in schizophrenia patients and healthy 
controls.  
 
 
4.7 Limitations of the Present Study 
 
          There are several limitations of this study. The present study sample did 
not include inpatients with schizophrenia. The sample included clinically stable 
and mildly symptomatically affected outpatients with schizophrenia. The sample 
size is limited to draw any major strong conclusions.  Since there is no previous 
study done on sleep and problem solving in patients with schizophrenia, this 
study on sleep and problem solving is more exploratory. We took extreme care to 
report and interpret the findings. 
 
4.8 Future Directions of Research 
 
         Future study has to be conducted on large sample size investigating the 
microstructures of sleep EEG. 
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SUMMARY 
There is an evidence of problem solving process being improved by sleep 
in the healthy controls. Previous studies show REM sleep enhances creative 
problem solving and slow wave sleep is also shown to have positive effects for 
problem solving process. Problem solving as well as sleep has been shown to be 
impaired in schizophrenia patients. The present study aimed at exploring and 
investigating relationships between sleep and problem solving in patients with 
schizophrenia.  
 
A consolidation paradigm was used to investigate the question. 
Participants were tested a day- and night-time condition following learning, 
separated by a week, with half of them being allocated to the night or the day 
condition first in a balanced design. Sleep parameters examined by means of a 
whole night polysomnography. 
 
The present study shows that patients with schizophrenia suffer from a 
wide range of cognitive deficits including sustained attention, verbal memory, 
working memory, long term memory, verbal fluency, problem solving and 
executive functions. Sustained attention, speed of processing and working 
memory deficits are more pronounced in patients with schizophrenia. 
Schizophrenia patients performed generally worse in the Tower of London test 
compared to the healthy controls. Patients took significantly longer to complete 
the Tower of London test. In general, sleep had no effect on task performance in 
contrast to a comparable wakefulness in both groups. Sleep parameters did not 
substantially differ between schizophrenia patients and healthy controls, except 
shorter sleep onset latency in the patients. Some performance measures were 
differently correlated to specific sleep parameters. In the patients, a higher 
number of K-complexes were associated with a higher number of solved tasks in 
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the Tower of London following sleep. In addition, a less time spent in slow wave 
sleep was associated with a more time taken to solve the Tower of London tasks. 
No comparable results were observed for the healthy controls. In the controls, 
less number of sleep spindles was associated with more total time taken in the 
Tower of London test.  
 
In sum, the present study revealed that sleep specific parameter the 
number of K-complexes had a beneficial effect on problem solving in patients 
with schizophrenia. Although this effect did not enhance total performance of 
the schizophrenia patients, the result pattern indicate that within the cognitive 
impairment of patients with schizophrenia, beneficial effects of sleep can be 
assessed. These promoting effects of sleep were nevertheless too weak to 
generally enhance the performance measures compared to a time of wakefulness 
or compared to the healthy controls. Nonetheless, they probably point to 
schizophrenia specific process during sleep, which may be helpful for the 
understanding of cognitive disturbances of this disorder. The overall results 
indicate different modes of problem solving associated to sleep in schizophrenia 
patients and healthy controls.  
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    Appendix A 
 
 
 
Figure A1 Mean scores of number of solved tasks in the Tower of London test - 
Day before night group - Schizophrenia patients (bars represent standard 
errors) 
 
 
Figure A2 Mean scores of number of solved tasks in the Tower of London test 
– Night before day group - Schizophrenia patients (bars represent standard 
errors) 
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Figure A3 Mean scores of total time taken in the Tower of London test – Day 
before night group - Schizophrenia patients (bars represent standard errors) 
 
 
 
Figure A4 Mean scores of total time taken in the Tower of London test – Night 
before day group - Schizophrenia patients (bars represent standard errors) 
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Figure A5 Mean scores of number of solved tasks in the Tower of London test 
– Day before night group - Healthy controls (bars represent standard errors) 
 
 
 
Figure A6 Mean scores of number of solved tasks in the Tower of London test 
– Night before day group - Healthy controls (bars represent standard errors) 
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Figure A7 Mean scores of total time taken in the Tower of London test – Day 
before night group - Healthy controls (bars represent standard errors) 
 
 
 
 
Figure A8 Mean scores of total time taken in the Tower of London test – Night 
before day group - Healthy controls (bars represent standard errors) 
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Figure A9 Mean scores of number of solved tasks in the Tower of London test - 
Day vs. night interval – (Schizophrenia patients) (bars represent standard 
errors) 
 
 
 
 
Figure A10 Mean scores of total time taken in the Tower of London test - Day 
vs. night interval – (Schizophrenia patients) (bars represent standard errors) 
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Figure A11 Mean scores of number of solved tasks in the Tower of London test 
- Day vs. night interval – (Healthy controls) (bars represent standard errors) 
 
 
 
 
Figure A12 Mean scores of total time taken in the Tower of London test - Day 
vs. night interval – (Healthy controls) (bars represent standard errors) 
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Appendix B 
 
B1 Experimental Task Results – Tower of London Measures – Preliminary 
Analyses. 
 
The mean scores and standard deviations of schizophrenia patients and 
healthy controls of the measures of the Tower of London are presented in Table 
B1 and Table B2. The figures of mean scores for the Tower of London measures 
were presented in Appendix A 
 
 
Table B1 Mean scores for the measures of the Tower of London – Number of 
solved tasks  
 Number of Solved Tasks 
 Schizophrenia Patients Healthy Controls 
 
      M                  SD          (Range) 
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    9.40                4.28          (1-14) 
 
    9.90                2.92          (3-14) 
9.33         1.63     (7-11) 
 
11.83         2.48     (8-15) 
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Post 
 
  10.70                2.26          (8-15) 
 
  10.70                2.79          (6-15) 
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11.67        1.36     (10-14) 
N
ig
ht
 B
ef
or
e 
D
ay
 
G
ro
up
 p
at
ie
nt
s 
N
 =
10
, 
C
on
tr
ol
s 
N
 =
 6
 
 
Night 
Block 
1 
 
Pre 
 
Post 
 
    9.20                 .77           (5-12) 
 
  10.60                 .61           (8-15) 
10.50        1.87     (8-13) 
 
11.67        1.63      (10-14) 
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Block 
2 
Pre 
 
Post 
  10.70                 .70           (7-14) 
 
  11.90                 .54           (9-14) 
11.67         2.06      (8-14) 
 
10.50         2.07      (8-13) 
M = Mean, SD = Standard Deviation, N = Number 
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Table B2 Mean scores for the measures of the Tower of London – Total time 
taken 
 Total Time Taken 
 
Schizophrenia Patients 
 
Healthy Controls 
 
M                   SD           (Range) 
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Night 
Block 
2 
Pre 
 
Post 
 
497.95            249.89    (264-938) 
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625.10            188.46    (414-1120) 
 
498.57            158.83    (337-920) 
378.16         102.11      (222-538) 
 
296.21           82.07      (190-407) 
 
Day 
Block 
2 
Pre 
 
Post 
429.61            108.88    (276-641) 
 
399.68            116.47   (276-643) 
253.51           61.22      (162-307) 
 
245.83           69.85      (149-320) 
M = Mean, SD = Standard Deviation, N = Number 
 
 
B 1.1 Results of Multivariate and Univariate Analyses of Variance for the 
Measures of the Tower of London (Schizophrenia Patients versus Healthy 
Controls) 
 
A 2 (Status: schizophrenia patients vs. healthy controls) x 2 (Group: day 
before night vs. night before day) x 2 (Block: block 1 vs. block 2) x 2 (pre-post: pre 
vs. post) four-way mixed MANOVA with repeated measures on the last two 
factors was performed using the number of solved tasks and total time taken as 
dependent variables. The multivariate and univariate results are presented in 
Table B3 and Table B4 respectively. 
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Table B3 Results of multivariate analyses of variance of the measures of the 
Tower of London (Schizophrenia patients vs. healthy controls) 
 
Effect F 
(2, 27) 
p η²  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group (Day Night / Night Day) 
Status (Patients vs. controls) 
Group x Status 
Block  
Block x Group 
Block x Status 
Block x Group  x Status 
Pre-post 
Pre-post x Group 
Pre-post x Status 
Pre-post x Group x Status 
Block x Pre-post 
Block x Pre-post x Group 
Block x Pre-post x Status 
Block x Pre-post x Group  x Status 
 
.12 
6.0 
.33 
22.93 
.36 
2.68 
.50 
19.22 
.09 
.89 
2.44 
10.33 
.02 
2.60 
.07 
 
 
.88 
.00** 
.72 
.000*** 
.69 
.08 
.61 
.000*** 
.90 
.42 
.10 
.000*** 
.97 
.09 
.92 
 
 
.00 
.30 
.02 
.62 
.02 
.16 
.03 
.58 
.00 
.06 
.15 
.43 
.00 
.16 
.00 
 
 
* = p < .05; ** = p < .01; *** = p < .001 
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Table B4 Univariate analysis of variance results for the measures of the Tower 
of London (Schizophrenia patients vs. healthy controls) 
 
Source F 
(1, 28) 
p η²  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measure : Number of solved tasks 
 
Group (Day Night / Night Day) 
Status (Patients vs. controls) 
Group x Status  
Block 
Block x Group  
Block x Status 
Block x Group x Status  
Pre-post 
Pre-post x Group 
Pre-post x Status 
Pre-post x Group x Status  
Block x Pre-post  
Block x Pre-post x Group 
Block x Pre-post x Status 
Block x Pre-post x Group x Status 
 
 
.08 
.92 
.08 
6.4 
.23 
1.14 
.99 
7.3 
.07 
.04 
5.0 
6.9 
.02 
3.8 
.02 
 
 
.77 
.34 
.77 
.01** 
.63 
.29 
.32 
.01** 
.79 
.84 
.03* 
.01** 
.88 
.06 
.88 
 
 
.00 
.03 
.00 
.18 
.00 
.03 
.03 
.20 
.00 
.00 
.15 
.19 
.00 
.12 
.00 
Measure : Total time taken 
 
Group (Day Night / Night Day) 
Status (Patient vs. controls) 
Group x Status  
Block 
Block x Group  
Block x Status  
Block x Group x Status  
Pre-post 
Pre-post x  Group 
Pre-post x Status 
Pre-post x Group x Status  
Block x Pre-post  
Block x Pre-post x Group 
Block x Pre-post x Status 
Block x Pre-post x Group x Status 
 
 
.16 
11.43 
.58 
29.75 
.31 
2.98 
.23 
36.51 
.15 
1.85 
.02 
20.77 
.00 
.11 
.07 
 
 
.68 
.00** 
.45 
.000*** 
.57 
.09 
.63 
.000*** 
.69 
.18 
.86 
.000*** 
.93 
.74 
.78 
 
 
.06 
.29 
.02 
.51 
.01 
.09 
.00 
.56 
.00 
.06 
.00 
.42 
.00 
.00 
.00 
       * = p < .05; ** = p < .01; *** = p < .001 
 
 Effects of the MANOVA 
 
Main Effects 
 
The main effect of the group was not significant F(2, 27) = .12, p = .88, 
partial eta squared = .30 showing day before night or night before day condition 
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does not differ significantly. There was a significant main effect of status F(2, 27) 
= 6.0, p = .00, partial eta squared = .30 with patients showing a poorer 
performance than control participants. There was a highly significant main effect 
of block F(2, 27) = 22.93, p = .000, partial eta squared = .62. Compared to the block 
1, in block 2 schizophrenia patients as well healthy controls solved more tasks 
and took significantly less time to complete the Tower of London test. The main 
effect of pre-post was also highly significant F(2, 27) = 19.22, p = .000, partial eta 
squared = .58. There was an increase in performance from pre to post test 
measures of the Tower of London test. 
 
Interaction Effects 
 
The block by pre-post interaction was highly significant F(2, 27) = 10.33, p 
= .000, partial eta squared = .43. The other interaction effects were not significant. 
 
Further to probe statistically significant effects, univariate results were 
examined on the dependent variables number of solved tasks and total time 
taken separately. 
 
Effects of the ANOVA 
 
Number of Solved Tasks 
 
Main Effects 
 
There was a significant main effect of block with regard to number of 
solved tasks M = 10.30 vs. 11.16, F(1, 28) = 6.4, p = .01, partial eta squared = .18. 
Compared with block 1, in block 2 measures both patients and control 
participants solved more number of tasks (Figure B1). There was also a 
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significant main effect of pre-post with regard to number of solved tasks M = 
10.37 vs. 11.09, F(1, 28) = 7.3, p = .01, partial eta squared = .20. Schizophrenia 
patients as well as healthy controls solved more number of tasks in the post test 
measures (Figure B2). The other main effects were not significant. 
 
 
 
Figure B1 Mean number of solved tasks in the Tower of London test at two 
measurement occasions (bars represent standard errors) 
 
 
 
Figure B2 Mean number of solved tasks in the Tower of London test at pre-
post measures (bars represent standard errors)  
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Interaction effects 
 
The interaction effect of pre-post by group by status was significant F(1, 
28) = 5.0, p = .03, partial eta squared = .15. Schizophrenia patients solved more 
tasks in the post test measures of the night time condition (Figure B3), whereas 
healthy controls solved more tasks in the post test measures of day time 
condition (Figure B4). The interaction effect of block by pre-post was also 
significant F(1, 28) = 6.9, p = .01, partial eta squared = .19. There was an increase 
in number of solved tasks in block 1 from pre to post test measures, whereas in 
the block 2 the number of solved tasks from pre to post test measures are 
relatively low (Figure B5). All other interaction effects were not significant. 
 
 
Figure B3 Schizophrenia patients solved a greater number of tasks in the 
Tower of London test in the post test measures of night time condition – Pre-
post by group by status interactions (Schizophrenia patients) 
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Figure B4 Healthy controls solved a greater number of tasks in the Tower of 
London test during the day (Post test measures). Number of solved tasks 
increased from pre to post day measures. Pre-post by group by status 
interactions (Healthy controls) 
 
 
Figure B5 Block by pre-post interactions (number of Solved tasks) in the 
Tower of London test. In block 1 total number of solved tasks increased from 
pre to post measure. But in block 2 there is not much increase in number of 
solved tasks from pre to post measures.  
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Total Time Taken 
 
Main Effects 
 
There was a significant main effect of status on total time taken M 532.04 
vs. 280.21, F(1, 28) = 11.43, p = .00, partial eta squared = .29. Schizophrenia 
patients took longer to complete the Tower of London test compared with the 
healthy controls (Figure B6). There was a highly significant main effect of block 
on total time taken M = 471.53 vs. 340.71, F(1, 28) = 29.75, p = .000, partial eta 
squared = .51. Compared with block 1, in block 2 the time taken to complete the 
Tower of London test significantly reduced (Figure B7). The main effect of pre-
post on total time taken was also highly significant M = 439.05 vs. 373.19 F(1, 28) 
= 36.51, p = .000, partial eta squared = .56. Compared with pre test measures, in 
post test measures both patients and healthy controls took significantly less time 
to complete the Tower of London test (Figure B8). The other main effects were 
not significant. 
 
Figure B6 Main effect of status with regard to total time taken in the 
Tower of London test. Compared with healthy controls schizophrenia 
patients took significantly longer to complete the Tower of London test 
(bars represent standard errors) 
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Figure B7 Highly significant main effect of block with regard to total 
time taken in the Tower of London test (bars represent standard errors). 
Participants took longer to complete the test in the first block. 
 
 
 
Figure B8 Highly significant main effect of pre-post with regard to total 
time taken in the Tower of London test (bars represent standard errors) 
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Interaction Effects 
 
The interaction effect of block by pre-post on total time taken was 
significant F(1, 28) = 20.77, p = .000, partial eta squared = .42. In both the blocks 
total time taken significantly reduced in the post test measures (Figure 3.16). All 
the other interaction effects were not significant. 
 
Figure B9 Block by pre-post interactions (total time taken) in the Tower 
of London test. In both blocks total time taken significantly reduced in 
post measures. 
 
Summary 
 
Compared with the control participants, schizophrenia patients took 
significantly longer to complete the Tower of London test. There were no 
significant difference between patients and controls with regard to number of 
solved tasks. Compared to the block 1, there is an increase in performance in the 
block 2 with regard to number of solved tasks and time taken to complete the 
Tower of London test. Schizophrenia patients solved more tasks in the post 
measures of the night time condition. Healthy controls solved more tasks on post 
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test measures of the day time condition. Schizophrenia patient’s as well healthy 
controls showed an improved performance from pre test measure to the post test 
measures. 
 
B 1.2 Results of the Multivariate Analyses of Variance for the Measures of the 
Tower of London (Schizophrenia Patients) 
 
A 2 (Group: day before night vs. night before day) x 2 (Block: block 1 vs. 
block 2) x 2 (Pre-post: pre vs. post) three-way mixed MANOVA with repeated 
measures on the last two factors was performed using the number of solved tasks 
and total time taken as dependent variables. The results are presented in Table 
B5 
 
Table B5 Results of the Multivariate and Univariate Analyses of Variance for 
the Measures of the Tower of London (Schizophrenia Patients) 
 
Source F 
(2, 17) 
p η² 
Group (Day Night / Night Day) 
Block 
Block x Group 
Pre-post 
Pre-post x Group 
Block x Pre-post 
Block x Pre-post x Group 
.39 
19.98 
.24 
12.54 
1.09 
6.98 
.12 
 
.67 
.000*** 
.78 
.000*** 
.35 
.00** 
.88 
 
.04 
.72 
.02 
.59 
.11 
.45 
.01 
 
Measure: Number of solved tasks 
 
Group (Day Night / Night Day) 
Block 
Block x Group 
Pre-post  
Pre-post x Group  
Block x pre-post 
Block x Pre-post x Group  
 
F (1, 18) 
 
.18 
7.9 
.16 
4.62 
2.12 
.24 
.04 
 
 
 
 
 
.67 
.01** 
.69 
.04* 
.16 
.62 
.83 
 
 
 
 
 
.01 
.30 
.00 
.20 
.10 
.14 
.00 
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Measure : Total time taken 
 
Group (Day Night / Night Day) 
Block                                
Block x Group  
Pre-post  
Pre-post x Group  
Block x Pre-post 
Block x Pre-post x Group  
F (1, 18) 
 
.62 
22.80 
.48 
25.12 
.02 
11.48 
.06 
 
 
 
 
 
.43 
.000*** 
.49 
.000*** 
.87 
.00** 
.80 
 
 
 
 
 
.03 
.55 
.02 
.58 
.00 
.39 
.00 
 
 
* = p < .05; ** = p < .01; *** = p < .001 
 
Effects of the MANOVA 
 
Main Effects 
 
There was a highly significant main effect of block F(2, 17) = 19.98, p = 
.000, partial eta squared = .72. Schizophrenia patients solved more tasks and took 
significantly less time to complete the Tower of London test. There was also a 
highly significant main effect of Pre-post F(2, 17) = 12.54, p = .000, partial eta 
squared = .59. There is an increase in performance from pre test to post test 
measures with regard to number of solved tasks and total time taken. The other 
main effects were not significant. 
 
Interaction Effects 
 
The block by pre-post interaction was significant F(2, 17) = 6.98, p = .00, 
partial eta squared = .45. All other interaction effects were not significant. 
 
Further to probe statistically significant effects, univariate results were 
examined on dependent variables solved tasks and total time taken separately. 
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Effects of the ANOVA 
 
Number of Solved Tasks 
 
Main Effects 
 
There was a significant main effect of block with regard to number of 
solved tasks M = 9.77 vs. 11.00, F(1, 18) = 7.9, p = .01, partial eta squared = .30. 
Schizophrenia patients solved more number of tasks in block 2 (Figure B10). 
There was a marginally significant main effect of Pre-post with regard to number 
of solved tasks M = 10.00 vs. 10.77 F(1, 18) = 4.62, p = .04, partial eta squared = 
.20. There was a minimal increase in performance from pre to post test measures 
with regard to number of solved tasks (Figure B11). The other main effects were 
not significant. 
 
 
 
Figure B10 Main effect of block with regard to number of solved tasks 
in the Tower of London test (bars represent standard errors) 
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Figure B11 Marginally significant main effect of pre-post with regard to 
number of solved tasks in the Tower of London test (bars represent 
standard errors) 
 
Interaction effects 
 
There were no significant interaction effects. 
 
Total Time Taken 
 
Main Effects 
 
There was a highly significant main effect of block with regard to total 
time taken M = 618.15 vs. 445.92, F(1, 18) = 22.80, p = .000, partial eta squared = 
.55 showing a reduced time taken in block 2 (Figure B12). There was also a highly 
significant main effect of pre-post with regard to total time taken M = 572 vs. 491, 
F(1, 18) = 25.12, p = .000, partial eta squared = .58 showing a reduced time taken 
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during post test measures (Figure B13). The other main effects were not 
significant. 
 
 
Figure B12 Highly significant main effect of block with regard to total 
time taken in the Tower of London test (bars represent standard errors) 
 
 
 
Figure B13 Highly significant main effect of Pre-post with regard to 
total time taken in the Tower of London test (bars represent standard 
errors) 
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Interaction Effects 
 
The interaction effect of block by pre-post with regard to total time taken 
was significant F(1, 18) = 11.48, p = .00, partial eta squared = .39. All other 
interaction effects were not significant. 
 
Summary 
 
There is no significant difference in the Tower of London test performance 
between day time condition and night time condition. Patients significantly 
improved in the Block 2 in the Tower of London test. Patients solved more 
number of tasks and took significantly less time to complete the Tower of 
London test in Block 2.  Pre to post test performance were evident among patient 
group.  
 
 
B 1.3 Results of the Multivariate and Univariate Analyses of Variance for the 
Measures of the Tower of London (Healthy Controls) 
 
A 2 (Group: day before night vs. night before day) x 2 (Block: block 1 vs. 
block 2) x 2 (Pre-post: pre vs. post) three-way mixed MANOVA with repeated 
measures on the last two factors was performed using the number of solved tasks 
and total time taken as dependent variables. The results are presented in Table 
B7 
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Table B6 Results of the multivariate and univariate analyses of variance for the 
measures of the Tower of London (Healthy controls) 
Source F 
(2, 9) 
p η² 
Group (Day Night / Night Day) 
Block 
Block x Group 
Pre-post 
Pre-post x Group 
Block x Pre-post 
Block x Pre-post x Group 
.15 
37.39 
.62 
26.36 
2.56 
44.65 
.03 
 
.86 
.000*** 
.57 
.000*** 
.13 
.000*** 
.96 
 
.03 
.89 
.12 
.85 
.36 
.90 
.00 
 
Measure: Number of solved tasks 
 
Group (Day Night / Night Day) 
Block 
Block x Group  
Pre-post  
Pre-post x Group  
Block x Pre-post 
Block x Pre-post x Group 
 
F (1, 10) 
 
.00 
1.0 
1.0 
4.3 
4.32 
16.89 
.00 
 
 
 
 
 
1.0 
.33 
.33 
.06 
.06 
.00** 
1.0 
 
 
 
 
 
.00 
.09 
.09 
.30 
.30 
.62 
.00 
 
 
 
Measure : Total time taken 
 
Group (Day Night / Night Day) 
Block 
Block x Group  
Pre-post  
Pre-post x Group  
Block x Pre-post 
Block x Pre-post x Group  
F (1,10) 
 
.33 
64.18 
.02 
48.62 
.71 
23.65 
.04 
 
 
.57 
.000*** 
.86 
.000*** 
.41 
.00** 
.83 
 
 
.03 
.86 
.00 
.82 
.06 
.70 
.00 
* = p < .05; ** = p < .01; *** = p < .001 
 
Effects of the MANOVA 
 
Main Effects 
 
There was a highly significant main effect of block F(2, 9) = 37.39, p = .000, 
partial eta squared = .89. This effect shows control participants solved more tasks 
and significantly less time to complete the Tower of London test during the 
200 
 
 
second measurement occasion. There was also a highly significant main effect of 
pre-post F(2, 9) = 26.36, p = .000, partial eta squared = .85. This effect shows an 
increased performance during the post test measures with regard to number of 
solved tasks and total time taken to complete the Tower of London test.  
 
Interaction Effects 
 
The block by pre-post interaction was highly significant F(2, 9) = 44.65, p = 
.000, partial eta squared = .90. The other interaction effects were not significant. 
 
Further to probe statistically significant effects, univariate results were 
examined on dependent variables solved tasks and total time taken separately. 
 
Effects of the ANOVA 
 
Number of Solved Tasks 
 
Main effects 
 
There were no significant main effects with regard to number of solved 
tasks. 
 
Interaction Effects 
 
The interaction effect of block by pre-post was significant F(1, 10) = 16.89, 
p = .00, partial eta squared = .62. The other interaction effects were not 
significant. 
 
Total Time Taken 
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Main Effects 
 
There was a highly significant main effect of block on total time taken M = 
325 vs. 236, F(1, 10) = 64.18, p = .000, partial eta squared = .86 with controls 
showing reduced time taken to complete the Tower of London test during 
second measurement occasion (Figure B14). Nevertheless, the main effect of pre-
post on total time taken was also highly significant M = 325 vs. 236, F(1, 10) = 
48.62, p = .000, partial eta squared = .82 with control participants showing a 
reduced time taken during post test measures (Figure B15).  
 
 
 
 
Figure B14 Highly significant main effect of block with regard to total 
time taken in the Tower of London test (bars represent standard errors) 
 
 
202 
 
 
 
 
Figure B15 Highly significant Main effect of pre-post with regard to 
total time taken in the Tower of London test (bars represent standard 
errors) 
  
 
Interaction Effects 
 
The interaction effect of block by pre-post on total time taken measure was 
significant F(1, 10) = 23.65, p = .00, partial eta squared = .70. All other interaction 
effects were not significant. 
 
Summary 
 
There was no significant difference in the Tower of London test 
performance between day time and night time condition. There was no 
significant difference with regard to the number of solved tasks in the Tower of 
London test, but there was a significant difference with regard to total time taken 
to complete the test.  
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APPENDIX C 
 
POSITIVE and NEGATIVE SYNDROME SCALE for SCHIZOPHRENIA 
(PANSS) 
 
 
Instructions:  Check one appropriate rating for each item following the specified clinical 
interview. Refer to the Rating Manual in the Reference Book for item definitions and descriptions 
of anchoring points. 
 
1= absent    2= minimal    3= mild     4= moderate     5= moderate severe     6= severe     7= extreme 
 
 
1. POSITIVE SUBSCALE 
 
P1 Delusions . . . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
P2 Conceptual disorganization  . . . . . . .  1 2 3 4 5 6 7 
P3 Hallucinatory behavior  . . . . . . . . . . . . 1 2 3 4 5 6 7 
P4 Excitement  . . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
P5 Grandiosity  . . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
P6 Suspicious/persecution  . . . . . . . . . . .  1 2 3 4 5 6 7 
P7 hostility  . . . . . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
 
Subtotal: _____ 
 
2. NEGATIVE SUBSCALE 
 
N1 Blunted Affect  . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
N2 Emotional withdrawal  . . . . . . . . . . . . .  1 2 3 4 5 6 7 
N3 Poor rapport  . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
N4  Passive/apathetic. . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
N5  Difficulty in abstract thinking  . . . . . . . . 1 2 3 4 5 6 7 
N6 Lack of spontaneity & flow of conversation 1 2 3 4 5 6 7 
N7 Stereotyped thinking  . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
 
Subtotal: _____ 
 
3. GENERAL PSYCHOPATHOLOGY SUBSCALE 
 
G1 Somatic concern  . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G2  Anxiety  . . . . . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G3 Guilt feelings  . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G4 Tension  . . . . . . . . . . . . . . . . . . . . . . . .  1 2 3 4 5 6 7 
G5 Mannerisms & posturing  . . . . . . . . . . . 1 2 3 4 5 6 7 
G6 Depression  . . . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G7  Motor retardation  . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G8  Uncooperativeness  . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G9  Unusual thought content  . . . . . . . . . . . 1 2 3 4 5 6 7 
G10  Disorientation  . . . . . . . . . . . . . . . . . . .  1 2 3 4 5 6 7 
G11  Poor attention  . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
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G12 Lack of judgment & insight  . . . . . . . . . 1 2 3 4 5 6 7 
G13 Disturbance of volition  . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G14 Poor impulse control  . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G15 Preoccupation  . . . . . . . . . . . . . . . . . . . 1 2 3 4 5 6 7 
G16 Active social avoidance  . . . . . . . . . . . . 1 2 3 4 5 6 7 
 
Subtotal:  _____ 
 
 
 
Total PANSS score (this is the sum of the 3 subtotals): _____ 
 
 
 
